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ABSTRACT 
Nicole Rae Tackmann: DISCOVERIES IN MDM2-MEDIATED P53 REGULATION IN VIVO 
(Under the direction of Yanping Zhang) 
 
The transcription factor p53 is a stress sensor and tumor suppressor. Its many target 
genes contribute to tumor suppression through regulation of cell cycle arrest, senescence, 
apoptosis, and metabolism. Ubiquitously transcribed and translated, p53 regulation is primarily 
mediated through mouse double minute 2 (MDM2). MDM2 binds to p53, inhibits its 
transcriptional activation capabilities, and harbors E3 ubiquitin ligase activity to facilitate p53 
degradation. Upon cellular stress, upstream signaling transducers modify or bind MDM2 to 
prevent its inhibition of p53.  
Ribosomal proteins (RPs) bind to MDM2 either in the response to ribosomal biogenesis 
stress or oncogenic overproduction of RPs, which occurs in cancer due to increased 
proliferation. p19ARF also transduces hyperproliferative signals, inhibiting MDM2 to stabilize 
p53. Both p19ARF- and RP-MDM2 binding are important for p53 activation following oncogenic 
c-MYC overexpression, but whether these interactions are interdependent was unknown. We 
utilized mice bearing the MDM2C305F mutation, which disrupts RPL11- and RPL5-MDM2 binding, 
crossed them with mice containing deletion of p19ARF, and examined c-MYC-induced 
tumorigenesis. We found that concomitant disruption of these signals enhanced tumorigenesis, 
indicating that RP-MDM2 and p19ARF-MDM2 binding are two distinct mechanisms causing c-
MYC-induced p53 activation. 
Further, we examined whether RP-MDM2 interaction could transduce proliferative 
signals in cancers driven by other oncogenes. We crossed MDM2C305F mice to mice bearing an 
HrasG12V transgene or an ApcMin allele, which promote melanoma and colorectal tumor 
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formation, respectively. We found that in response to RAS stimulation, RPL11 and RPL5 do not 
participate in MDM2 inhibition. In response to APC deletion, RPL11 and RPL5 expression and 
MDM2 binding are increased in a colon-specific manner. As a result, MDM2C305F mice 
experience increased colorectal tumorigenesis and decreased p53 activation. Collectively, these 
results suggest that RP-MDM2 interaction is important for transducing individual oncogenic 
stress signals in a p19ARF-independent manner. 
We have also examined the role of MDM2 E3 ligase activity in controlling p53 following 
the overexpression of c-MYC. Using mice bearing the MDM2Y487A mutation, which disrupts 
MDM2 E3 ligase activity, we found that MDM2 E3 ligase activity is dispensable for regulating 
p53 following oncogenic c-MYC overexpression and surprisingly that its disruption may provide 
a survival advantage. 
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CHAPTER 1: INTRODUCTION1 
 Since its discovery almost 40 years ago (DeLeo et al., 1979; Kress et al., 1979; Lane 
and Crawford, 1979; Linzer and Levine, 1979), the transcription factor tumor protein 53 (TP53, 
hereafter referred to as p53) has been one of the most highly studied proteins. p53 is famously 
known as the ‘guardian of the genome’ (Efeyan and Serrano, 2007; Lane, 1992) due to its 
participation in the repair of damaged DNA, but it has been appreciated that p53 contributes to a 
multitude of cellular functions, including but not limited to: cell cycle arrest, programmed cell 
death (apoptosis), cell senescence, cell differentiation, energy metabolism, angiogenesis, cell 
communication, organismal fertility and immune response (Menendez et al., 2009). Considering 
these various functions, p53 is thought to be a master regulator of stress response that plays a 
crucial role in cancer prevention.  
Much of p53 research has focused on the downstream targets that contribute to its 
function as a stress regulator, but the signals that contribute to p53 activation both at basal 
levels and in response to stress are also being actively pursued. This introduction will initially 
explore the known functions of p53 and its role as a tumor suppressor. Next, this introduction 
will delve into the regulation of p53 in vivo, and explore the upstream cancer-associated factors 
that contribute to p53 activation. Finally, the purpose of this dissertation will be addressed, 
                                               
1 Portions of this chapter discussing in vivo MDM2 and MDMX studies were adapted from a review article 
published in Journal of Molecular Cell Biology. I wrote the manuscript, Yanping Zhang and I edited the 
manuscript, and Yanping Zhang finalized the manuscript. The original citation is as follows: Tackmann, 
N.R., and Zhang, Y. (2017). Mouse modelling of the MDM2/MDMX-p53 signalling axis. Journal of 
Molecular Cell Biology 9, 34-44.  
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which focuses on clarifying the contributions of the upstream and downstream signals 
responsible for p53 regulation in vivo.  
 
p53 functions 
The broadest, most well-studied function of p53 is that of a transcription factor. In the 
presence of other cofactors p53 binds DNA, typically in the promoter region of a gene, and 
activates or represses the expression of that gene. There are more than one hundred genes 
that have been characterized as p53 targets, and new p53 target genes are discovered every 
year. Broadly, targets of p53 transcriptional activation participate in promoting cell cycle arrest, 
apoptosis, DNA damage repair, and senescence, as well as controlling cell metabolism. A host 
of stress signals converge to activate p53, including DNA damage, oxidative stress, nutrient 
depletion, hypoxia, nucleolar stress, and proliferative signals, most of which are present in the 
tumor ecosystem.  
Although p53 is widely known as a tumor suppressor protein, upon its discovery p53 was 
originally classified as an oncogene (DeLeo et al., 1979; Kress et al., 1979; Lane and Crawford, 
1979; Linzer and Levine, 1979). It is now well known that p53, encoded by TP53, is frequently 
mutated or inactivated in various cancers (Muller and Vousden, 2013). Though p53 mutations 
are commonly found throughout the length of the protein, the most common p53 mutations 
occur within the DNA-binding domain of p53 and are thought to render p53 functionally inactive 
as a transcription factor (Pavletich et al., 1993). However, p53 mutations can confer new 
oncogenic functions, including novel protein binding partners, increased protein stability, and 
chemotherapeutic resistance in cells (Blandino et al., 1999; Dittmer et al., 1993; Muller and 
Vousden, 2014; Olive et al., 2004; Song et al., 2007). These discoveries surrounding the 
oncogenic properties of p53 mutants clarified the original confusion surrounding the tumor 
suppressor status of p53.  
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Interestingly, mice deficient for p53 are viable, but tend to develop tumors (typically 
lymphomas) and die by 6 months of age (Donehower et al., 1992). Mice with heterozygous p53 
deletion, on the other hand, tend to develop a wider range of neoplasms, including sarcomas, 
carcinomas, and lymphomas. This is similar to the pathology of human patients with Li-
Fraumeni syndrome, a dominant familial condition in which patients inherit a mutated or null 
copy of p53, rendering them susceptible to spontaneous tumor development. 
In its role as a transcription factor, p53 binds tightly to specific DNA sequences via its 
central DNA binding domain. Following binding, p53 recruits other transcription or chromatin-
modifying proteins to promote or repress gene transcription. The transactivation domain of p53 
binds to two subunits of the TFIID complex, TAFII40 and TAFII60, as well as several other 
TATA-binding protein-associated factors, which promote the formation of the transcription 
preinitiation complex (Farmer et al., 1996; Martin et al., 1993; Seto et al., 1992; Thut et al., 
1995). p53 also binds to a number of chromatin modifying factors, including p300, a histone 
acetyltransferase (Lill et al., 1997). The acetylation of histone lysine residues in enhancer and 
promoter regions is thought to promote more open chromatin structures that are associated with 
transcriptional activation of genes (Eberharter and Becker, 2002). 
The requirements of p53-mediated gene regulation have been extensively studied using 
both in vitro DNA binding assays and in vivo chromatin immunoprecipitation (ChIP). Several 
groups have described a 20-base-pair consensus p53 response element (RE) (Funk et al., 
1992; Wang et al., 1995). The consensus sequence for the p53 RE is 
RRRCWWGYYY…n…RRRCWWGYYY, where R represents a purine, Y represents a 
pyrimidine, W represents an A or T, and n represents a 0-13 base pair spacer (Menendez et al., 
2009). However, many p53 target genes have mismatches within the consensus sequence, and 
in fact some validated p53 targets only contain half of the canonical response element, deemed 
a “half site” (Jordan et al., 2008). The high variability within verified p53 response elements 
likely provides fine-tuning of the p53 regulatory network, as certain response elements may only 
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be bound by p53 under certain contexts. However, the heterogeneity of p53 RE sequences has 
also led to challenges and disagreement within the field. For instance, the distinct differences in 
RE sequences or protein-protein interactions specifically required for p53-mediated gene 
suppression are not fully understood. 
As stated above, p53 target genes are implicated in a wide range of functions. One of 
the most well-characterized p53 target genes, cdkn1a codes for the cell cycle regulator 
p21WAF1/CIP1 (p21 hereafter) (el-Deiry et al., 1993). Following DNA damage and other stresses, 
p53 transcriptionally upregulates p21, inducing a G1 to S phase cell cycle arrest. This arrest 
allows the cells to pause and repair DNA damage before continuing forward with cell division. 
p53 promotes DNA damage repair by transactivating GADD45α (growth arrest and DNA 
damage inducible alpha), which stimulates DNA excision repair through increased binding with 
PCNA (proliferating cell nuclear antigen) (Smith et al., 1994). p53 activation also engages the 
induction of apoptotic machinery, including target genes such as bax (BCL-2-associated X 
protein), puma (p53 upregulated modulator of apoptosis), apaf1 (apoptotic protease-activating 
factor 1), and noxa (phorbol-12-myristate-13-acetate-induced protein 1) (Moroni et al., 2001; 
Nakano and Vousden, 2001; Oda et al., 2000; Toshiyuki and Reed, 1995). BAX is a BCL-2 
family protein that contributes to the permeabilization of the mitochondrial membrane (Chipuk et 
al., 2004; Pastorino et al., 1998), while PUMA directs BAX to the mitochondrial membrane (Kim 
et al., 2009). APAF1 forms a complex with cytochrome c to facilitate the activation of caspase 3 
(Li et al., 1997; Zou et al., 1997), while NOXA interacts with other BCL-2 family proteins to 
promote the release of caspase-9 (Oda et al., 2000). More recently, new p53 targets functioning 
in the control of cell metabolism have also been discovered, including TIGAR (TP53 induced 
glycolysis regulatory phosphatase), PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3), MCD (malonyl-CoA decarboxylase), GLS2 (glutaminase 2), GLUT1 (glucose 
transporter 1), and GLUT4 (glucose transporter 4) (Bensaad et al., 2006; Franklin et al., 2016; 
Hu et al., 2010; Liu et al., 2014b; Schwartzenberg-Bar-Yoseph et al., 2004). These metabolic 
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targets are highly varied in their functions. GLUT1 and GLUT4 regulate the import of glucose 
into the cell, while TIGAR and PFKFB3 regulate the flux of glucose into either glycolysis 
(producing ATP and pyruvate) or into the pentose phosphate pathway (producing NADPH and 
nucleotides). MCD participates in fatty acid oxidation, and GLS2 is an important tumor-
suppressive regulator of glutamine metabolism (Liu et al., 2014a; Szeliga et al., 2014; Zhang et 
al., 2013a). Through the transcriptional regulation of all of these targets and others, p53 is 
thought to control the stress response of a cell, mediating a choice between cell death in the 
case of irreparable damage, or DNA damage repair and cell survival. 
Although the canonical p53 functions in promoting cell cycle arrest, apoptosis, and 
senescence have long thought to be the primary mechanisms of p53 tumor suppression, recent 
mouse modeling has revealed that these p53 effectors may not be the primary barriers to tumor 
formation and progression. For example, Li et al. (2012) recently modeled a p53 mouse in which 
three lysine residues in the DNA binding domain of p53 were mutated to arginine (known as 
p533KR mice), thus preventing the acetylation of those residues, which is important for p53-
mediated transcriptional upregulation of the target genes p21, PUMA, and NOXA. Canonical 
apoptotic targets, senescence targets and other cell cycle arrest targets are unable to be 
transcriptionally upregulated in the p533KR mouse. Surprisingly, compared to p53-/- mice, p533KR 
mice are resistant to tumor formation. The reciprocal experiment was performed by another 
group using p21-/-;noxa-/-;puma-/- triple knockout mice, with similar results (Valente et al., 2013). 
These studies suggest that the primary tumor suppressive functions of p53 may be contingent 
on its metabolic targets or other protein interactions. Although canonical p53 targets like p21 
can still be used as a barometer for p53 activity, these studies have forced the field to 
reevaluate its philosophy about p53-mediated tumor suppression. 
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Overview of MDM2/MDMX-mediated p53 regulation 
While p53 transcription and translation are largely believed to occur ubiquitously, basal 
p53 levels and activity are kept relatively low. In response to various stress-inducing stimuli, p53 
becomes stabilized and activated, allowing it to serve as a nuclear transcription factor. In 
general, p53 post-translational modifications are thought to dictate the stability, localization, and 
activity of p53. For example, p53 ubiquitination mediates its nuclear export and degradation, 
while acetylation or phosphorylation of p53 at various residues contributes to its activation or 
choice of target genes (Barlev et al., 2001).  
p53 regulation is multifaceted and two additional proteins are considered critically 
important for proper control: mouse double minute 2 (MDM2) and mouse double minute 4 
(MDM4, also known as MDMX), which cooperate to govern the posttranslational stability, 
localization, and activity of p53 (Hu et al., 2007; Wade et al., 2010). MDM2 was first discovered 
in the 3T3DM mouse tumor cell line, in which it was amplified through minute circular 
chromosomes (Fakharzadeh et al., 1991). MDM2 is widely considered to be the primary 
negative regulator of p53, and it is theorized to achieve p53 inhibition through two distinct 
mechanisms. MDM2 harbors E3 ubiquitin ligase activity towards p53 through its RING domain, 
catalyzing the transfer of ubiquitin to p53 from an E2-conjugating enzyme (Haupt et al., 1997; 
Honda et al., 1997; Jackson and Berberich, 2000; Kubbutat et al., 1997). The ubiquitination of 
p53 leads to its export from the nucleus into the cytoplasm, where it can be degraded by the 
26S proteasome (Lohrum et al., 2001). MDM2 also inhibits p53 activity by binding to the p53 
transactivation domain through its N-terminal p53 binding domain (Chen et al., 1993).  
Both MDM2 and MDMX can directly bind to the p53 transactivation domain and inhibit 
p53-mediated transcription of its target genes (Chen et al., 1993; Shvarts et al., 1996). MDM2 
and MDMX are highly homologous, sharing similar p53-binding domains and RING domains 
(Shvarts et al., 1996). MDM2 and MDMX interact via their RING domains to form a heterodimer, 
and this heterodimer has been proposed to promote more efficient p53 inhibition than MDM2 or 
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MDMX alone (Tanimura et al., 1999). In addition to regulating p53 stability and activity, mdm2 
was also discovered to be a p53 target gene (Barak et al., 1993). It is thought that following p53-
activation, this feedback loop is important for returning p53 to basal levels and activity. 
Although approximately 50% of cancers have a mutation in p53 (Muller and Vousden, 
2013), it is less commonly appreciated that WT p53 is often functionally inactivated. This is 
commonly accomplished through aberrantly expressed MDM2 or MDMX, which reduce total and 
nuclear p53 levels and activity (Tovar et al., 2006). This trend is supported by in vivo data. 
Transgenic Mdm2 or MdmX overexpression in mice supports increased spontaneous tumor 
development due to decreased p53 activity (Jones et al., 1998; Xiong et al., 2010). Mice bearing 
a cancer-associated human SNP contributing to increased Mdm2 transcription are also 
susceptible to decreased p53 function and increased tumorigenesis (Bond et al., 2004; Post et 
al., 2010), suggesting that naturally occurring MDM2 “overexpression” (as opposed to 
transgenic overexpression) contributes to p53 functional inactivation and cancer. 
In general, p53 activation and stabilization is thought to occur two ways. In response to 
stress, upstream signaling proteins place posttranslational marks on p53 (such as 
phosphorylation) that prevent its interactions with MDM2 and MDMX. Second, these upstream 
signaling proteins inhibit MDM2 or MDMX via direct protein interaction or by posttranslational 
modification. These activities serve to prevent MDM family protein mediated p53 inhibition and 
degradation.  
 
In vivo studies of MDM-mediated p53 regulation 
Lessons from knockout mice 
In vivo models have furthered our understanding of the physiologic intricacies of p53 
regulation by MDM2 and MDMX. Although early in vitro work demonstrated that MDM2 could 
bind to p53 and mask p53 transactivation activity (Chen et al., 1993; Oliner et al., 1993), the 
degree of MDM2 importance to p53 regulation was not fully appreciated until the creation of 
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Mdm2 deletion alleles in the mouse (de Oca Luna et al., 1995; Jones et al., 1995). Surprisingly, 
mice deficient for MDM2 die between embryonic days 4.5−6.5, with pronounced levels of 
apoptosis throughout the embryo. This embryonic lethality caused by loss of MDM2 is rescued 
by concomitant loss of p53, suggesting that the primary function of MDM2 during 
embryogenesis is to inhibit undue p53 activation or accumulation. These studies also 
established that MDM2 and p53 are expressed ubiquitously during embryonic development. 
 MDM2-mediated p53 regulation also remains essential in the adult mouse. The p53-
dependent embryonic lethality caused by MDM2 deficiency renders the study of MDM2 in p53 
regulation difficult in vivo. To address this, Christophorou et al. (2005) developed a mouse 
model expressing the hormone-binding domain of a modified estrogen receptor placed at the 3’ 
end of the TP53 coding sequence, therefore generating a switchable chimeric p53 protein 
(p53ER hereafter) that is only active in the presence of tamoxifen or 4-hydroxytamoxifen (4-
OHT). The p53ER protein behaves like a null allele in the absence of tamoxifen, which allows 
for the generation of MDM2-deficient mice and the study of MDM2-dependent p53 regulation in 
the adult mouse. Ringshausen et al. (2006) then crossed p53ER/- mice with Mdm2+/- mice to 
generate Mdm2-/-;p53ER/- mice. Strikingly, all Mdm2-/-;p53ER/- mice died within 5-6 days after a 
single tamoxifen injection and displayed severe anemia and bone marrow ablation. Several 
proliferative tissues were also severely atrophied, including small intestine and colon tissue. On 
the other hand, classically radio-insensitive tissues such as the heart and kidney appeared 
normal following tamoxifen treatment. However, in all tissues examined, p53 was more 
transcriptionally active, though not to levels associated with cell death, suggesting that the loss 
of MDM2 allows for spontaneous p53 activation throughout the body (Ringshausen et al., 2006). 
In a similar study, Zhang et al. (2014a) used a conditional Mdm2 deletion allele 
(Mdm2FM) (Grier et al., 2002) coupled with a whole body, tamoxifen-inducible, Cre-mediated 
recombination allele (CreER) to study the effects of whole body Mdm2 loss at various stages of 
aging, since overall p53 activity has been shown to decline with age (Feng et al., 2007). Similar 
 
9 
 
to Mdm2-/-;p53ER/- mice, 2-4 month old Mdm2FM/−;CreER mice experience p53-mediated 
morbidity within a few days after tamoxifen injection. In addition to extensive damage to radio-
sensitive tissues, Mdm2FM/−;CreER mice also display extensive levels of apoptosis/atrophy in 
the kidney and liver, radio-insensitive tissues. It appears that loss of Mdm2 results in 
spontaneous p53 stabilization and activation in most organs and that MDM2 is required for 
viability in mice of all ages. 
Several other studies (Table 1.1) have generated tissue-specific deletions of Mdm2 
using conditional Mdm2 deletion alleles combined with tissue-specific Cre expression, including 
expression in differentiated intestinal smooth muscle cells, erythroid, and cardiac tissue 
(Boesten et al., 2006; Grier et al., 2006; Maetens et al., 2007; Xiong et al., 2006). Others have 
coupled whole body Mdm2 deletions with tissue-specific reintroduction of p53 (Francoz et al., 
2006). Most tissues in which Mdm2 has been deleted, especially those that are highly 
proliferative, exhibit substantially increased levels of apoptosis, suggesting that basal MDM2-
mediated p53 regulation is critical in nearly all tissues and that too much p53 can be lethal.  
Similar to MDM2, loss of MDMX in the mouse is also embryonic lethal, with concomitant 
TP53 deletion rescuing the lethality (Parant et al., 2001), suggesting that MDM2 and MDMX 
play non-redundant roles in the inhibition of p53 activation or stabilization. Interestingly, 
overexpression of an MDM2 transgene (Mdm2Tg/+) can rescue MDMX deletion (Steinman et al., 
2005), hinting that MDM2 is capable of restraining undue p53 activity in vivo but that it may 
require MDMX for efficient inhibition. From these studies, it is possible to speculate that MDMX 
serves to either directly enhance MDM2 inhibitory functions or enhance its stability. 
 It also appears that MDMX is less important to p53 regulation in the adult mouse than 
MDM2. Garcia et al. (2011) combined MdmX+/- mice with the p53ER model to generate MdmX-/-
;p53ER/- mice and tested whether, like MDM2, MDMX is critical to p53 suppression in the adult 
mouse. Surprisingly, MdmX-/-;p53ER/- mice injected with tamoxifen daily live an average of 29 
days. Spontaneous p53 activity was also observed in select tissues. Six hours after tamoxifen 
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injection and in the absence of MDMX, the mRNA expression of p53 cell cycle target gene 
cdkn1a (p21) was significantly increased in almost all tissues examined. However, the mRNA 
expression of puma, a p53 apoptotic target, was only significantly increased in radio-sensitive 
tissues. The expression of p21 following p53ER restoration correlated with decreased 
proliferation in tissues, while the expression of puma correlated with increased apoptosis. In 
contrast to Mdm2-/-;p53ER/- mice, MdmX-/-;p53ER/- mice are remarkably tolerant to temporary 
p53ER restoration. After daily injections of tamoxifen for one week, MdmX-/-;p53ER/- mice 
displayed significant loss of cell proliferation in the spleen, bone marrow, and thymus tissue, but 
following withdrawal of tamoxifen, the mice were able to recover without long-term adverse 
consequences. Tissue-specific p53 restoration studies in MdmX-/- mice and tissue-specific 
deletions of MdmX have further indicated that the necessity of MDMX in p53 regulation is 
context dependent; conversely, many conditional deletion studies support the idea that MDM2 is 
critical in the suppression of basal p53 in almost all situations. 
Consistent with this idea, several groups have suggested that MDMX serves to enhance 
MDM2-mediated p53 degradation (Badciong and Haas, 2002; Gu et al., 2002; Linke et al., 
2008). The relatively better survival of MdmX-/-;p53ER/- mice compared to Mdm2-/-;p53ER/- mice in 
response to transient p53ER restoration suggests that MDM2 is at least capable of restraining 
p53 on its own for short periods of time, but it is conceivable that efficient MDM2-mediated p53 
inhibition or degradation is required for long-term viability. Indeed, the levels of p53 are 
increased in MdmX-/-;p53ER/- MEFs compared to MEFs containing MDMX (Garcia et al., 2011), 
supporting the idea that MDMX plays some role in regulating p53 stability in vivo. It is possible 
that in MdmX-/-;p53ER/- mice p53ER accumulates to levels that could require MDMX 
enhancement of MDM2-mediated p53 inhibition, indicated by the eventual lethality of continuous 
tamoxifen injection in MdmX-/-;p53ER/- mice. 
Overall, MDM2 and MDMX deletion models have suggested the following notions about 
MDM2- and MDMX-mediated p53 regulation: (i) MDM2 is the master regulator of p53 and is 
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necessary to prevent p53-dependent cell death at all stages (ii) MDMX may serve to enhance 
MDM2-mediated p53 inhibition and/or degradation in a developmental and tissue-specific 
manner. 
 
Mechanisms of MDM2- and MDMX-mediated p53 regulation: lessons from knockin and 
transgenic mice 
In vitro studies have allowed us to identify mechanisms of MDM2- and MDMX-
dependent p53 inhibition, while in vivo studies have allowed us delineate the biologically 
relevant contributions of these mechanisms. In particular, several mouse models (Figure 1.1a 
and Table 1.2) have helped to clarify p53 regulation in vivo. 
MDM2/MDMX heterodimer formation and p53 binding 
Early in vitro studies suggested that the primary mechanism of MDM2- and MDMX-
dependent p53 inhibition was mediated through direct MDM2 and MDMX binding to the p53 
transactivation domain, causing disruption of p53 activity (Kussie et al., 1996; Oliner et al., 
1993; Shvarts et al., 1996). These studies also revealed that MDM2 could act as an E3 ubiquitin 
ligase towards p53, causing its degradation by the proteasome and suggesting a dual regulatory 
mechanism (Haupt et al., 1997; Honda et al., 1997). To directly test whether or not 
MDM2/MDMX-p53 binding alone could restrain p53 activity in vivo, Itahana et al. (2007) created 
mice bearing a mutation in the MDM2 RING domain (MDM2C462A) that disrupts MDM2 E3 ligase 
activity and MDM2-MDMX binding. Homozygous MDM2C462A mutation results in p53-dependent 
embryonic lethality before embryonic day 7.5, suggesting that MDM2- or MDMX-p53 interaction 
alone is not sufficient to permit embryonic development and that MDM2-MDMX heterodimer 
formation and/or MDM2 E3 ligase activity may be the primary mechanisms for MDM2/MDMX-
mediated p53 suppression in vivo. 
Studies in MdmX knockin mice also appear to corroborate that MDM2/MDMX-p53 
binding is insufficient for p53 inhibition, particularly during embryogenesis. Pant et al. (2011) 
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generated an allele carrying an in-frame deletion of the MDMX RING domain (MdmXΔRING). At 
the same time, Huang et al. (2011) generated an allele carrying a point mutation in the MDMX 
RING domain (MdmXC462A). Both of these alleles disrupt MDM2-MDMX interaction without 
altering MDM2. Mice homozygous for either MdmXΔRING or MdmXC462A exhibit p53-dependent 
embryonic lethality. Although these two mouse models both disrupt MDM2/MDMX binding and 
present p53-dependent homozygous embryonic lethality, there have been several observations 
in apparent contradiction. First, when combined with a p53neo allele, which expresses ~15% of 
WT p53 levels (low enough to permit embryonic development), MEFs containing MDMXΔRING 
appear to display greater p53 activity with no difference in p53 stabilization compared to MEFs 
containing WT MDMX, suggesting that MDMX does not necessarily contribute to MDM2-
mediated p53 degradation. On the other hand, MdmXC462A/C462A embryos present both increased 
p53 abundance and activity. These observations suggest that the MDM2-MDMX interaction is 
required for efficient p53 activity inhibition, but may or may not be required for p53 degradation 
during embryogenesis. The discrepancy between these mouse models has challenged the 
interpretation of in the in vivo necessity of MDM2-MDMX binding. 
Complicating these observations further, Pant et al. (2011) also generated a Cre-
inducible MDMX RING deletion allele (MDMXflxRING) and crossed these mice with mice 
containing a tamoxifen-dependent Cre allele (CreER). When adult MdmXflxRING/ΔRING;CreER mice 
were injected with tamoxifen to generate recombined MdmXΔRING/ΔRING mice, the mice appeared 
healthy. Most p53 target genes, with the exception of p21, showed little change in expression, 
suggesting that while required for embryogenesis, MDM2-MDMX heterodimer formation is 
dispensable for the regulation of p53 activity in adult mice. Whether p53 stability is affected by 
this loss in vivo has not been determined and remains an interesting question. From these 
studies in mice, it appears that MDM2-MDMX heterodimer formation is important for p53 
suppression, but the mechanism of this inhibition is still incompletely understood.  
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MDM2 E3 ligase activity 
The recently developed MDM2Y487A mouse model (Tollini et al., 2014) provided insight 
into the necessity of MDM2 E3 ligase activity in both basal and stress-dependent p53 
regulation. As an extension of the MDM2C462A model, in which both MDM2 E3 ligase activity and 
MDM2-MDMX interaction are disrupted, the MDM2Y487A mutation disrupts MDM2 E3 ubiquitin 
ligase activity while maintaining MDM2-MDMX interaction. Surprisingly, unlike MDM2C462A, 
MDMXΔRING, or MDMXC462A mice, MDM2Y487A mice survive into adulthood, with little phenotypic 
differences from WT mice under normal, unstressed conditions, clearly indicating that MDM2 E3 
ligase activity is not essential for regulating p53 during embryonic development. While no 
degradation of p53 is observed in MDM2Y487A MEFs, basal p53 activity is slightly increased 
compared to WT MEFs. This suggests that either MDM2-p53 or MDMX-p53 binding is not 
sufficient for complete p53 activity suppression, or that without E3 ligase-mediated degradation 
by MDM2, increased levels of p53 are also spontaneously more active.  
Although Mdm2Y487A/Y487A mice appear normal under unstressed conditions, these mice 
are highly sensitive to even sub lethal doses of ionizing radiation (IR), succumbing to p53-
dependent hematopoietic failure within about 20 days after exposure, indicating that MDM2 E3 
ligase activity is necessary for p53 degradation and suppression during DNA damaging 
conditions. The relative normalcy of Mdm2Y487A/Y487A mice under unstressed conditions suggests 
that MDM2-MDMX heterodimerization may be particularly important for suppressing chronic, 
basal levels of p53 activation, such as what might occur during embryogenesis, while MDM2 E3 
ligase activity is dispensable under these conditions. However, under stressed conditions where 
p53 is acutely activated, such as DNA damaging conditions, the MDM2-MDMX heterodimer 
appears to be insufficient for restraining p53 in the adult mouse. These conditions appear to 
require the further degradation of p53, mandating the use of MDM2 E3 ligase activity. 
Shortly after it was observed to harbor the ability to ubiquitinate p53, MDM2 was also 
discovered to harbor autoinhibitory ubiquitination activity. In the presence of DNA damage, this 
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autoubiquitination results in MDM2 destabilization, allowing for further p53 stabilization (Honda 
and Yasuda, 2000; Stommel and Wahl, 2004). Mutations in the MDM2 RING domain have been 
shown to increase the stability of overexpressed MDM2 protein (Honda and Yasuda, 2000), but 
the MDM2C462A and MDM2Y487A mouse models have specifically challenged the notion that 
MDM2 autoubiquitination occurs in vivo. The MDM2C462A and MDM2Y487A mutations disrupt 
MDM2 E3 ligase activity, yet the half-life and ubiquitination levels of MDM2 do not change, 
suggesting that in the live mouse MDM2 stability is likely mediated by the activity of other E3 
ligases (Itahana et al., 2007; Tollini et al., 2014). These two independent E3 ligase activity-
disrupting mutations of MDM2 have shown that MDM2 E3 ligase activity is not required for basal 
MDM2 degradation in vivo (Itahana et al., 2007; Tollini et al., 2014), although whether or not 
MDM2-MDMX interaction is required for MDM2 ubiquitination is still unclear. In vitro MDMX 
overexpression has been shown to stabilize MDM2, and this stabilization is dependent on the 
RING domain of each protein (Linares et al., 2003; Tanimura et al., 1999). Conversely, 
knockdown of MDMX has resulted in reduced MDM2 expression (Gu et al., 2002). Because of 
this, it was previously proposed that MDMX could redirect MDM2 E3 ligase activity from MDM2 
unto itself and stabilize MDM2, but if MDM2 autoubiquitination does not truly occur in vivo, this 
may not be the case. Further, the MDMXC462A mutation disturbs MDM2-MDMX interaction 
without directly altering MDM2, and in the absence of MDM2-MDMX binding, Huang et al. 
observed that MDM2 ubiquitination was disrupted in vivo (Huang et al., 2011). However, mice 
containing MDMXΔRING, which also does not interact with MDM2, display no difference in MDM2 
half-life compared to mice containing wild type MDMX (Pant et al., 2011). Resolving these 
conflicting observations will be important to understanding the regulation of MDM2 stability. 
In contrast, in vivo models have agreed that MDM2 does control MDMX stability. For 
example, Mdm2Y487A/Y487A mice lacking MDM2 E3 ligase activity have increased protein levels of 
MDMX (Tollini et al., 2014), which is in line with in vitro studies suggesting that that MDM2 E3 
ligase activity acts to ubiquitinate MDMX (Kawai et al., 2003; Pan and Chen, 2003). In addition, 
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MDMXΔRING, which does not have the ability to interact with MDM2, is not degraded compared to 
MDMX in untreated or IR-treated MEFs (Pant et al., 2011). 
In vitro studies have suggested that through their respective RING domains (Tanimura et 
al., 1999), MDMX serves to facilitate MDM2-mediated p53 ubiquitination (Linares et al., 2003). 
This facilitation could occur indirectly, which has been shown to occur in vitro, meaning that 
MDMX could redirect any possible MDM2 autoinhibitory ubiquitination unto itself, stabilizing 
MDM2 for p53 ubiquitination (Pan and Chen, 2003). In addition, it is possible that MDMX could 
directly facilitate p53 ubiquitination, meaning that MDMX could directly enhance the transfer of 
ubiquitin to p53. However, neither of these hypotheses have been directly tested in vivo.  
Stress-induced mdm2 transcription 
It is hypothesized that following stress, p53 transactivates mdm2 to facilitate its own 
degradation, instituting a regulatory feedback loop. Recently, this idea was directly tested in 
vivo, when Pant and Lozano (2014) generated mice bearing the Mdm2P2 allele. Point mutations 
were introduced to two p53 REs within the Mdm2 promoter region, preventing p53-mediated 
transactivation. In response to several p53-inducing stresses, p53 stabilization occurred in a 
similar manner in Mdm2P2 mice compared to WT mice, but p53 activity persisted longer in 
Mdm2P2 mice and MEFs, suggesting that basal levels of MDM2 are sufficient for p53 regulation 
in unstressed cells, but that the p53-MDM2 feedback loop is required for restraining stress-
induced p53 in vivo. In addition, the heterozygous deletion of MdmX appeared to enhance p53 
stability in Mdm2P2/P2;MdmX+/- MEFs, further suggesting the possibility that MDMX may enhance 
the degradation of stress-induced p53. 
Upstream p53 signaling through MDM2 and MDMX - DNA damage 
Activation of p53 requires transient inhibition of MDM2 and/or MDMX association, which 
is mediated through upstream signaling factors. Knockin mouse models have allowed us to 
appreciate the complex interactions of MDM2 and MDMX in p53 regulation, but they have also 
been used to delineate the contributions of many upstream signals to overall p53 activation 
 
16 
 
(Table 2). For instance, in vitro studies have shown that in response to DNA damage, ATM 
phosphorylates MDM2, inhibiting MDM2 E3 ligase activity and RING domain-dependent 
oligomer formation, thus stabilizing p53 (Cheng et al., 2009; Cheng et al., 2011). To specifically 
test the importance of ATM-mediated MDM2 phosphorylation at serine 394 (serine 395 in 
human), Gannon et al. (2012) generated the MDM2S394A mouse, replacing serine 394 with an 
alanine and disrupting MDM2 phosphorylation in vivo. Basal p53 levels and activity were 
unchanged in these mice, but in response to lethal doses of IR, MDM2S394A mice experience 
reduced p53 stabilization and activation. This translates to increased survival compared to WT 
mice, indicating that MDM2 serine 394 phosphorylation is an important event preceding the 
propagation of p53 stabilization and activation following IR-mediated DNA damage.  
MDMX is also phosphorylated following DNA damage, a signal which contributes to its 
own degradation. ATM phosphorylates MDMX serine 403 (402 in mouse) (Pereg et al., 2005), 
while CHK2 can phosphorylate serine 342 and serine 367 (341 and 367 in mouse) facilitating 
MDM2-mediated degradation of MDMX and stabilization of p53 (Chen et al., 2005; LeBron et 
al., 2006; Okamoto et al., 2005; Pereg et al., 2006). To study the importance of MDMX 
phosphorylation to p53 activation following DNA damage in vivo, Wang et al. (2009) generated 
MDMX3SA mice, in which serine 341, serine 367, and serine 402 of MDMX are replaced with 
alanine residues. Upon loss of MDMX phosphorylation capability, MDMX3SA appears to be 
stabilized at basal levels. Following IR treatment, MDMX3SA remains stable compared to MDMX, 
and p53 protein levels and transcriptional activity are lower in MDMX3SA MEFs and tissue. In 
addition, MDMX3SA mice are resistant to lethal IR treatment. These results are in congruence 
with the reduced basal and DNA damage-induced p53 activity observed in MDMX3SA mice, 
suggesting that MDMX phosphorylation and subsequent degradation is important for proper p53 
activation. These results also suggest that basal MDMX phosphorylation could be required for 
allowing basal levels of p53 activity.  
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It is clear from these studies that modification of MDM2 and MDMX by upstream 
signaling proteins mediates p53 activation in response to DNA damage in vivo. Interestingly, 
MDM2S394A mice are somewhat susceptible to tumor formation, indicating that ATM-mediated 
MDM2 phosphorylation is likely important for allowing proper p53 activation in response to 
endogenous, cancer-causing DNA damage events. Other upstream signals contribute to p53 
response to cancer-causing events, including the expression of oncogenes, which is described 
in further detail below. 
 
Oncogene-driven p53 activation 
p19ARF-mediated p53 regulation 
It is unsurprising that p53, in its role as a stress responder and tumor suppressor, is able 
to sense hyperproliferative signals mediated by activation or overexpression of oncogenes. 
Largely, this signaling is thought to be mediated by p19ARF (p14ARF in human), another tumor 
suppressor protein. Interestingly, p19ARF is named for the fact that it is read from an alternative 
reading frame of the Ink4a locus, from which another tumor suppressor protein, p16Ink4a (cyclin-
dependent kinase inhibitor 2A), is also transcribed (Ouelle et al., 1995).  
p19ARF has been demonstrated to perform both p53 dependent and independent 
functions towards overall tumor suppression, but for the purposes of this dissertation, I will focus 
on discussing the p53 dependent functions of p19ARF (Eischen et al., 1999; Kamijo et al., 1997; 
Qi et al., 2004). Sustained levels of oncogene activation (by proteins including MYC, BCR-ABL, 
RAS, and E2F1) activate the transcription of the Ink4a locus through as of yet unclear 
mechanisms (de Stanchina et al., 1998; Palmero et al., 1998; Radfar et al., 1998; Zindy et al., 
1998). Following upregulation, p19ARF interacts with MDM2 through its central acidic domain. 
MDM2-p19ARF interactions have been shown to have multifaceted mechanisms of action 
towards MDM2 inhibition. For example, p19ARF can sequester MDM2 in the nucleolus, 
preventing MDM2-p53 interaction (Tao and Levine, 1999; Weber et al., 1999), as well as 
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promote MDM2 degradation (Zhang et al., 1998). As a result of these interactions, p19ARF 
prevents MDM2-mediated p53 inhibition (Pomerantz et al., 1998). The current dogma holds that 
p19ARF is the primary signal from oncogene-induced hyperproliferation to p53 activation. 
Like p53-/- mice, p19Arf-/- mice develop spontaneous tumors, although with a longer 
latency to eventual death (6 months for p53-/- mice versus about 12 months for p19Arf-/- mice) 
(Donehower et al., 1992; Kamijo et al., 1999). In the presence of oncogene expression, this 
transformation is hastened. For example, when p19Arf+/- mice are placed into an Eμ-Myc 
background, lymphoma progression is typically accelerated, and the second p19Arf allele tends 
to be lost with high frequency (Eischen et al., 1999). 
There is also evidence to suggest that a feedback loop exists for p19ARF following the 
activation of p53 (Stott et al., 1998). In the absence of p53, p19ARF levels tend to be elevated 
in MEFs (Palmero et al., 1998). In addition, mutations in p53 or overexpression of MDM2 tend to 
be correlated with increased expression of p19ARF, with WT p53 re-expression resulting in 
decreased p19ARF protein levels and transcription levels (Kamijo et al., 1998; Robertson and 
Jones, 1998; Stott et al., 1998). Although p19ARF has not been shown to be a p53 target gene 
and the mechanism of its downregulation is still unclear, p19ARF downregulation following p53 
activation likely represents another mechanism through which undue p53 activation is 
prevented.  
 
Ribosomal protein-mediated MDM2-p53 regulation 
Although oncogenes can stimulate p53 activation through p19ARF, it has been recently 
appreciated that other consequences of oncogene activation can invoke p53 stabilization. 
Accelerated cell growth and division drive increased assembly of the protein-producing 
machinery, namely ribosomes, which are important in both cancer progression and p53 
activation.  
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Ribosomes are primarily responsible for translating mRNA to protein. In eukaryotes, the 
ribosome consists of ribosomal RNA (rRNA) and ribosomal proteins (RPs). During ribosomal 
biogenesis, RNA polymerase I (POLI) transcribes the 47S precursor rRNA, which is processed 
into the 5.8S, 18S, and 28S rRNAs. Meanwhile, POLIII transcribes the 5S rRNA, and POLII 
transcribes the genes coding the 79 ribosomal proteins, which are then translated in the 
cytoplasm and imported back into the nucleolus. Then, these RPs and rRNAs are assembled in 
approximately equimolar concentrations, where they form the 40S and 60S ribosomal subunits. 
The 40S subunit contains 30 unique RPs and a copy of the 18S rRNA, while the 60S subunit 
contains 49 unique RPs and a copy of each of the 5S, 5.8S and 28S rRNAs (Odintsova et al., 
2003; Vladimirov et al., 1996). The subunits are then exported from the nucleolus into the 
nucleoplasm, and then again exported into the cytoplasm where they form the 80S ribosome.  
Ribosome assembly is highly coordinated and essential for cell homeostasis and cell 
cycle progression. In yeast, it has been estimated that up to 60% of a cell’s energy is devoted to 
producing ribosomes (Warner, 1999). In addition, ribosome production is thought to be tightly 
coordinated with cell cycle progression. For instance, inhibition of rRNA synthesis via POLI or 
POLIII inhibition leads to G1 cell cycle arrest (Gomez-Herreros et al., 2013), while 
downregulation of RPL5 or RPL11 prohibits the translation of cyclins and prohibits cell cycle 
progression in a p53 independent manner (Teng et al., 2013). Disturbing any step of the 
assembly can result in what is called “nucleolar stress,” which is catastrophic to normal cellular 
functions.  
Ribosome biogenesis dysfunction  
Disruption of ribosomal biogenesis can occur in many ways, including the interruption of 
rRNA synthesis/processing, oncogenic activation, mutation/deletion of RPs, and changes in 
nutrient abundance. First, disruptions in rRNA synthesis can be produced pharmacologically. 
For example, in low concentrations Actinomycin D, a DNA damaging chemotherapeutic, inhibits 
POLI and prevents the transcription of the 47S precursor rRNA (Perry and Kelley, 1970; Sobell 
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et al., 1971). Similarly, 5-fluorouracil, a nucleotide analog also used as a chemotherapeutic, 
incorporates into rRNA, disrupting its synthesis and processing (Wilkinson et al., 1975). 
Ribosome biogenesis is also commonly misregulated in cancer. In particular, the c-MYC 
oncogene is a master regulator of ribosomal biogenesis and directly upregulates the 
transcription of many RPs (van Riggelen et al., 2010). MYC-mediated stimulation of ribosomal 
biogenesis occurs in several ways. First, MYC serves as a transcription factor with its binding 
partner MAX (myc-associated factor X), directly binding to REs known as E-Box motifs, which 
are present in the promoters of several RPs. MYC/MAX then recruit histone modifiers and other 
coregulatory factors, including TRRAP (transformation/transcription domain-associated protein), 
GCN5 (histone acetyltransferase GCN5), and TIP60 (histone acetyltransferase KAT5) to alter 
chromatin structure and promote gene transcription (McMahon et al., 2000). As well as 
promoting the production of RPs, MYC also regulates other factors required for ribosomal 
biogenesis, including B23 (nucleophosmin or NPM), NCL (nucleoloin), BOP1 (block of 
proliferation 1), NOP56 (nucleolar protein 56), FBL (fibrillarin), and DKC1 (dyskerin) (Watson et 
al., 2002). Independent of MAX, MYC can also associate with POLIII and stimulate the 
transcription of the 5S rRNA (Gomez-Roman et al., 2003). It has been recently appreciated that 
RP regulation directly contributes to the progression of c-MYC driven cancer. For example, loss 
of one allele of rpl24 drastically suppresses MYC driven lymphoma (Barna et al., 2008).  
Finally, given the intense energetic demand of ribosome production, it is unsurprising 
that changes in extracellular nutrient abundance can also drastically alter ribosomal biogenesis 
(Boulon et al., 2010). A key regulator of this process is the mTOR (mammalian target of 
rapamycin) complex, a well-characterized sensor of nutrient and growth factor status (Zoncu et 
al., 2011). Upstream changes in nutrient abundance, including amino acids, dictate mTOR 
activity (Hara et al., 1998). mTOR has been shown to control the transcription of the precursor 
47S and 5S rRNAs through controlling the localization and activity of all three RNA polymerases 
(Claypool et al., 2004; Hannan et al., 2003; Mahajan, 1994; Mayer et al., 2004). mTOR inhibition 
 
21 
 
also limits rRNA processing (Iadevaia et al., 2011). Likewise, the transcription of ribosomal 
protein mRNAs is also under mTOR control, though through unclear mechanisms (Powers and 
Walter, 1999). Through all of these activities, mTOR plays a direct role in regulating ribosome 
assembly in response to nutrient status (Li et al., 2006). 
Once active, mTOR also directly controls the phosphorylation of S6K (ribosomal protein 
S6 kinase beta-1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein) (Gingras et al., 
1999; Pullen and Thomas, 1997; Saitoh et al., 2002). Phosphorylated S6K then phosphorylates 
many other targets, including RPS6 (Ruvinsky and Meyuhas, 2006). The full consequences of 
RPS6 phosphorylation are poorly understood, but it has been postulated that it facilitates 
recruitment of the ribosome to the 5’ mRNA cap, facilitating translation (Roux et al., 2007). 
Meanwhile, phosphorylated 4E-BP1 releases eIF4E (eukaryotic translation initiation factor 4E) 
from inhibitory binding, allowing eIF4E (as part of a multisubunit complex) to recruit 40S 
ribosomal subunits to the 5’ cap of mRNAs and initiate translation. Through all of these 
activities, mTOR serves to couple nutrient sensing to ribosome biosynthesis and overall protein 
translation initiation.  
It is also important to note that loss of RP function is also associated with several 
disorders in humans, broadly classified as “ribosomopathies” (Narla and Ebert, 2010). Patients 
with these disorders tend to present with anemia and bone marrow failure, correlating with 
increased p53 activity. p53 plays an important role in regulating ribosome biogenesis, discussed 
below. 
p53 monitors ribosome biogenesis  
As a stress responder, p53 monitors changes in ribosomal biogenesis. Like p19ARF, 
several RPs have been found in vitro to bind the central zinc finger domain of MDM2, including 
RPL11, RPL5, and RPL23 (Chen et al., 2007; Dai and Lu, 2004; Dai et al., 2004; Zhang and Lu, 
2009; Zhang et al., 2003). In contrast, RPs have not yet been shown to bind to MDMX (Gilkes et 
al., 2006). It is thought that in the presence of nucleolar stress or altered ribosomal biogenesis, 
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RPs that are unaffiliated with a ribosome will bind to MDM2 and inhibit MDM2-mediated p53 
degradation to stabilize and activate p53 (Dai et al., 2004; Liu et al., 2016b). In this way, p53 is 
able to monitor that the supply of RPs is balanced and available for the assembly of ribosome 
machinery. RP-MDM2 binding is hypothesized to occur in two ways. First, it has been shown 
that disruption of the nucleolus allows RPs to be released into the nucleoplasm, where they can 
bind MDM2 (Bai et al., 2014; Bhat et al., 2004). Second, it has been shown that in the presence 
of altered ribosome biogenesis (via rps6 deletion), the translation of certain ribosomal proteins 
(specifically RPL11) is increased even in the absence of direct nucleolar disruption (Fumagalli et 
al., 2009b). An imbalance in RP translation would presumably allow for the production of more 
non-ribosome affiliated RPs, allowing for increased RP-MDM2 binding and increased p53 
activation.  
Interestingly, although cancer-associated mutations in MDM2 appear to be rare, several 
have been shown to occur in the zinc finger domain and disrupt RP-MDM2 interactions 
(Lindström et al., 2007). One of the more common of these cancer-associated mutations, 
MDM2C305F, resides in the region of RPL11 and RPL5 binding and prevents their interaction with 
MDM2, but allows other RPs (including RPL23) to maintain binding. In order to directly test the 
role of RPL11- and RPL5-MDM2 interaction towards p53 activation in vivo, Macias et al. (2010) 
generated the MDM2C305F mouse. Although mice bearing the MDM2C305F mutation present with a 
normal lifespan, they are highly susceptible to c-MYC induced tumorigenesis, due to reduced 
p53 activation (Macias et al., 2010). From this study, it was first confirmed that RP-MDM2 
interactions could directly translate oncogenic signals to p53 in vivo. 
It has also become increasingly apparent that RPs serve to regulate p53 in response to 
nutrient availability. This is not surprising, as p53 regulates cellular energy homeostasis 
(Vousden and Ryan, 2009; Zhang et al., 2010). Consistently, the MDM2C305F mouse, with its 
impaired RP-MDM2 binding, is deficient in p53-mediated fatty acid oxidation in response to 
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fasting (Liu et al., 2014b) and p53-mediated fat storage in response to sustained high-fat diet 
feeding (Liu et al., 2017).  
Though 16 RPs have been shown to bind to MDM2 (Liu et al., 2016b), RPL11 and RPL5 
appear to be particularly important for p53 activation due to ribosome biogenesis stress. While 
RP overexpression has been shown to elicit p53 stress response, others have shown that 
depletion of RPL5 or RPL11 can abrogate nucleolar stress-induced p53 activation caused by 
RPS6 downregulation (Fumagalli et al., 2012). The distinct importance of RPL11 and RPL5 
towards p53 activation is not completely understood, but several observations point to their 
importance in ribosome assembly. RPL5 and RPL11 bind with the 5S rRNA to produce a pre-
ribosomal complex prior to the formation of the 60S subunit (Donati et al., 2013). In addition, 
RPL11 and RPL5 reside in the interface of the 60S and 40S ribosome subunits (Ben-Shem et 
al., 2010), which suggests that their disruption could be particularly harmful to ribosome 
assembly. Much of RP-MDM2 pathway research has focused on RPL11 and RPL5, and the 
contributions of other RPs towards p53 activation remain incomplete. 
 
p19ARF participates in the regulation of ribosome biogenesis 
Although p19ARF has been shown to interact with and regulate MDM2, it also plays a 
role ribosome biogenesis, complicating our understanding of the necessities of each of these 
functions towards the activation of p53. As mentioned previously, p19ARF is often localized to 
the nucleolus, where ribosome biogenesis occurs. p19ARF appears to exhibit increased 
nucleolar localization during progression towards replicative senescence, as well as in the 
presence of increased c-MYC expression (Weber et al., 1999), suggesting that p19ARF may 
contribute to or enhance RP-mediated p53 activation. Later discoveries clearly suggested this 
possibility. 
For example, nucleolar p19ARF had been found to suppress rRNA transcription by 
preventing the nucleololar localization of RNA helicase DDX5 and RNA polymerase I 
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transcription termination factor TTF-I (Lessard et al., 2010; Saporita et al., 2011), as well as to 
inhibit the processing of the 47S precursor RNA (Sugimoto et al., 2003). p19ARF also interacts 
with and degrades B23 (Bertwistle et al., 2004; Itahana et al., 2003), a protein that chaperones 
the import of other auxiliary ribosome biogenesis factors (Lindström, 2010). In addition to 
degrading B23, p19ARF sequesters B23 in the nucleolus (Brady et al., 2004), preventing it from 
performing its chaperoning functions. 
These studies indicate that p19ARF is intimately linked to ribosome biogenesis, adding 
another level to its regulation of p53. Importantly, these studies raise the question of whether 
p19ARF contributes to facilitating RP-MDM2 interaction through its ability to disrupt ribosome 
assembly and processing. It is evident that RPs and p19ARF play intertwining roles to regulate 
MDM2, and teasing out the individual contributions of these functions will be important towards 
understanding the biology of p53 activation. 
 
p53 and cancer therapies 
A growing number of studies have suggested targeting mutant p53 or restoring WT p53 
as cancer treatment strategy (Burgess et al., 2016; Soragni et al., 2016), and many drugs 
specifically targeting MDM2-p53 or MDMX-p53 interaction have been developed (Burgess et al., 
2016; Vassilev et al., 2004; Wade et al., 2013). Mouse models have supported these strategies 
in principle. For example, MDMX loss in c-MYC-driven tumors extends survival after p53ER 
restoration (Garcia et al., 2011), and CreER-mediated p53neo restoration in transplanted MDM2-
overexpressing tumors also appears to extend survival in mice (Li et al., 2014). However, so far 
these treatment strategies have enjoyed limited efficacy in the clinic.  
In vivo studies have also suggested that other approaches could be taken to restore p53 
function in human cancers harboring WT p53, such as inhibiting MDM2-MDMX binding or 
MDM2 E3 ligase activity. The inhibition of MDM2 E3 ligase activity may be especially attractive 
as a treatment strategy, because the MDM2Y487A mouse model shows that genetic ablation of 
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MDM2 E3 ligase activity is tolerated by the adult mouse as well as the developing embryo 
(Tollini et al., 2014), which suggests that this strategy could avoid toxicity issues. In response to 
p53-activating stimuli, cells containing MDM2Y487A demonstrate increased p53 stability and 
activity. Although several inhibitors of MDM2 E3 ligase activity have been identified and shown 
to stabilize p53 (Herman et al., 2011; Roxburgh et al., 2012; Yang et al., 2005), their activity and 
specificity may not yet be sufficient for human use. So far, MDM2 E3 ligase inhibitors have not 
been tested in humans, but several other small-molecule MDM2 antagonists are currently in 
Phase I trials (Burgess et al., 2016). Mouse models have also suggested that complete 
restoration of p53 function in the presence of radiation should be used with caution, as 
abundant p53 activity is toxic to several tissues (Ringshausen et al., 2006; Tollini et al., 2014; 
Zhang et al., 2014a). Understanding p53 and its regulation in cancer will be important to 
understand for utilization and the potential repercussions of p53-reactivating therapies. 
 
Dissertation goals 
Mouse models of altered MDM2 and MDMX have given us a clearer understanding of 
the in vivo roles of MDM2 and MDMX in p53 regulation (Figure 1) and established that MDM2 
and MDMX proteins are master p53 regulators. Broadly, this dissertation will focus on 
characterizing the in vivo roles of RP-MDM2 interaction in p53-mediated tumor prevention. I will 
also present preliminary data exploring the in vivo functional consequences of the loss of MDM2 
E3 ligase function (while maintaining MDMX interaction) on p53 activity in response to MYC-
driven lymphoma. Below is a more detailed summary of the goals of this dissertation.  
First, although RP-MDM2 interaction has been shown to promote p53 activation and 
tumor suppression in MYC-induced lymphoma (Macias et al., 2010), it was unknown whether 
these interactions are dependent on p19ARF (Eischen et al., 1999), the canonical oncogene 
activation signal to p53 that is also heavily involved in nucleolar signaling. Chapter 2 will 
specifically explore how, in the context of c-MYC-driven lymphoma progression, RPs likely 
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function independently of p19ARF to induce p53 tumor suppressive functions. To answer this 
question, this work will rely on the use of the MDM2C305F mouse, in which RPL11- and RPL5-
MDM2 interactions are disrupted, coupled with mice containing a p19ARF deletion allele. 
Likewise, Chapters 3 and 4 will touch on the importance of p19ARF independent RP-MDM2 
interactions in other cancer contexts. 
Second, although the RP-MDM2-p53 response pathway has been shown to be 
important for preventing c-MYC driven cancer, it was unknown whether RP-MDM2 interactions 
could be induced by other cancer drivers. Protein-producing machinery is thought to be critical 
for supporting uncontrolled proliferation, so it is possible that cancers that are not initiated by c-
MYC could still promote p53 activation through RP-MDM2 interactions. Chapters 3 and 4 of this 
dissertation will explore how the RP-MDM2-p53 pathway is regulated in response to RAS 
oncogene overexpression and APC deletion, also using the MDM2C305F mouse. 
Third, although RP-MDM2 interaction appears to be important for p53 activation in 
lymphoma, it is possible that this is a tumor- or tissue-specific phenomena. Clearly, different 
tissue and cancer types will have vastly different cell and genomic architectures. If this 
knowledge is to be used towards the discovery of new therapies, it is important to determine in 
which cell/tissue/tumor contexts RP-MDM2 interactions may be the most consequential. 
Chapters 3 and 4 will explore how RP-MDM2 interactions are differentially important in 
melanoma, small intestine, and colon cancers. 
Finally, Chapter 5 will explore how preventing p53 degradation by genetically 
manipulating MDM2 E3 ligase activity could allow for increased p53 activity and organismal 
longevity, suggesting the possibility that MDM2 E3 ligase inhibitors could be used in the future 
as a safe method of reactivating p53 and allowing it to perform its tumor suppressive functions. 
Ultimately, the studies presented here aim to understand the intricacies of MDM2/MDMX-p53 
regulation in order to facilitate the development of future therapies.  
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Table 1.1 Mdm2 and MdmX knockout mice 
Tissue MDM 
model 
p53 
alleles 
Cre 
transgene 
Phenotypes and p53 responses Refs 
Whole Body Mdm2puro WT N/A Decreased body weight, hematopoietic defects, 
increased apoptosis, increased p53 activity 
(Mendrysa et 
al., 2003) 
MdmXΔEx6 
(Truncation) 
WT N/A Embryonic lethality, increased p53 activity on 
p53ΔP/ΔP background 
(Bardot et al., 
2015) 
Central 
Nervous 
System 
Mdm2-/- p53LSL/- Nestin-Cre Embryonic lethality, increased p53 protein levels 
and activity, increased apoptosis 
(Francoz et 
al., 2006) 
MdmX-/- p53LSL/- Nestin-Cre Microcephaly, growth retardation, increased p53 
activity and cell cycle arrest 
Mdm2FM/FM WT Nestin-Cre Neonatal lethality, hydrancephaly, increased p53 
protein levels and activity, aberrant apoptosis and 
proliferation 
(Grier et al., 
2002; Xiong et 
al., 2006) 
MdmXFX/FX WT Nestin-Cre Neonatal lethality, porencephaly, increased p53 
activity, aberrant apoptosis and proliferation  
Mdm2-/- p53ER/- N/A No discernable phenotypes (Ringshausen 
et al., 2006) 
MdmX-/- p53ER/- N/A Increased p53 activity, increased apoptosis in 
subventricular zones 
(Garcia et al., 
2011) 
Bone Mdm2F11-12 WT Col3.6-Cre E19.5 lethality, skeletal defects, elevated p53 
activity but not protein levels, reduced proliferation 
(Lengner et 
al., 2006) 
Intestine 
 
Mdm2FM/FM WT Villin-Cre Normal lifespan, intestinal abnormalities with 
eventual recovery, increased p53 activity and 
protein levels 
(Valentin-
Vega et al., 
2008) 
MdmXFX/FX WT Villin-Cre No major defects, increased p53-dependent 
apoptosis and activity in proliferating cells 
(Valentin-
Vega et al., 
2009) 
Mdm2-/- p53ER/- N/A Atrophy of villi and crypts, increased apoptosis (Ringshausen 
et al., 2006) 
MdmX-/- p53ER/- N/A Increased apoptosis (Garcia et al., 
2011) 
Mdm2FM/- WT CAG-Cre 
(Tamoxifen) 
Atrophy in villi and increased apoptosis in crypts 
of 2-4 month old mice, no phenotypes in 16-18 
month old mice 
(Zhang et al., 
2014a) 
Heart 
 
 
 
Mdm2FM/- WT αMyhc-Cre E13.5 lethality, severe defects, increased p53 
protein and apoptosis 
(Grier et al., 
2006) 
MdmXFX/- WT αMyhc-Cre Normal, with some premature death at 12 months 
of age 
Mdm2FM/- WT CAG-Cre 
(Tamoxifen) 
Tissue fibrosis, increased p53 activity and protein 
levels 
(Zhang et al., 
2014a) 
Mdm2-/- p53ER/- N/A No discernable phenotypes (Ringshausen 
et al., 2006) 
MdmX-/- p53ER/- N/A No discernable phenotypes (Garcia et al., 
2011) 
Endothelium Mdm2FM/FM WT Tie2-Cre Embryonic lethality, severe vascular defects, 
increased p53 activity 
(Zhang et al., 
2012) 
Skin Mdm2F11-12 WT K5-Cre Progressive hair loss and decreased skin 
elasticity, increased p53 protein levels and 
activity, increased senescence  
(Gannon et 
al., 2011) 
Smooth 
Muscle 
Mdm2FM/FM WT Sm22-
CreERT2 
Death within 12 days after tamoxifen injection, 
increased p53 protein levels and activity, 
increased apoptosis 
(Boesten et 
al., 2006) 
MdmXFX/FX WT Sm22-
CreERT2 
No discernable phenotypes 
Red Blood 
Cells 
 
Mdm2FM/FM WT EpoR-GFP-
Cre 
E13 lethality, defects in erythropoiesis, increased 
p53 activity 
(Maetens et 
al., 2007) 
MdmXFX/FX WT EpoR-GFP-
Cre 
Death between E12.5 and 21 days after birth, 
anemia, increased p53 activity 
Lens 
Epithelial 
Cells 
 
Mdm2FM/FM WT Le-Cre Defects in lens development, normal birth ratios 
but hyperglycemia and neonatal lethality (1 week) 
present, increased p53 levels and apoptosis, 
decreased cell proliferation 
(Zhang et al., 
2014b) 
 
MdmXFX/FX WT Le-Cre Eyeless, normal birth ratios and survival into 
adulthood, increased p53 levels and apoptosis, 
decreased cell proliferation 
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Table 1.2 Mdm2 and MdmX knockin mice 
MDM 
model 
Modification Phenotypes and p53 responses Refs 
Mdm2C462A Disrupts RING domain 
and MDMX interaction 
Embryonic lethal, increased p53 stability and activity (Itahana et al., 
2007) 
Mdm2S394A Disrupts ATM 
phosphorylation 
Radioresistant, accelerated spontaneous and MYC-induced 
tumor formation, resistance to radiation-induced lymphoma 
(Carr et al., 
2016; Gannon 
et al., 2012) 
Mdm2C305F Disrupts ribosomal 
protein interaction 
Decreased p53 stabilization and activity following ribosomal 
stress, increased MYC-induced tumors, increased APC 
loss-induced colon tumors 
(Liu et al., 
2016a; Macias 
et al., 2010; 
Meng et al., 
2015b) 
Mdm2Y487A Disrupts E3 ligase 
function 
Increased p53 stability, increased p53 activity after 
irradiation, increased radiosensitivity 
(Tollini et al., 
2014) 
Mdm2SNP309G Increases Mdm2 
expression 
Increased spontaneous tumorigenesis, reduced p53 levels (Post et al., 
2010) 
Mdm2P2 Disrupts p53-mediated 
Mdm2 transcription 
Prolonged p53 activity after DNA damage, no apparent 
change in p53 stability, increased radiosensitivity 
(Pant and 
Lozano, 2014) 
Mdm22DD Mimics constitutive AKT 
phosphorylation in 
mammary tissue 
Accelerated ERBB2-induced tumors, decreased p53 
expression 
(Cheng et al., 
2010) 
MdmXΔRING Removes RING domain 
functions 
Embryonic lethal, increased p53 activity (Pant et al., 
2011) 
MdmXC462A Disrupts RING domain 
and MDM2 binding 
Embryonic lethal, increased p53 activity and protein levels (Huang et al., 
2011) 
MdmX3SA Disrupts AKT, ATM, and 
CHK2 phosphorylation 
Radioresistant, accelerated MYC-induced tumor formation, 
decreased p53 protein levels and activity 
(Wang et al., 
2009) 
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Figure 1. p53 regulation requirements are context dependent 
 
A. Schematic of MDM2 and MDMX protein modifications that have been generated by knockin 
mouse models.  
 
B. During embryogenesis, both MDM2 and MDMX are required for proper control of p53 activity. 
The formation of an MDM2-MDMX heterodimer is also required to restrain p53, but MDM2 E3 
ligase activity is dispensable at this time. 
 
C. In unstressed adult tissues, the necessity of MDMX or MDM2-MDMX heterodimer formation 
for proper p53 control is tissue-dependent. MDM2-mediated p53 ubiquitination may still occur in 
these tissues, which may require MDMX.  
 
D. After stress, such as DNA damage, MDM2 E3 ligase activity is required to return p53 protein 
to basal levels and control p53 activity. This may or may not require MDM2-MDMX heterodimer 
formation. 
 
p53 BD=p53 binding domain, NLS=nuclear localization signal, NES=nuclear export signal, 
ACIDIC=acidic domain, ZINC=zinc finger domain, RING=RING finger domain, Ub=ubiquitin, 
E2=E2 ubiquitin-conjugating enzyme 
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CHAPTER 2: ONCOGENIC C-MYC-INDUCED LYMPHOMAGENESIS IS INHIBITED NON-
REDUNDANTLY BY THE P19ARF-MDM2-P53 AND RP-MDM2-P53 PATHWAYS2 
INTRODUCTION 
The MYC protein (c-MYC) is a helix-loop-helix leucine zipper transcriptional regulator, 
which forms specific DNA-binding heterodimers with the MAX protein to control a variety of 
normal cellular functions (Meyer and Penn, 2008). In addition, c-MYC facilitates the recruitment 
of POLI to ribosomal DNA promoters (Arabi et al., 2005), promotes the transcription of 
ribosomal proteins (RPs) by activating POLII (Menssen and Hermeking, 2002) and activates 
POLIII-mediated transcription of 5S ribosomal RNA and transfer RNA (Gomez-Roman et al., 
2003). c-MYC also transactivates many other genes involved in ribosomal biogenesis (De 
Marval and Zhang, 2011). Increased c-MYC expression is frequently observed in human 
cancers and it can confer a growth advantage to cells by providing constitutive proliferative 
signals (Mateyak et al., 1997). However, c-MYC overexpression may also initiate an 
endogenous apoptotic program (Evan et al., 1992), and through this function trigger a potent 
tumor surveillance response that effectively opposes hyperproliferation by killing those cells in 
which c-MYC levels exceed a safe threshold (Packham and Cleveland, 1995). 
The p53 transcription factor is a critical tumor suppressor, and when activated it triggers 
cell cycle arrest, differentiation, apoptosis and senescence. The TP53 gene is mutated in ~50% 
of all human tumors and is often referred to as the ‘guardian’ of the genome (Lane, 1992; Meng 
                                               
2 This chapter is adapted from a research article originally published in Oncogene. Xuan Meng, Yanping 
Zhang and I designed the study. Xuan Meng performed all of the experiments. Xuan Meng, Yanping 
Zhang, and I analyzed the data. Xuan Meng, Yanping Zhang and I wrote and edited the manuscript. 
Jiahong Dong and Yanping Zhang finalized the manuscript. The original citation is as follows: Meng, X., 
Carlson, N., Dong, J., and Zhang, Y. (2015a). Oncogenic c-Myc-induced lymphomagenesis is inhibited 
non-redundantly by the p19Arf–Mdm2–p53 and RP–Mdm2–p53 pathways. Oncogene 34, 5709-5717. 
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et al., 2014). p53 is primarily regulated by the E3 ubiquitin ligase MDM2, which binds to p53 to 
both block its transactivation domain and to promote its ubiquitination and degradation. 
However, p53 enhances mdm2 transcription, thus forming an autoregulatory feedback loop (Wu 
et al., 1993). The tumor suppressor p19ARF (p14ARF in human) is transcribed from an 
alternative reading frame of the INK4a/ARF locus. p19ARF physically binds to MDM2, inhibiting 
its E3 ligase activity, thereby stabilizing and activating p53, which constitutes a p19ARF-MDM2-
p53 signaling pathway (Sherr, 2006). Oncogenic c-MYC-driven tumors receive a selective 
advantage from inactivation of the p19ARF-MDM2-p53 pathway, diminishing its protective 
checkpoint function and accelerating normal cell progression to malignancy; this accelerated 
progression to malignancy is observed in Eμ-Myc;p19Arf−/− transgenic mice, a model for 
Burkitt’s lymphoma, which die of lymphoma within a few weeks of birth (Eischen et al., 1999). 
Previous evidence has demonstrated that several RPs such as RPL5, RPL11 and 
RPL23 interact with MDM2 to inhibit its E3 ligase function, thereby stabilizing and activating 
p53, suggesting an RP-MDM2-p53 pathway (Zhang and Lu, 2009). In vivo studies have 
established the physiological significance of the RP-MDM2 interaction in responding to 
ribosomal stress to activate p53, providing evidence for a p53 checkpoint mediated by the RP-
MDM2 interaction, which is capable of monitoring the integrity of ribosome biogenesis (Macias 
et al., 2010). Furthermore, with use of the Eμ-Myc transgenic mouse model, which constitutively 
expresses c-MYC in the B-cell lineage and develops B-cell lymphoma at an early age (Adams et 
al., 1985), we have demonstrated that the RP-MDM2-p53 pathway, similar to the p19ARF-
MDM2-p53 pathway, plays a critical role in preventing oncogenic c-MYC-induced 
lymphomagenesis (Macias et al., 2010). 
Previous studies have shown that p19ARF can disturb ribosomal biogenesis by 
interacting with nucleophosmin (B23/NPM) and inhibiting pre-ribosomal RNA processing 
(Itahana et al., 2003; Sugimoto et al., 2003). More recently, it has been shown that p19ARF 
inhibits the function of RNA polymerase I transcription termination factor TTF-I (Lessard et al., 
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2010) and DDX5 RNA helicase (Saporita et al., 2011) by preventing their nucleolar localization, 
thereby inhibiting ribosomal biosynthesis. These studies raise an interesting question as to 
whether the p19ARF-MDM2-p53 and the RP-MDM2-p53 pathways might function in a linear 
manner as a p19ARF-RP-MDM2-p53 pathway, where p19ARF additionally activates p53 by 
inhibiting RP biosynthesis. As such, p19ARF deletion or MDM2C305F mutation, which disrupts 
RP-MDM2 binding, would result in similar consequences in the context of c-MYC 
overexpression. To gain insight into the interrelationship and possible cooperative mechanisms 
between p19ARF-MDM2-p53 and RP-MDM2-p53 pathways, we studied tumorigenesis in mice 
with disruption of each pathway individually and in combination. 
 
RESULTS  
MDM2C305F mutation does not accelerate p19Arf deletion initiated spontaneous tumor 
development 
Previous studies have shown that mice with homozygous deletion of p19Arf (p19Arf−/−) 
are predisposed to spontaneous tumor development (Kamijo et al., 1999), whereas mice with 
homozygous mutation of Mdm2C305F (henceforth referred to as Mdm2m/m), which prevents MDM2 
binding to RPL5 and RPL11 (Lindström et al., 2007), do not develop spontaneous tumors 
(Macias et al., 2010). Because p19ARF interacts with and inhibits B23/NPM (Itahana et al., 
2003; Sugimoto et al., 2003), RNA polymerase I TTF-I (Lessard et al., 2010) and DDX5 
(Saporita et al., 2011) and as these factors are all involved in ribosomal biosynthesis, we 
speculated that the p19ARF-MDM2-p53 and the RP-MDM2-p53 pathways might be functionally 
interconnected. We crossed p19Arf−/− and Mdm2m/m mice to generate double-heterozygous 
Mdm2+/m;p19Arf+/− mice and then intercrossed the Mdm2+/m;p19Arf+/− mice to generate 
Mdm2m/m;p19Arf−/− compound mice. Of the 186 pups born from intercross of the double-
heterozygotes, a predicted Mendelian inheritance was observed (Figure 2.1a, shown are only 
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three genotypes for simplicity), indicating that concurrent disruption of p19ARF-MDM2-p53 and 
RP-MDM2-p53 pathways does not affect embryogenesis and early development.  
A survival study was carried out to examine the effect of concurrent p19Arf deletion and 
Mdm2C305F mutation on spontaneous tumor formation and lifespan in the mice. Consistent with 
previous studies, mice heterozygous for Mdm2C305F mutation (Mdm2+/m) and p19Arf deletion 
(p19Arf+/−) did not show any pathological or physiological changes. In addition, we did not 
observe any phenotypic changes in double-heterozygous Mdm2+/m; p19Arf+/− mice (data not 
shown). Consistent with previous reports (Kamijo et al., 1999), mice with homozygous deletion 
of p19Arf were predisposed to tumors, mostly lymphomas, and died shortly after the 
development of disease, resulting in a notably shorter lifespan compared to WT mice (Figure 
2.1b). However, mice with homozygous Mdm2C305F mutation did not show observable 
differences in spontaneous tumor formation and lifespan from the WT littermates. Interestingly, 
double-homozygous compound mice (Mdm2m/m;p19Arf−/−) did not show accelerated 
spontaneous tumor formation compared to mice with only p19Arf deletion, instead they 
displayed slightly decelerated tumor formation (Figure 2.1b; log-rank test P=0.06); the reasons 
for the deceleration remain unclear. We have noticed that the mean latency for survival of the 
p19Arf−/− mice in our experiment is 16 months, significantly longer than the previous report of ~ 
10 months (Kamijo et al., 1999). One likely reason for the difference is that our mice are in 
>99% pure C57BL6 background as compared to a mixed 129svj/C57BL6 background in the 
previous study. It has been reported that C57BL6 mice are more resistant to spontaneous tumor 
formation than 129svj mice (Hoag, 1963; Smith et al., 1973), and C57BL6 mice are more 
efficient in total leukocyte recruitment than 129svj mice (White et al., 2002), a function important 
in preventing lymphomagenesis (Shetty et al., 2012). 
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Concurrent disruption of the p19ARF-MDM2-p53 and the RP-MDM2-p53 pathways further 
accelerates oncogenic c-MYC-induced lymphomagenesis 
To further investigate the consequence of disruption of the p19ARF-MDM2-p53 and the 
RP-MDM2-p53 pathways on tumorigenesis, we generated Eμ-Myc transgenic mice on Mdm2m/m 
and p19Arf−/− backgrounds individually and in combination, and compared their tumor-free 
survival time. Eμ-Myc;WT mice died of pre-B/B-cell lymphoma with a mortality curve consistent 
with previous studies (Figure 2.2) (Adams et al., 1985; Eischen et al., 1999). The median 
survival of Eμ-Myc;p19Arf+/− mice was 15.6 weeks, significantly shorter than Eμ-Myc;WT mice 
(Figure 2.2a, P=0.003), whereas the median survival for Eμ-Myc;Mdm2+/m mice was not 
significantly different from that of Eμ-Myc;WT mice (Figure 2.2b, P=0.5). In contrast, 
homozygous Eμ-Myc;p19Arf−/− and Eμ-Myc;Mdm2m/m mice developed aggressive, rapid onset 
pre-B/B-cell lymphoma with a mean survival of 10.1 and 11.6 weeks, respectively (Figures 2.2a-
b), indicating that both p19ARF-MDM2 and RP-MDM2 binding function as barriers to oncogenic 
c-MYC-induced tumorigenesis. 
To determine if the RP-MDM2-p53 and p19ARF-MDM2-p53 represent two parallel 
pathways or a single linear p19ARF-RP-MDM2-p53 pathway against Eμ-Myc transgene-induced 
lymphomas, we generated Eμ-Myc;Mdm2m/m;p19Arf−/− compound mice and evaluated the 
impact of the double mutation on mouse survival. Remarkably, Eμ-Myc;Mdm2m/m;p19Arf−/− mice 
demonstrated a median survival of 7.6 weeks, evidently shorter than the lifespan observed in 
either Eμ-Myc;Mdm2m/m or Eμ-Myc;p19Arf−/− mice (Figure 2.3a). These data indicate that the 
p19ARF-MDM2-p53 and the RP-MDM2-p53 interactions likely represent two independent 
signaling pathways possessing non-overlapping tumor suppression functions. We noticed that 
the mean survival of Eμ-Myc;p19Arf−/− mice is significantly shorter than that of Eμ-Myc;Mdm2m/m 
mice (10.1 vs 11.6 weeks; Figure 2.3a, P=0.0001). This indicates that in addition to directly 
inhibiting MDM2 and activating p53, p19ARF may also partially exert its function through the 
RP-MDM2-p53 pathway by inhibiting ribosomal biogenesis (Itahana et al., 2003; Sugimoto et 
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al., 2003). No significant difference in body weight gain was observed among the genotypes in 
the early stages of the mouse lifespan (Figure 2.3b). In later stages, however, the Eμ-
Myc;p19Arf−/− mice grow larger, and the Eμ-Myc;Mdm2m/m mice grow smaller than the Eμ-
Myc;WT control mice. The reason for this discrepancy is unclear. In the final stages of their life, 
the mice began to lose weight from cancerous cachexia, indicating that these Eμ-Myc 
transgenic mice die of cachexia due to malignant tumor development. 
 
Mdm2m/m;p19Arf−/− mice demonstrate accelerated c-MYC-induced tumorigenesis and metastasis 
Splenomegaly is a common result of infiltration of lymphomas. Eμ-Myc transgenic mice 
typically present with a massive enlargement of the spleen (Sidman et al., 1988). We measured 
the length of the spleens from mice at 9 weeks of age. As shown in Figure 2.4a, Eμ-Myc;WT 
mice had an average spleen length of 1.6 cm, as compared to 1.1 cm spleen length in WT, non-
transgenic mice. Both homozygous Mdm2C305F mutation and p19Arf deletion accelerated 
splenomegaly, with average spleen size increased in Eμ-Myc;Mdm2m/m and Eμ-Myc;p19Arf−/− 
transgenic mice to 2.4 and 2.5 cm, respectively. Compound mice harboring both Mdm2C305F 
mutation and p19Arf deletion demonstrated further accelerated splenomegaly, and the average 
spleen length of Eμ-Myc;Mdm2m/m;p19Arf−/− mice was 3.8 cm at 9 weeks of age. 
We next examined the invasive nature of Eμ-Myc-induced lymphomas in the spleen, 
liver, and kidney tissues isolated from 9 week old mice. Spleen metastasis occurred earlier than 
other organs, and the structure of the spleens in mice harboring Eμ-Myc transgene was already 
destroyed at this age. As shown in Figure 2.4b, expression of the Eμ-Myc correlates with an 
increased number of small lymphocytes within the cords and sinuses, as well as some nodular 
aggregates surrounding a small vessel, indicative of spleen metastasis. The most significant 
metastasis was observed in the spleen of Eμ-Myc;Mdm2m/m;p19Arf−/− compound mice. Similar to 
the spleen, lymphocyte infiltration in the liver can be seen in each of the Eμ-Myc transgenic 
mice, specifically in the region surrounding the central veins. Not surprisingly, the most obvious 
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liver metastasis was observed in Eμ-Myc;Mdm2m/m;p19Arf−/− compound mice (Figure 2.4b). 
Kidney metastasis usually occurs in advanced or late-stage lymphomas, and metastatic tumor 
cells were detected as diffuse and disorganized cells infiltrating between the glomerulus and 
tubules (Eischen et al., 2004). As shown in Figure 2.4b, in WT, Eμ-Myc;WT, Eμ-Myc;Mdm2m/m 
and Eμ-Myc;p19Arf−/− mice, kidneys revealed no discernible pathological phenotype, and 
lymphocyte infiltration is only obvious in the compound Eμ-Myc;Mdm2m/m;p19Arf−/− mice. 
Together, these data indicate that individually disrupting the p19ARF-MDM2-p53 pathway by 
p19Arf deletion or the RP-MDM2-p53 pathway by Mdm2C305F mutation augments the invasive 
nature of Eμ-Myc-induced lymphoma. Simultaneous disruption of both pathways, as seen in Eμ-
Myc;Mdm2m/m;p19Arf−/− mice, leads to even more malignant and aggressive lymphomagenesis. 
To determine if cells in Eμ-Myc-expressing spleens retained their proliferative capacity, 
Ki-67 staining was used to assess cellular proliferation by immunohistochemistry (IHC). As 
shown in Figure 2.5a, in the absence of the Eμ-Myc transgene Ki-67 expression was barely 
detectable in the spleen of 9 week old WT mice (Ki-67 index 0.4). In Eμ-Myc;WT mice, we 
detected increased numbers of Ki-67-positive cells (Ki-67 index 2.8); the number of Ki-67-
positive cells was further increased in spleens from Eμ-Myc;Mdm2m/m and Eμ-Myc;p19Arf−/− 
mice (Ki-67 index 12.2 and 14.6, respectively). In spleens of Eμ-Myc;Mdm2m/m;p19Arf−/− 
compound mice the number of Ki-67-positive cells was even further increased (Ki-67 index 
53.9). 
To examine apoptosis in the spleen tumors of the transgenic mice, TUNEL (terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) immunohistochemical 
analysis was performed. Representative pictures of TUNEL-stained sections are shown in 
Figure 2.5b. Consistent with previous studies that Eμ-Myc induces apoptosis in transgenic 
spleens, in spleens of 9 week old Eμ-Myc;WT, Eμ-Myc;Mdm2m/m and Eμ-Myc;p19Arf−/− mice, we 
detected high levels of TUNEL-positive apoptotic cells (14.6, 13.6, and 14.4%, respectively). 
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However, in spleens of Eμ-Myc;Mdm2m/m;p19Arf−/− compound mice the number of TUNEL 
positive apoptotic cells decreased to 6.2%. 
Local invasion and distant metastasis of lymphomas are commonly observed in Eμ-Myc 
transgenic mice; we therefore analyzed liver tissues from individual mice for signs of metastasis. 
Eμ-Myc transgenic mice were monitored for signs of moribund conditions (Toth et al., 2014), 
and moribund mice were killed and the livers were collected and examined for sign of 
metastasis. Tumors were detected in the livers of Eμ-Myc;WT transgenic mice at an average 
age of 22 weeks (Figure 2.6). In contrast, tumor onset in the liver was detected much earlier in 
Eμ-Myc;Mdm2m/m, Eμ-Myc;p19Arf−/− and Eμ-Myc;Mdm2m/m;p19Arf−/− mice, with progressively 
shorter time of onset at 13, 11 and 9 weeks, respectively (Figure 2.6). These results 
demonstrate that individually the Mdm2C305F mutation and p19Arf deletion promote local 
invasion and distant metastasis of Eμ-Myc-induced lymphomas, with p19Arf deletion having a 
stronger effect than Mdm2C305F mutation, which is consistent with the shorter lifespan of the Eμ-
Myc;p19Arf−/− mice compared to the Eμ-Myc;Mdm2m/m mice (Figure 2.3a). Concurrent 
Mdm2C305F mutation and p19Arf deletion further accelerates the aggressiveness of the 
lymphoma, resulting in an even shorter lifespan, consistent with the notion that the p19ARF-
MDM2-p53 and the RP-MDM2-p53 represent two non-redundant, independent pathways for 
tumor suppression. 
 
The p19ARF-MDM2-p53 and the RP-MDM2-p53 pathways function independently in oncogenic 
c-MYC-induced p53 activation 
Oncogene c-MYC induces p53 to promote apoptosis, functioning as part of a major 
tumor suppression network. Because Eμ-Myc-induced lymphomagenesis in mice can be further 
accelerated by concurrent disruption of the p19ARF-MDM2-p53 and the RP-MDM2-p53 
pathways compared to disruption of either pathway alone, we reasoned that the two pathways 
could each individually be required for oncogenic c-MYC-induced p53 activation. To test this 
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hypothesis, spleen extracts from 4 week old, non-tumor-bearing Eμ-Myc;WT, Eμ-Myc;Mdm2m/m, 
Eμ-Myc;p19Arf−/− and Eμ-Myc;Mdm2m/m;p19Arf−/− transgenic mice, as well as from their non-
transgenic counterparts, were analyzed for p53 expression. At this age the spleens harboring 
the Eμ-Myc transgene are moderately hyperplastic, but still comparable in size and morphology 
to the spleens of non-transgenic mice (data not shown). The Eμ-Myc transgene markedly 
induced p53 protein expression in WT mouse spleens (Figure 2.7a, lane 2), which is 
accompanied by increased expression of p19ARF, RPL5 and RPL11, all of which are known 
transcriptional targets of c-MYC (van Riggelen et al., 2010; Zindy et al., 1998). The Eμ-Myc 
transgene also induced p53 expression in Eμ-Myc;Mdm2m/m and Eμ-Myc;p19Arf−/− spleens to a 
similar level, although slightly lower than what is detected in Eμ-Myc;WT spleens (Figure 2.7a, 
compare lanes 2, 4 and 6). Remarkably, p53 induction was not observed Eμ-
Myc;Mdm2m/m;p19Arf−/− compound mouse spleens (Figure 2.7a, lane 8). These data 
demonstrate that individual disruption of the p19ARF-MDM2-p53 pathway by p19Arf deletion or 
the RP-MDM2-p53 pathway by Mdm2C305F mutation does not block c-MYC induction of p53, 
while simultaneous disruption of both pathways blocks c-MYC-induced p53 expression. To 
ascertain whether these observations are Eμ-Myc transgene specific, we infected early passage 
WT, Mdm2m/m, p19Arf−/− and Mdm2m/m;p19Arf−/− MEF cells with retrovirus expressing pBabe-c-
MYC to determine if transient expression of c-MYC gives rise to similar results. Consistent with 
observations made in mouse spleens, transient expression of pBabe-c-MYC resulted in p53 
induction in WT, Mdm2m/m and p19Arf−/− MEFs, but not in Mdm2m/m;p19Arf−/− MEFs (Figure 
2.7b). Furthermore, the increased protein level of p53 was directly correlated with its 
transcriptional activity, indicated by S-18 phosphorylation of p53 in the spleens (p21 was 
undetectable in spleens; Figure 2.7a), and increased p21 protein level in pBabe-c-MYC infected 
MEFs (Figure 2.7b). 
To corroborate the protein analysis, we carried out quantitative PCR (qPCR) to further 
examine p53 activity in 4 week old, non-tumor-bearing Eμ-Myc;WT, Eμ-Myc;Mdm2m/m, Eμ-
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Myc;p19Arf−/− and Eμ-Myc;Mdm2m/m;p19Arf−/− mouse spleens and in spleens from their non-
transgenic counterparts. We chose p53 targets involved in cell cycle regulation (p21), apoptosis 
induction (bax and apaf1) and metabolic regulation (tigar) to determine whether p53 is activated 
universally for its target genes. Induction of each of these p53 target genes was evident in Eμ-
Myc;WT, Eμ-Myc;Mdm2m/m and Eμ-Myc;p19Arf−/− mouse spleens, but not in Eμ-
Myc;Mdm2m/m;p19Arf−/− mouse spleens (Figure 2.8), consistent with protein analysis. Together, 
our data indicate that not only can the p19ARF-MDM2-p53 and the RP-MDM2-p53 pathways be 
independently responsible for oncogenic c-MYC induction of p53, but also that the two 
pathways together contribute to most if not all p53 tumor suppressor response to c-MYC 
activation. Disabling both pathways results in undetectable p53 activation by oncogenic c-MYC 
overexpression. 
 
DISCUSSION 
The importance of p19ARF-MDM2-p53 and RP-MDM2-p53 signaling pathways in 
defending against oncogenic c-MYC induced tumorigenesis is well established, and studies 
have shown that disruption of each of the two pathways by deletion or mutation accelerates the 
progression of malignancy in c-MYC expressing mice (Eischen et al., 1999; Macias et al., 2010). 
In this study, we generated and analyzed mice with concurrent disruption of these two pathways 
and compared p53 activity and tumorigenesis to mice with disruption of each pathway alone. 
The significance and implications of these findings are discussed below. 
 
The p19ARF-MDM2-p53 and the RP-MDM2-p53 signaling pathways act independently in 
oncogenic c-MYC-induced p53 activation 
The generation of Mdm2m/m mice has allowed for a detailed in vivo characterization of the 
role of RP-MDM2 binding in p53 activation and tumor suppression. Unlike the disruption of the 
p19ARF-MDM2-p53 pathway by p19Arf deletion, which results in spontaneous tumor 
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development (Kamijo et al., 1997), disruption of the RP-MDM2-p53 pathway by Mdm2C305F 
mutation does not result in spontaneous tumor development (Macias et al., 2010). The different 
tumorigenic potential between the two mouse models could be a result of the nature of the two 
pathways in each of the mouse models. In p19Arf−/− mice the entire p19Arf gene is deleted, 
disrupting p19ARF-MDM2 binding as well as all other p19ARF-related functions; in Mdm2m/m 
mice, however, the single-point mutation in mdm2 is less disruptive, and while MDM2C305F 
mutant protein cannot properly bind to RPL5/RPL11, it retains binding to other RPs like RPL23 
(Lindström et al., 2007), thus only reducing but not eliminating the functions of this pathway. 
Alternatively, it is conceivable that the p19ARF-MDM2-p53 pathway primarily responds to 
deregulated oncogenes, which inflict a great risk of tumor formation if left unchecked, whereas 
the RP-MDM2-p53 pathway may primarily respond to deregulated ribosome biosynthesis, which 
may play a lesser role in promoting cancerous growth. 
In addition, it has been shown that p19ARF binds to and inhibits the ability of c-MYC to 
induce hyperproliferation and transformation (Qi et al., 2004; Zhang et al., 2013b) indicating that 
loss of p19ARF could contribute to c-MYC-induced tumorigenesis by at least two mechanisms. 
Similarly, it has been shown that RPL11 binds to c-MYC and inhibits its transcriptional activity 
(Dai et al., 2007) and that RPL5, cooperatively with RPL11, guides the RNA-induced silencing 
complex to c-MYC mRNA and mediates the degradation of c-MYC mRNA (Liao et al., 2014). 
These studies in combination with our results point to the importance of both p19ARF and RP 
signaling in c-MYC-induced lymphomagenesis. Our results agree with the notion that Eμ-Myc-
induced lymphomagenesis can be accelerated by disruption of negative regulators of c-MYC in 
each pathway in addition to disruption of p53 activation. 
Our study also addresses the degree of cooperation between the p19ARF-MDM2-p53 
and RP-MDM2-p53 pathways in p53 response to oncogenic c-MYC overexpression. When 
Mdm2C305F mutation or p19Arf deletion occur individually, c-MYC overexpression still elicits 
sufficient p53 response; however, when Mdm2C305F mutation and p19Arf deletion occur 
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concurrently, c-MYC overexpression does not elicit p53 activation. Given the role of oncogenic 
c-MYC in promoting aberrant ribosomal biogenesis, the p19ARF-independent, c-MYC-mediated 
induction of p53 in p19Arf−/− cells is conceivably dependent on c-MYC-induced overexpression 
of RPs, which activate p53 through interaction with MDM2 (Macias et al., 2010). Conversely, 
activation of p53 by c-MYC in Mdm2m/m mice is p19ARF dependent, as the p19ARF-MDM2-p53 
pathway remains intact in mice and c-MYC can induce p19ARF expression (Figures 2.7-8). Our 
data suggest that p53 responds to c-MYC overexpression via two independent signaling 
pathways: p19ARF-MDM2-p53 and RP-MDM2-p53. Each pathway conveys a share of c-MYC 
signaling to p53, and disruption of either one reduces, but not eliminates, p53 response to c-
MYC overexpression. Consequently, disrupting either pathway will accelerate c-MYC-induced 
tumor formation, as illustrated by shortened survival times of Eμ-Myc;Mdm2m/m and Eμ-
Myc;p19Arf−/− mice compared to Eμ-Myc;WT mice. Disrupting both pathways further accelerates 
c-MYC-induced tumorigenesis, as illustrated by the comparatively shorter tumor-free lifespan of 
Eμ-Myc;Mdm2m/m;p19Arf−/− compound mice. Our data support a model in which the RP-MDM2-
p53 and p19ARF-MDM2-p53 pathways represent two non-redundant, parallel mechanisms for 
p53 induction (Figure 2.9). Intriguingly, the lack of detectable p53 activation in the Eμ-
Myc;Mdm2m/m;p19Arf−/− compound mice implies that other active mechanisms transmitting 
oncogenic c-MYC signal to p53 either may not exist or be insufficient to raise p53 to a 
detectable level. 
The p19ARF-MDM2 connection mediates a p53-dependent checkpoint in response to a 
broad range of oncogenic insults, including elevated expression of c-MYC, E2F1, RAS, E1A and 
BCR-ABL. However, the RP-MDM2 connection provides evidence for a prevailing in vivo 
checkpoint for the integrity of ribosome biogenesis to invoke p53 response if the process goes 
awry. Given that overexpression of many oncogenes promotes fast growth and proliferation, 
which inevitably requires accelerated ribosomal biogenesis it is reasonable to speculate that the 
RP-MDM2-p53 signaling pathway, in addition to responding to c-MYC overexpression, may also 
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respond to other deregulated oncogenes that cause superfluous ribosomal biogenesis. The 
Mdm2m/m mouse model provides a convenient tool to investigate whether the RP-MDM2-p53 
pathway, as in the case of the p19ARF-MDM2-p53 pathway, functions generally in oncogenic 
signaling surveillance, capable of responding to a broad range of deregulated oncogenes, or is 
only specific to oncogenic c-MYC. 
 
EXPERIMENTAL PROCEDURES 
Cell culture 
Primary MEFs were isolated on embryonic (E) day 13.5 and grown in a 37°C incubator 
with 5% CO2 in Dulbecco’s modified Eagle’s medium supplied with 10% fetal bovine serum and 
penicillin-streptomycin. For retroviral infections, WT, Mdm2m/m, p19Arf−/− and Mdm2m/m;p19Arf−/− 
MEFs were infected with retroviruses expressing c-MYC or pBabe control vector, and selected 
with puromycin (2.5 μg/ml) for 3 days. Infected MEFs were then allowed to recover for 48 h and 
harvested for analysis. MEFs at passage 4 were used for growth curves, western blotting (WB) 
and other analyses. 
 
Mouse experiments 
Mice were bred and maintained strictly under protocol (13-044) approved by the 
Institutional Animal Care and Use Committee in the University of North Carolina Animal Care 
Facility. Mdm2m/m females were bred with p19Arf−/− males to obtain Mdm2+/m;p19Arf+/− offspring, 
which were then crossed with Mdm2+/m;p19Arf+/− mice to obtain Mdm2m/m;p19Arf−/− compound 
mice. For c-MYC-mediated tumorigenesis studies, Mdm2m/m;p19Arf−/− females were bred with 
Eμ-Myc transgenic males to obtain Eμ-Myc;Mdm2+/m;p19Arf+/− offspring, which were then 
crossed with Mdm2+/m;p19Arf+/− mice to obtain Eμ-Myc;Mdm2m/m;p19Arf−/− compound mice. Eμ-
Myc mice were purchased from Jackson Laboratory (002728). For survival studies, mice were 
palpated regularly for early signs of inguinal lymph node enlargement and monitored for tumor 
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progression and signs of morbidity. Moribund mice were humanely euthanized. Mouse tumors 
and organs were fixed in formalin for histopathology and snap frozen for protein and RNA 
extraction. 
 
Protein analysis 
For western blots, MEFs were lysed with 0.5% (Tergitol, Sigma, St Louis, MO, USA) NP-
40 lysis buffer. For mouse tissue protein extraction, tissue from the spleen, thymus and 
lymphomas was ground by mortar and pestle with liquid N2, and protein was extracted with 
0.5% NP-40 lysis buffer. Mouse monoclonal anti-MDM2 (2A10, Calbiochem, Billerica, MA, 
USA), mouse monoclonal anti-p53 (NCL-505, Novocastra, Buffalo Grove, IL, USA), mouse 
monoclonal anti-Actin (MAB1501, Chemicon International, Billerica, MA, USA), goat polyclonal 
anti-p53 (FL-393, Santa Cruz Biotechnology, Dallas, TX, USA) and rat monoclonal anti-p19ARF 
(5-C3-1, Santa Cruz Biotechnology) antibodies were purchased commercially. Rabbit polyclonal 
antibodies to p21 were gifts from Dr. Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal antibodies 
to RPL5 and RPL11 were made in house as previously described (Lindström et al., 2007). 
 
Measurement of mouse tissue 
Spleens, kidneys and livers from 9 week old mice were excised, photographed and 
weighed. All procedures involving mice were carried out according to protocol 13-044, approved 
by the University of North Carolina Institutional Animal Care and Use Committee. 
 
Histopathology 
Animals were autopsied and all tissues were examined regardless of their pathological 
status. Spleen, kidney and liver tissue from Eμ-Myc;WT, Myc;Mdm2m/m, Eμ-Myc;p19Arf−/− and 
Eμ-Myc;Mdm2m/m;p19Arf−/− transgenic mice, as well as tissue from non-transgenic counterparts 
were fixed overnight in 10% phosphate-buffered formalin and then transferred to 70% ethanol. 
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Samples were sent to the UNC Histology Core Facility for paraffin embedding. Paraffin blocks 
were sectioned at 5-mm intervals for successive layers and stained with H&E for histopathology 
examination. 
 
Proliferation analysis 
Ki-67 IHC staining of mouse spleen samples was used to detect proliferating cells. 
Antigen retrieval for antibody on formalin-fixed paraffin sections was carried out by boiling 
paraffin samples in citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase activity was 
quenched by incubation in 3% H2O2 in methanol for 10 min. Antibody detection was carried out 
with purified mouse anti Ki-67 primary antibody (BD Pharmingen, San Diego, CA, USA) and 
biotin-conjugated anti-mouse secondary antibody (Vector Laboratories, Burlingame, CA, USA). 
Ki-67-expressed cells were stained brown color by biotin-peroxidase kit (VECTASTAIN Elite, 
Vector Laboratories). The ratio of positively stained cells to total cells was calculated. Student’s 
t-test (P<0.05 was considered significant) was used to compare the differences in proliferation 
levels between the different mouse genotypes. 
 
Apoptosis analysis 
Levels of apoptosis in mouse spleen sections were assessed by the TUNEL assay 
according to instructions (ApopTag Peroxidase in situ kit, S7100, Millipore, Temecula, CA, 
USA). 
 
Quantitative real-time PCR  
Total RNA was isolated using an RNeasy kit (74104, Qiagen, Hilden, Germany) and 
cDNA was synthesized using SuperScript III (18080400, Life Technologies, Waltham, MA, 
USA). qPCR was performed with SYBR green master mix using the 7900HT fast real-time PCR 
system (Applied Biosystems, Waltham, MA, USA) according to manufacturers' instructions. 
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Data were collected and exported with SDS 2.2.2 software (Applied Biosystems). Relative 
expression was calculated using actin as an internal control as indicated. Primers used were as 
follows: p21, 5′-CCTGGTGATGTCCGACCTG-3′ and 5′-CCATGAGCGCATCGCAATC-3′; bax, 
5′-GGACAGCAATATGGAGCTGCAGAGG-3′ and 5′-GGAGGAAGTCCAGTGTCCAGCC-3′; 
apaf1, 5′-CGGTGAAGGTGTGGAATGTCATTACCG-3′ and 5′-
GGATTTCTCCATTGTCATCTCCAGTTGC-3′; tigar, 5′-CGATCTCACGAGGACTAAGCAGACC-
3′ and 5′-GCCAAAGAGCTTTCCAAACCGCTGC-3′; and actin, 5′-
CCACAGCTGAGAGGGAAATCGTGC-3′ and 5′CCAGAGCAGTAATCTCCTTCTGCATCC-3′. 
 
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5 Software (Graph-Pad 
Software, San Diego, CA, USA). Kaplan-Meier survival analysis was carried out to assess 
lifespan. 
 
Ethics statement 
Investigation has been conducted in agreement with the ethical standards according to 
the Declaration of Helsinki, national and international guidelines, and has been approved by the 
authors' institutional review board. 
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Figure 2.1 Disruption of the p19ARF-MDM2-p53 pathway, but not the RP-MDM2-p53 
pathway, results in spontaneous tumor development.  
 
A. The image shown are expected and observed birth ratios from a total of 186 mice obtained 
from Mdm2+/m;p19Arf+/− mice intercrosses (shown only three genotypes for simplicity).  
 
B. Kaplan-Meier survival curves for WT, Mdm2m/m, p19Arf−/− and Mdm2m/m;p19Arf−/− mice are 
shown. Two to five mice of the same gender were housed in each cage, and the mice were 
observed over a 24 month period. Median survival time of p19Arf−/− and Mdm2m/m;p19Arf−/− mice 
was 16 and 19 months, respectively. There was no significant difference between survival of 
p19Arf−/− and Mdm2m/m;p19Arf−/− mice (analyzed by log-rank test, P=0.06). 
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Figure 2.2 c-MYC-induced lymphomagenesis is accelerated by Mdm2m/m or p19Arf−/− 
alterations. 
 
A. Survival of Eμ-Myc transgenic p19Arf deletion mice. The median survival time for each 
genotype was as follows: Eμ-Myc;WT (20.7 weeks), Eμ-Myc;p19Arf+/− (15.6 weeks) and Eμ-
Myc;p19Arf−/− (10.1 weeks). Log-rank test, P=0.003 between Eμ-Myc;WT and Eμ-Myc;p19Arf+/− 
mice; P<0.0001 between Eμ-Myc;p19Arf+/− and Eμ-Myc;p19Arf−/− mice.  
 
B. Survival of Eμ-Myc transgenic Mdm2C305F mutation mice. The median survival times were as 
follows: Eμ-Myc;WT (20.7 weeks), Eμ-Myc;Mdm2+/m (17.9 weeks) and Eμ-Myc;Mdm2m/m (11.6 
weeks). Log-rank test, P=0.5 between Eμ-Myc;WT and Eμ-Myc;Mdm2+/m mice; P<0.0001 
between Eμ-Myc;Mdm2+/m and Eμ-Myc;Mdm2m/m mice. 
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Figure 2.3 c-MYC-induced lymphomagenesis is further accelerated by concurrent 
Mdm2m/m;p19Arf−/− alterations. 
 
A. Survival of Eμ-Myc;WT (20.7 weeks), Eμ-Myc;Mdm2m/m (11.6 weeks), Eμ-Myc;p19Arf−/− (10.1 
weeks) and Eμ-Myc;Mdm2m/m;p19Arf−/− (7.6 weeks) mice. Log-rank test, P=0.0001 between Eμ-
Myc;Mdm2m/m and Eμ-Myc;p19Arf−/− mice; P<0.0001 between Eμ-Myc;p19Arf−/− and Eμ-
Myc;Mdm2m/m;p19Arf−/− mice.  
 
B. Body weight of mice expressing Eμ-Myc. 
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Figure 2.4 Mdm2m/m;p19Arf−/− compound mice demonstrate accelerated lymphoma 
formation. 
 
A. Length of 9 week old (±3 days) mouse spleens of WT (n=5), Eμ-Myc;WT (n=5), Eμ-
Myc;Mdm2m/m (n =5), Eμ-Myc;p19Arf−/− (n=5) and Eμ-Myc;Mdm2m/m;p19Arf−/− (n=5) mice. Spleen 
length was measured and the median lengths were as follows: WT (1.14 cm), Eμ-Myc;WT (1.56 
cm), Eμ-Myc;Mdm2m/m (2.36 cm), Eμ-Myc;p19Arf−/− (2.54 cm) and Eμ-Myc;Mdm2m/m;p19Arf−/− 
(3.82 cm). Data are represented as mean ±SEM and were analyzed by Student’s t-test. 
***P<0.001; **P<0.01.  
 
B. H&E staining of spleen, liver and kidney tissues. WT mouse spleen serves as a positive 
control for normal spleen structure. Structure of spleens from Eμ-Myc transgenic mice was 
destroyed by lymphocyte infiltration. Lymphocyte infiltration was observed as dark blue staining. 
The malignant cells are dispersed and the nuclei are larger than normal lymphocytes. 
Aggregates of small lymphocytes are observed in the livers and kidneys of Eμ-Myc transgenic 
mice. Scale bar, 400 μm. 
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Figure 2.5 Mdm2m/m;p19Arf−/− compound mice exhibit accelerated c-MYC-induced tumor 
progression.  
 
A. Representative Ki-67 staining of spleens from different genotypes of 9 week old mice, as 
indicated. Brown staining indicates Ki-67-positive proliferating cells. Scale bar, 100 μm. The Ki-
67 index (calculated as the percentage of Ki-67-positive tumor cells vs total cells in the view 
field from at least five randomly chosen fields along the edge of spleens) for the genotypes 
assayed are indicated in parentheses: WT (0.4), Eμ-Myc;WT (2.8), Eμ-Myc;Mdm2m/m (12.2), Eμ-
Myc;p19Arf−/− (14.6 ) and Eμ-Myc;Mdm2m/m;p19Arf−/− (53.9) mice. Data are represented as 
mean ±SEM. ***P<0.001.  
 
B. Representative TUNEL staining of spleens from different genotypes of 9 week old mice. The 
percentage of TUNEL-positive cells in the view field was calculated from at least five randomly 
chosen fields along the edge of spleens and is indicated in parentheses: WT (8.4%), Eμ-
Myc;WT (14.6%), Eμ-Myc;Mdm2m/m (13.6%), Eμ-Myc;p19Arf−/− (14.4%) and Eμ-
Myc;Mdm2m/m;p19Arf−/− (6.2%). Data are represented as mean±SEM. ***P<0.001; **P<0.01. 
Scale bar, 200 μm. 
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Figure 2.6 Mdm2m/m;p19Arf−/− compound mice exhibit accelerated liver metastasis.  
 
H&E staining of livers from different genotypes of similar metastasis stage. Mouse livers were 
collected at the time of death. Time of metastasis is indicated in parentheses: Eμ-Myc;WT (22 
weeks), Eμ-Myc;Mdm2m/m (12.5 weeks), Eμ-Myc;p19Arf−/− (11 weeks) and Eμ-
Myc;Mdm2m/m;p19Arf−/− (9 weeks). Scale bar, 400 μm. 
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Figure 2.7 The RP-MDM2-p53 and p19ARF-MDM2-p53 signaling pathways function 
independently in oncogenic c-MYC-induced p53 stabilization.  
 
A. Extracts from spleens of 4 week old, non-tumor-bearing Eμ-Myc;WT, Eμ-Myc;Mdm2m/m, Eμ-
Myc;p19Arf−/− and Eμ-Myc;Mdm2m/m;p19Arf−/− transgenic mice and spleens from their non-
transgenic counterparts were analyzed by western blot.  
 
B. Early passage WT, Mdm2m/m, p19Arf−/− and Mdm2m/m;p19Arf−/− MEFs were infected with 
retrovirus expressing either pBabe vector (-) or pBabe-c-MYC (+), selected by puromycin for 3 
days, then allowed to recover for 48 h before harvesting for western blot analysis. 
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Figure 2.8 The RP-MDM2-p53 and p19ARF-MDM2-p53 signaling pathways function 
independently in oncogenic c-MYC-induced p53 activation. 
 
(A-D) mRNA levels of p21 (A), bax (B), apaf1 (C) and tigar (D) in spleens of 4 week old, non-
tumor-bearing Eμ-Myc;WT, Eμ-Myc;Mdm2m/m, Eμ-Myc;p19Arf−/− and Eμ-Myc;Mdm2m/m;p19Arf−/− 
transgenic mice, and in spleens of their non-transgenic counterparts, analyzed by qPCR. All 
samples were analyzed in triplicate. Data are calculated from three independent experiments 
and normalized to actin. Data are represented as mean ±SEM, and were analyzed by Student’s 
t-test. *P<0.1; **P<0.01; ***P<0.001; and NS indicates no significant difference. 
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Figure 2.9 A model depicting non-overlapping functions of the p19ARF-MDM2-p53 and 
the RP-MDM2-p53 pathways in oncogenic c-MYC-induced p53 activation.  
 
In WT cells, oncogenic c-MYC signal engages with both p19ARF-MDM2-p53 and RP-MDM2-
p53 pathways, resulting in maximum MDM2 inhibition and p53 stabilization and activation (first 
panel). In cells with p19Arf deletion (second panel) or MDM2C305F mutation (third panel), c-MYC 
signal engages with one of the remaining pathways to induce p53, but to a lesser degree. In 
cells with concurrent p19Arf deletion and MDM2C305F mutation, c-MYC overexpression cannot 
induce p53 to detectable levels (fourth panel).  
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CHAPTER 3: RPL23 LINKS ONCOGENIC RAS SIGNALING TO P53-MEDIATED TUMOR 
SUPPRESSION3 
INTRODUCTION 
The tumor suppressor gene TP53 is mutated in about 50% of all human cancers (Lane, 
1992). As a transcription factor, p53 triggers cell cycle arrest, differentiation, apoptosis, and 
senescence in response to a variety of stresses. MDM2 is the primary negative regulator of p53, 
and it accomplishes this by both binding to and inhibiting the transactivation domain of p53 
(Momand et al., 2011), as well as serving as an E3 ubiquitin ligase for p53 degradation (Geyer 
et al., 2000; Honda et al., 1997). Meanwhile, p53 enhances mdm2 transcription, forming an 
autoregulatory feedback loop (Wu et al., 1993). 
It has been demonstrated that several ribosomal proteins (RPs), such as RPL5, RPL11, 
and RPL23, interact with MDM2 to inhibit its E3 ligase function, thereby stabilizing and 
activating p53, suggesting an RP-MDM2-p53 signaling pathway (Zhang and Lu, 2009). 
Ribosomal biogenesis is one of the most energetically demanding and tightly regulated 
processes during cell growth and proliferation. Because cancer cells undergo uncontrolled 
growth and proliferation, they require accelerated ribosomal biogenesis, mandating increased 
RP production. Using knockin mice bearing an MDM2C305F point mutation, which prevents 
                                               
3 This chapter is adapted from a research article originally published in Cancer Research. Xuan Meng, 
Adrienne Cox, Yanping Zhang and I contributed to the design of the study. Xuan Meng completed all 
mouse breeding/dissection and qPCR experiments. Xuan Meng, Conying Wu, Jing Yang and I completed 
RAS retroviral overexpression in MEFs and WB analyses of MEFs and tissue. Xuan Meng, Shijie Liu, and 
I completed the IHC and histopathological staining. Xuan Meng, Adrienne Cox, Yanping Zhang and I 
analyzed the data. I wrote and edited the manuscript with Xuan Meng, Adrienne Cox, and Yanping 
Zhang. Jiahong Dong and Yanping Zhang finalized the manuscript. Xuan Meng and I are co-first authors 
on the study. The original citation is as follows: Meng, X., Tackmann, N.R., Liu, S., Yang, J., Dong, J., 
Wu, C., Cox, A.D., and Zhang, Y. (2016). RPL23 links oncogenic RAS signaling to p53-mediated tumor 
suppression. Cancer Research 76, 5030-5039. 
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binding of RPL5 and RPL11 to MDM2 (Lindström et al., 2007), previous studies have 
established the physiologic significance of the RP-MDM2 interaction in responding to ribosomal 
stress and demonstrated that the RP-MDM2-p53 pathway is critical in preventing oncogenic c-
MYC-induced lymphomagenesis in mice (Macias et al., 2010). 
The tumor suppressor p19ARF (p14ARF in human) is uniquely transcribed from an 
alternative reading frame of the INK4a/ARF gene locus. Similar to RPL11 and RPL5, p19ARF 
can inhibit MDM2 E3 ligase activity by directly binding to MDM2, stabilizing and activating p53, 
instituting a p19ARF-MDM2-p53 signaling pathway (Sherr, 2006). Previous studies have shown 
that mice with homozygous deletion of p19ARF (p19Arf-/-) are predisposed to spontaneous 
tumor development (Kamijo et al., 1999). In addition, oncogenic proteins, such as c-MYC and 
RAS, can drive tumors by selectively inactivating the p19ARF-MDM2-p53 pathway. Accelerated 
cancer progression is observed in Eµ-Myc;p19Arf-/- transgenic mice, which die of lymphoma 
within a few weeks of birth (Eischen et al., 1999), and in HrasG12V;p19Arf-/- transgenic mice, 
which die of melanoma within a few months of birth (Chin et al., 1997), demonstrating the 
importance of p19ARF in tumor suppression. 
Overexpression of oncogenic RAS induces cell-cycle arrest in WT murine keratinocytes, 
which is mediated by increased expression of p19ARF (Lin and Lowe, 2001). Conversely, 
oncogenic RAS transforms p19Arf-/- MEFs by bypassing p53-mediated checkpoint control 
(Kamijo et al., 1997). The RP-MDM2-p53 signaling pathway responds to deregulated ribosomal 
biogenesis caused by c-MYC overexpression to activate p53 and prevent tumorigenesis 
(Macias et al., 2010). Given that overexpression of RAS promotes growth and proliferation, 
which like c-MYC overexpression involves enhanced ribosomal biogenesis, we sought to 
determine whether the RP-MDM2-p53 signaling pathway might also respond to oncogenic RAS 
overexpression and play a role in tumor suppression. 
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RESULTS 
MDM2C305F mutation partially rescues oncogenic H-RAS-induced tumorigenesis 
We crossed Mdm2m/m mice with mice expressing an activated melanocyte-specific 
HrasG12 transgene and examined melanomagenesis in the HrasG12V;Mdm2m/m transgenic mice. 
Consistent with previous studies (Chin et al., 1997), HrasG12V;p19Arf-/- mice developed 
spontaneous melanomas, and the median survival of the transgenic mice was about 6 months 
(Figure 3.1, red line). Unexpectedly, however, the median survival for HrasG12V;Mdm2m/m;p19Arf-
/- compound mice was significantly longer than that of Hras;p19Arf-/- mice at more than 12 
months (Figure 3.1, purple line, P=0.0007). This result indicates that, in contrast to accelerating 
oncogenic c-MYC-induced tumorigenesis (Macias et al., 2010), the MDM2C305F mutation partially 
rescues oncogenic RAS-induced tumorigenesis. Tumors from HrasG12V;Mdm2m/m;p19Arf-/- mice 
were indistinguishable to those from HrasG12V; p19Arf-/- mice (Figures 3.2-3). Although the 
latency of tumors differed depending on the presence or absence of MDM2C305F mutation, the 
histologic characteristics of established tumors were equivalent between tumors from 
HrasG12V;Mdm2m/m;p19Arf-/- mice and those from HrasG12V;p19Arf-/- mice, indicating that the 
MDM2C305F mutation does not ultimately affect the pathophysiologic nature of tumors induced 
upon p19ARF deletion and oncogenic RAS overexpression. 
We next determined the proliferative capacities of melanomas from the HrasG12V;p19Arf-/- 
and HrasG12V;Mdm2m/m;p19Arf-/- mice. As shown in Figure 3.4a, tumors from HrasG12V;p19Arf-/- 
mice displayed a higher percentage of Ki-67-positive cells (Ki-67 index 51.8) than tumors from 
HrasG12V;Mdm2m/m;p19Arf-/- mice (Ki-67 index 11.8). TUNEL (terminal deoxynucleotidyl 
transferase mediated dUTP-biotin nick end labeling) immunohistochemical analysis was 
performed to measure levels of apoptosis. Tumors isolated from HrasG12V;Mdm2m/m;p19Arf-/- 
mice displayed a significantly higher percentage of TUNEL-positive cells (13.6%) than those of 
HrasG12V;p19Arf-/- tumors (3.2%; Figure 3.4b). These data suggest that the MDM2C305F mutation 
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decelerates oncogenic RAS-induced tumorigenesis by inhibiting proliferation and inducing 
apoptosis. 
The deceleration of RAS-induced tumorigenesis by MDM2C305F mutation was 
unexpected. Because p53 is the primary target of MDM2, we therefore compared basal levels of 
p53 in HrasG12V;p19Arf-/- and HrasG12V;Mdm2m/m;p19Arf-/- tumors. As shown in Figure 3.5a, 
HrasG12V;Mdm2m/m;p19Arf-/- tumors expressed higher levels of p53. To determine whether p53 
activity also correlated with expression in these tumors, we analyzed p21 and found that there 
was greater p21 staining in HrasG12V;Mdm2m/m;p19Arf-/- tumors compared with HrasG12V;p19Arf-/- 
tumors (Figure 3.5b). We then used a tumor-free system to compare whether the MDM2C305F 
mutation had any effect on basal p53 accumulation. We analyzed p53 levels in WT, Mdm2m/m, 
p19Arf-/-, and Mdm2m/m;p19Arf-/- MEFs. Mdm2m/m MEFs expressed higher levels of p53 than did 
WT MEFs (Figure 3.5c). Likewise, Mdm2m/m;p19Arf-/- MEFs expressed higher levels of p53 than 
did p19Arf-/- MEFs. Thus, the deceleration of RAS-induced tumorigenesis by MDM2C305F 
mutation correlates with higher levels of p53 expression and activity. 
 
RAS induces RPL23 expression via MEK/PI3K and mTOR pathways 
Previous studies have shown that MDM2C305F mutation accelerates oncogenic c-MYC-
induced tumorigenesis in mice due to loss of RPL11-MDM2 interaction (Macias et al., 2010). 
However, the MDM2C305F mutation does not affect MDM2 binding to RPL23 (Lindström et al., 
2007; Macias et al., 2010); and like RPL11, RPL23 interacts with MDM2 and activates p53 (Dai 
et al., 2004; Jin et al., 2004). To provide further insight for the deceleration of RAS-induced 
tumorigenesis by the MDM2C305F mutation, we sought to determine whether RAS, like c-MYC 
(Guo et al., 2000; Kim et al., 2000), could also upregulate RP expression. We assessed the 
levels of RPL11 and RPL23 in RAS overexpressing mice. Interestingly, the protein levels of 
RPL23, but not RPL11, were elevated in pretumor mouse melanocytes expressing the HrasG12V 
transgene (Figures 3.6a-b, compare lane 1 with lane 3, and lane 2 with lane 4). 
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Furthermore, we infected MEFs with retrovirus-expressing pBabe-HRASG12V and found 
that the expression of RPL23 was induced by ectopic HRASG12V (Figure 3.6c, compare lane 1 
with lane 3, and lane 2 with lane 4). Conversely, the expression of RPL11 was unaffected by 
either endogenous or ectopic HRASG12V (Figure 3.6). We also observed elevated levels of rpl23 
mRNA in HRASG12V retrovirus-infected WT, Mdm2m/m, p19Arf-/-, and Mdm2m/m;p19Arf-/- MEFs 
(Figure 3.7). On the other hand, rpl11 mRNA levels remained unchanged in these cells (Figure 
3.8). The induction of RPL23 by oncogenic RAS also appears to be p53 independent, because 
infection of pBabe-HRASG12V retrovirus resulted in RPL23 overexpression to similar levels in 
both WT and p53-null MEFs (Figure 3.9a).  
We noticed that the levels of RPL23 were higher in Mdm2m/m mouse skin tissue and 
Mdm2m/m MEFs compared with their counterparts expressing WT MDM2 (Figure 3.6a, compare 
lane 1 with lane 2; Figure 3.6b, compare lane 1 with lane 2). To analyze this phenomenon, we 
examined RPL23 expression in multiple tissues, including MEFs, spleen, liver, and skin. We 
found that RPL23 levels were indeed higher in tissues of Mdm2m/m mice than in those of WT 
mice (Figure 3.9b). Furthermore, tumors from HrasG12V;Mdm2m/m;p19Arf-/- mice showed stronger 
RPL23 staining than those from HrasG12V;p19Arf-/- mice (Figure 3.9c). To further investigate the 
MDM2C305F mutation-mediated increase of RPL23 protein levels, we analyzed rpl23 mRNA in 
WT and Mdm2m/m MEFs and observed elevated levels in Mdm2m/m MEFs (Figure 3.9d). To test 
whether the elevated levels of RPL23 can also be explained by increased protein stability, we 
performed a protein half-life assay using early passage MEFs. A normal rate of protein 
degradation was observed for RPL23 in Mdm2m/m MEFs (Figure 3.10a), indicating that the 
stability of RPL23 is not altered by MDM2C205F mutation. An unaltered rate of protein 
degradation was also observed for RPL11 in Mdm2m/m MEFs (Figure 3.10b-d). 
We examined RPL23 subcellular localization by immunofluorescence staining, and no 
difference was observed between WT and Mdm2m/m cells (Figure 3.11a). Elevated RPL23 
expression was also observed in Mdm2m/m cells under a p53-null background (Figure 3.11b), 
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indicating that it is a p53-independent event. These data indicate that the MDM2C305F mutation 
increases rpl23 mRNA levels and RPL23 protein production. We have yet to explain the 
mechanism for the increase of rpl23 mRNA expression in cells with the MDM2C305F mutation, but 
we believe that the increased rpl23 mRNA and protein levels are likely a cause for the increased 
p53 expression (Figure 3.5c) and the deceleration of RAS-induced tumorigenesis observed in 
HrasG12V;Mdm2m/m;p19Arf-/- mice (Figure 3.1).  
It has been previously shown that regulation of RPL23 can occur at the translational 
level through mRNA cap binding of eukaryotic translation initiation factor 4E (eIF4e) (Mamane et 
al., 2007), a well-characterized downstream target of the mTOR pathway. We therefore 
investigated the mechanism of RAS-induced RPL23 expression at translational control. 
Because mTOR is a known downstream target of RAS signaling, we hypothesized that RAS 
induction of RPL23 could be mediated by the mTOR signaling pathway. To test this idea, we 
infected WT MEFs with pBabe-HRASG12V retrovirus and followed with rapamycin treatment to 
inhibit mTOR activity. Expression of RPL23, but not RPL11, was induced by RAS 
overexpression in MEF cells; however, upon treatment with rapamycin RAS-induced RPL23 
expression was inhibited (Figure 3.12a). Consistent with observations made in MEFs, RPL23 
expression was elevated in human embryonic kidney (HEK-293T) cells infected with pBabe-
HRASG12V retrovirus, and the expression was inhibited by rapamycin (Figure 3.12b). These data 
indicate that RAS regulates RPL23 translation through an mTOR-dependent mechanism. 
RAS signaling to mTOR can occur through PI3K and mitogen activated protein kinase 
(MEK) pathways. To further investigate the signaling pathways through which RAS induces 
RPL23 expression, we infected WT MEFs and HEK-293T cells with pBabe-HRASG12V retrovirus 
and treated the cells with small-molecule inhibitors of RAS signaling. RPL23 induction by RAS 
was partially inhibited by treatment with either the MEK inhibitor trametinib or the PI3K inhibitor 
LY294002, respectively (Figure 3.13). Together, these data suggest that RAS mediated 
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induction of RPL23 translation is mTOR dependent and mediated by both PI3K and MEK 
signaling pathways. 
 
RAS induces p53 expression in the absence of p19ARF  
Oncogenic RAS induces p19ARF-dependent activation of p53 (Serrano et al., 1997). To 
determine whether p19ARF is required for RAS-induced p53 expression in our system, we 
analyzed pretumor skin extracts from p19Arf-/- and Mdm2m/m;p19Arf-/- mice expressing HrasG12V 
transgene for p53 expression. Interestingly, in the absence of p19ARF, the HrasG12V transgene 
still induced p53 expression (Figure 3.14a, compare lane 1 with lane 3), and the induction was 
further augmented by MDM2C305F mutation (Figure 3.14a, compare lane 3 with lane 4). A similar 
conclusion was reached using MEFs infected with pBabe-HRASG12V retrovirus, which resulted in 
p53 accumulation in p19ARF-null MEFs (Figure 3.14b, compare lane 1 with lane 3), and this 
HRASG12V-induced p53 expression was further increased in Mdm2m/m;p19Arf-/- MEFs compared 
with p19Arf-/- MEFs (Figure 3.14b, compare lane 3 with lane 4). These results indicate that 
oncogenic RAS can induce p53 in a p19ARF-independent manner. This is consistent with the 
observation that HRASG12V-induced RPL23 expression in p19ARF-null mice and cells (Figures 
3.6b, 3.7c-d). 
We noticed that even though oncogenic RAS can induce p53 accumulation in the 
absence of p19ARF, the levels of the induction were notably reduced compared with those in 
the presence of p19ARF. In the presence of p19ARF the HrasG12V transgene induced an 
approximately 2.5-fold increase of p53 in mouse melanocytes (Figure 3.14c, compare lane 1 
with lane 3), whereas in the absence of p19ARF the HrasG12V transgene induced an 
approximately 1.5-fold increase of p53 (Figure 3.14a, compare lane 1 with lane 3). Similarly, 
ectopic expression of pBabe-HRASG12V induced an approximately 3-fold increase of p53 in WT 
MEFs (Figure 3.14d, compare lane 1 with lane 3), whereas the same virus induced an only 1.6-
fold increase of p53 in p19Arf-/- MEFs (Figure 3.14b, compare lane 1 with lane 3). This evidence 
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supports the notion that there exists a p19ARF-independent signaling pathway engaged by 
oncogenic RAS to induce p53 accumulation.  
 
RPL23 is required for RAS induction of p53 in the absence of p19ARF 
Given that oncogenic RAS induces expression of RPL23, and that ectopic expression of 
RPL23 can stabilize p53 by inhibiting MDM2-mediated p53 ubiquitination and degradation (Dai 
et al., 2004; Jin et al., 2004), we wanted to investigate whether RPL23 is necessary for 
oncogenic RAS-mediated accumulation of p53 in the absence of p19ARF. We knocked down 
RPL23 by siRNA in p19Arf-/- MEFs, infected the cells with pBabe-HRASG12V retrovirus, and 
examined p53 levels. Downregulation of RPL23 significantly attenuated RAS-induced p53 
expression in p19Arf-/- MEFs (Figure 3.15a) as well as in Mdm2m/m;p19Arf-/- compound MEFs 
(Figure 3.15b), suggesting that in the absence of p19ARF, RPL23 is a major mediator of p53 
expression induced by oncogenic RAS. On the other hand, in the presence of p19ARF 
downregulation of RPL23 did not affect RAS induction of p53 (Figure 3.15c-d). This suggests 
that p19ARF is the primary responder to oncogenic RAS expression whereas the RPL23-
mediated response might be a fail-safe mechanism that comes into play upon loss of p19ARF. 
 
DISCUSSION 
Both RPL23 and p19ARF induce p53 expression in response to oncogenic RAS insult 
We have provided evidence that the induction of p53 by oncogenic RAS does not occur 
solely through p19ARF (Figure 3.14), and that another pathway to p53 induction exists through 
RPL23 (Figure 3.15). There are several possible reasons for this redundancy. First, p19ARF 
and RPL23 could work together to produce a more rapid and robust p53 response to oncogenic 
RAS expression than either one alone. We have shown that in the absence of p19ARF, p53 can 
still be induced by RAS through RPL23, but that this happens to a lesser degree than when 
p19ARF is present (Figure 3.14), suggesting that the two pathways could act concurrently 
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(Figure 3.16a). However, we believe it is more likely that p19ARF, as a canonical tumor 
suppressor, is the primary responder to RAS overexpression and that RPL23 acts as a backup 
response to induce p53 activation, particularly when the function of p19ARF is lost. This notion 
is supported by the observation that knockdown of RPL23 by siRNA does not significantly 
attenuate p53 activation by RAS when p19ARF is present (Figures 3.15c-d), but it does so 
when p19ARF is absent (Figures 3.15a-b). 
The loss of p19ARF in the presence of RAS overexpression can drive tumor progression 
through inactivation of the p19ARF-MDM2-p53 pathway (Chin et al., 1997), so the presence of a 
backup mechanism for p53 activation would be advantageous for tumor prevention. In support 
of this idea, Mdm2m/m mice which demonstrate increased levels of RPL23 (Figures 3.6 and 3.9) 
and higher levels of p53 (Figure 3.14) under a p19ARF deletion background, are more resistant 
to RAS overexpression-induced tumors as compared with mice with p19ARF deletion alone 
(Figure 3.1). Different RPs respond to specific oncogenic stresses to stabilize p53. In general, 
deregulated oncogenes drive cell growth and proliferation, which requires accelerated ribosomal 
biogenesis. 
This current study and studies by others have demonstrated that RAS and c-MYC can 
drive expression of RPs. Although RP upregulation is generally associated with oncogenic 
growth, it appears that RPs can also serve as tumor-suppressive signaling molecules. It is 
presently unclear why multiple RPs interact with MDM2 and appear to have similar functions in 
p53 stabilization. We propose that the RP-MDM2 interaction represents a system of checkpoints 
for cell growth, and here we have provided evidence to suggest that the different RPs may 
respond to distinct oncogenic stimuli to engage the MDM2-p53 pathway. For example, RPL23, 
but not RPL11, is specifically induced by RAS overexpression (Figures 3.6-8), whereas previous 
studies have shown that RPL11 responds to oncogenic c-MYC overexpression (Macias et al., 
2010). The MDM2C305F mutation specifically disrupts interaction of RPL11 but not RPL23 with 
MDM2. Creation of the Mdm2m/m mice thus allowed us to dissect the distinct contributions of 
 
64 
 
RPL11 and RPL23 to p53 induction by oncogenic c-MYC and oncogenic RAS overexpression, 
respectively. To date, at least 16 RPs have been shown to bind directly to MDM2 and modulate 
p53 in a similar fashion (Kim et al., 2014), but the specific signals that these RPs transduce 
have yet to be elucidated. We postulate that a possible reason that so many RPs bind MDM2 is 
to confer insult-specific modulation of p53. In this study, we demonstrate that RPL23 can 
respond to RAS to induce p53. However, although our data demonstrate that RPL23 is essential 
for RAS-induced p53 expression in the absence of p19ARF, we cannot conclude whether other 
RPs may have a role in the pathway, given that there are 16 RPs have been shown to bind to 
MDM2 and affect p53. Significant investigation will be required to parse out whether other RPs 
respond to specific stress signals to induce p53 activation and which signals are responsible for 
each potential RP-MDM2 interaction and subsequent p53 activation. 
 
RPL23 expression via the MEK-PI3K and mTOR pathways  
We have shown that the increased latency to tumor formation in 
HrasG12V;Mdm2m/m;p19Arf-/- mice compared with HrasG12V;p19Arf-/- mice is possibly due to 
oncogenic HRASG12V overexpression combined with MDM2C305F mutation-induced RPL23 
expression, leading to increased p53 accumulation and activation. RAS induces rpl23 mRNA 
expression (Figure 3.7) and protein production through both MEK and PI3K signaling pathways 
(Figure 3.13), which are dependent on mTOR but independent of p53 (Figure 3.9a). It is likely 
that RAS induction of RPL23 is mediated through both an increase in transcription, as well as 
an increase in mTOR-dependent translation (Figure 3.12). Although our results suggest that 
RAS can induce p53 through increased inhibition of MDM2 by RPL23, we cannot rule out the 
possibility that RPL23 induction by RAS can induce p53 through an MDM2-independent 
mechanism. Previous studies have shown that mTOR can upregulate p53 translation (Astle et 
al., 2012), and because mTOR is a downstream target of RAS, it is also possible that 
upregulation of RPL23 could aid in mTOR-dependent increases in p53 translation. 
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MDM2C305F mutation facilitates an increase in rpl23 mRNA expression, and we have 
shown that MDM2C305F mutation does not affect RPL23 protein stability or subcellular 
localization. Although how MDM2C305F mutation increases rpl23 mRNA transcription is presently 
unclear, several possibilities can be envisioned. First, RP-MDM2 interactions are thought to 
occur in response to perturbations of ribosomal biogenesis (Zhang and Lu, 2009). We speculate 
that there is some low level of basal RP-MDM2 interaction, mildly inhibiting MDM2, to allow for 
normal physiologic levels of p53 expression. It is possible that upon loss of RPL11-MDM2 
binding due to MDM2C305F mutation, the basal level of MDM2 inhibition is decreased and RPL23 
could be upregulated as a compensatory mechanism to counteract the decrease in MDM2 
inhibition. 
Second, ribosomal biogenesis and RP expression is a highly-coordinated process, with 
imbalances in RP ratios often causing p53-dependent cell-cycle arrest. In the case of 
MDM2C305F mutation, the loss of RPL11-MDM2 binding could liberate RPL11, leading to an 
increase in the relative levels of RPL11 in the RP pool and creating imbalances in otherwise 
tightly regulated RP ratios. To combat this imbalance, the cell may increase expression of other 
RPs, including, in this case, RPL23. 
Finally, a possibility formally remains, for reasons yet unknown, that MDM2C305F mutation 
could facilitate low but constitutive overexpression of RAS and RAS target genes. The Mdm2m/m 
mouse, with its elevated expression of endogenous RPL23, serves as a useful in vivo tool for 
investigating the function and mechanism of a RAS-RPL23-MDM2-p53 pathway, without the 
effects of RPL11-MDM2 binding, and sets the stage for further investigations of RP-MDM2-p53 
pathway activation. 
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EXPERIMENTAL PROCEDURES 
Immunoblotting and immunoprecipitation 
For Western blotting, MEFs were lysed with 0.5% NP-40 lysis buffer. For mouse tissue 
protein extraction, tissue from the skin and lymphomas was ground by pestle and mortar with 
liquid N2, and protein was extracted with 0.5% NP-40 lysis buffer. To assess the half-life of 
RPL11 and RPL23, low passage MEF cells were treated with cycloheximide (50 mg/mL), 
chased for the indicated time points, and harvested with SDS lysis buffer (2% SDS, 10% 
glycerol, 50 mmol/L Tris). Mouse monoclonal anti-MDM2 (2A10; Calbiochem), mouse 
monoclonal anti-p53 (NCL-505; Novocastra), goat polyclonal anti-p53 (FL-393, Santa Cruz 
Biotechnology), mouse monoclonal anti-ACTIN (MAB1501; Chemicon International), rabbit 
monoclonal anti-β-TUBULIN (ab179513; Abcam), rabbit monoclonal anti-RAS (ab52939; 
Abcam), mouse monoclonal anti-RAS (BD610001; BD Biosciences), rat polyclonal anti-p19ARF 
(Santa Cruz Biotechnology), rabbit polyclonal anti-phospho (Ser473)-AKT (9271S; Cell 
Signaling Technology), mouse monoclonal antiphospho-p44/42 (Thr202/204) ERK1/2 (9107S; 
Cell Signaling Biotechnology), rabbit monoclonal anti-phospho (Ser473)-AKT(4060S; Cell 
Signaling Technology), rabbit polyclonal anti-AKT (9272S; Cell Signaling Technology), 
rabbitmonoclonal anti-phospho-p44/42 (Thr201/Tyr204) ERK1/2 (4370S;Cell Signaling 
Technology), rabbit polyclonal anti-ERK1/2 (9102S; Cell Signaling Technology) and anti-
GAPDH (RM2002; Ray Antibody Biotechnology) antibodies were purchased commercially. 
Rabbit polyclonal antibodies to p21 were gifts from Dr. Yue Xiong (University of North Carolina 
at Chapel Hill, Chapel Hill, NC). Rabbit polyclonal antibodies to RPL11 and RPL23 were made 
in house as described previously (Lindström et al., 2007). Procedures and conditions for 
immunoprecipitation were performed as described previously (Itahana et al., 2003). 
 
 
 
 
67 
 
Immunohistochemical analysis 
Antigen retrieval for antibody on formalin-fixed paraffin sections was done by boiling 
paraffin samples in citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase activity was 
quenched by incubation in 3% H2O2 in methanol for 10 min. Ki-67 IHC staining of mouse spleen 
samples was used to detect proliferating cells. Antibody detection was performed with purified 
mouse anti-Ki-67 primary antibody (BD Pharmingen) and biotin-conjugated anti-mouse 
secondary antibody (Vector Laboratories). Ki-67-expressing cells were stained brown using a 
biotin-peroxidase kit (Vectastain Elite, Vector Laboratories). The ratio of positively stained cells 
to total cells was calculated. Student t test (P < 0.05 was considered significant) was used to 
compare the differences in proliferation levels between the different mouse genotypes. 
Antibodies to p53 (CM5; Leica Biosystems), BAX (#554104; BD Biosciences), and p21 (DCS 
60.2; Thermo Scientific) were purchased commercially, whereas antibodies to RPL23 were 
made in-house as described previously (Lindström et al., 2007). 
 
Mouse experiments 
Mice were bred and maintained strictly under protocol (13-044) approved by the 
Institutional Animal Care and Use Committee in the University of North Carolina Animal Care 
Facility. Mdm2m/m females were bred with p19Arf-/- males to obtain Mdm2+/m;p19Arf+/- offspring, 
which were then crossed with Mdm2+/m;p19Arf+/- mice to obtain Mdm2m/m;p19Arf-/- compound 
mice. For RAS-mediated tumorigenesis studies, Mdm2m/m;p19Arf-/- females were bred with 
HrasG12V transgenic males to obtain HrasG12V;Mdm2+/m;p19Arf+/- offspring, which were then 
crossed with Mdm2+/m;p19Arf+/- mice to obtain HrasG12V;Mdm2m/m;p19Arf-/- compound mice. 
HrasG12V transgenic mice were generously provided by Norman Sharpless (University of North 
Carolina at Chapel Hill). For survival studies, mice were palpated regularly for early signs of skin 
tumors and monitored for tumor progression and signs of morbidity. Moribund mice were 
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humanely euthanized. Mouse tumors and organs were fixed in formalin for histopathology and 
snap frozen for protein and RNA extraction. 
 
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5 Software (GraphPad 
Software). Kaplan-Meier survival curves were generated to assess lifespan. Quantitative PCR 
data are represented as mean ±SEM, and were analyzed by the Student’s t test. 
 
Apoptosis analysis 
Apoptosis levels of mouse tumor sections were assessed by the terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) assay (ApopTaq 
Peroxidase in situ Kit, S7100, Millipore, Temecula, CA).  
 
Histopathology 
Animals were autopsied and all tissues were examined regardless of their pathological 
status. Skin, tail and tumor tissue from HrasG12V;WT, HrasG12V;Mdm2m/m, HrasG12V;p19Arf-/- and 
HrasG12V;Mdm2m/m;p19Arf-/- transgenics, as well as tissue from nontransgenic counterparts were 
fixed overnight in 10% phosphate-buffered formalin and then transferred to 70% ethanol. 
Samples were sent to the UNC Histology Core Facility for paraffin embedding. Paraffin blocks 
were sectioned at 5-mm intervals for successive layers and stained with Hematoxylin and Eosin 
for histopathological examination. 
 
Cell culture 
Primary MEFs were isolated on embryonic day 13.5 and grown in a 37°C incubator with 
5% CO2 in Dulbecco’s Modified Eagle’s medium supplied with 10% fetal bovine serum and 
penicillin-streptomycin. For viral infections, WT, Mdm2m/m, p19Arf-/- and Mdm2m/m;p19Arf-/- MEFs 
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were infected with retroviruses expressing HRASG12V or pBabe control vector and selected with 
puromycin (2.5 μg/mL) for 3 days. Retrovirus-infected MEFs were then allowed to recover for 48 
h and harvested for analysis. For rapamycin treatments, retrovirus-infected cells were allowed to 
recover for 24 h before treatment with rapamycin (200 nM) for 18 h. For RAS inhibitor 
treatments, cells were infected with retroviruses expressing H-RASG12V or pBabe control vector 
and selected with puromycin (2.5 μg/mL) for two days. Retrovirus-infected cells were then 
allowed to recover for 24 h before treatment with trametinib or LY294002 for 8 h (HEK-293T) or 
48 h (MEFs) and harvested for analyses. MEFs at passage 1 to 4 were used for growth curves, 
western blotting and other analyses. 
 
siRNA interference 
Purified and annealed duplex small interfering RNA (siRNA) oligonucleotides targeting 
nucleotides relative to the translation initiation codon of mouse RPL23 (sequence: 
AATTCCGGATTTCCTTGGGTC) and control scrambled siRNA oligonucleotides were 
synthesized at Dharmacon (Lafayette, Colo.). Transfection was performed by using 
Lipofectamine and Plus reagents (Invitrogen) according to the manufacturer’s instructions. 
 
Quantitative PCR 
Total RNA was isolated using an RNeasy kit (74104, Qiagen, Hilden, Germany) and 
cDNA was synthesized using SuperScript III (18080400, Life Technologies, Waltham, MA, 
USA). qPCR was performed with SYBR Green master mix using the 7900HT Fast Real-time 
PCR system (Applied Biosystems, Waltham, MA, USA) according to the manufacturer's 
instructions. Data were collected and exported with SDS 2.2.2 software (Applied Biosystems). 
Relative expression was calculated using β-GAPDH as an internal control as indicated. Primers 
used were as follows: rpl23, 5’-GGACATGGTGATGGCCACAGTTAAG-3’ and 5’-
ACACTCCTTTGCCACTGGACCTG-3’; rpl11, 5’-CCTTTGGCATCCGGAGAAATGAGAAG-3’ 
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and 5’-GATCCCAATGCTTGGGTCGTATTTGATG3-’; and β-GAPDH, 5′-
AGGTCGGTGTGAACGGATTTG-3′ and 5′-TGTAGACCATGTAGTTGAGGTCA-3′. 
 
Immunofluorescence and confocal imaging 
Cells were fixed in 4% paraformaldehyde for 10 min at room temperature and 
permeabilized in 0.2% Triton X-100 for 5 min at 4°C. Permeabilized cells were blocked for 30 
min in 0.5% bovine serum albumin (BSA) in PBS, incubated in rabbit anti-RPL23 and mouse 
anti-B23/NPM (32-5200, Invitrogen) antibodies overnight at 4°C with rocking, and incubated with 
Alexa Fluor® secondary antibodies (488 donkey anti-rabbit and 594 donkey anti-mouse, 
Jackson ImmunoResearch) for 30 min at room temperature. Cells were mounted in 
fluorescence mounting medium (Dako, Carpenteria, CA, USA) and analyzed using an Olympus 
IX81 inverted microscope with SPOT™ digital microscope camera and imaging software 
(SPOT™ Imaging Solutions, Sterling Heights, MI, USA).  
 
Ethics statement 
This investigation has been conducted in accordance with ethical standards, the 
Declaration of Helsinki, national and international guidelines, and has been approved by the 
authors' Institutional Review Board. 
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Figure 3.1 MDM2C305F mutation partially rescues HRAS-induced tumorigenesis.  
 
Kaplan-Meier survival curves for HrasG12V;WT, HrasG12V;Mdm2m/m, HrasG12V;p19Arf-/-, and 
HrasG12V;Mdm2m/m;p19Arf-/- are shown. Median survival time for HrasG12V;p19Arf-/- mice was 6.4 
months. There was a significant difference between survival curves for HrasG12V;p19Arf-/- and 
HrasG12V;Mdm2m/m;p19Arf-/- mice (analyzed by log-rank test; P=0.0007). 
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Figure 3.2 MDM2C305F mutation does not affect the pathophysiology of p19ARF deletion 
and oncogenic RAS overexpression in tumor free skin tissue. 
 
A. H&E staining of the tumor-free skin areas of 16 week old WT, Mdm2m/m, p19Arf-/- and 
Mdm2m/m;p19Arf-/- mice. Scale bar, 200 µm. 
 
B. H&E staining of the tumor-free skin areas of 16 week old HrasG12V;WT, HrasG12V;Mdm2m/m, 
HrasG12V;p19Arf-/-, and HrasG12V;Mdm2m/m;p19Arf-/- mice. Scale bar, 200 µm. 
 
C. H&E staining of the skin tumors of HrasG12V;p19Arf-/- and HrasG12V;Mdm2m/m;p19Arf-/- mice. 
Skin tumors were collected at the time of death. Scale bar, 200 µm. 
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Figure 3.3 MDM2C305F mutation does not affect normal skin tissue. 
 
A. H&E staining of the tumor-free tails of 16 week old WT, Mdm2m/m, p19Arf-/-, and 
Mdm2m/m;p19Arf-/- mice. Scale bar, 200 µm. 
 
B. H&E staining of the tumor-free tails of 16 week old HrasG12V;WT, HrasG12V;Mdm2m/m, 
HrasG12V;p19Arf-/-, and HrasG12V;Mdm2m/m;p19Arf-/- mice. Scale bar, 200 µm. 
 
C. H&E staining of the tail tumors of HrasG12V;p19Arf-/- and HrasG12V;Mdm2m/m;p19Arf-/- mice. 
Tumors were collected at the time of death. Scale bar, 200 µm. 
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Figure 3.4 MDM2C305F mutation partially rescues HRAS-induced tumorigenesis. 
 
A. Representative Ki-67 staining of skin tumors from 16 week old mice. Brown staining, Ki-67-
positive proliferating cells; scale bar, 200 µm. The Ki-67 index (calculated as the percentage of 
Ki-67-positive tumor cells vs total cells in the view field from at least five randomly chosen fields 
along the edge of tumors) for the genotypes assayed is indicated in parentheses: 
HrasG12V;p19Arf-/- mice (51.8) and HrasG12V;Mdm2m/m;p19Arf-/- mice (11.8). Data are represented 
as mean ±SEM; ***, P < 0.001.  
 
B. Representative TUNEL staining of skin tumors from different genotypes of 16 week old mice; 
scale bar, 200 µm. The percentage of TUNEL-positive cells in the view field was calculated from 
at least five randomly chosen fields along the edge of tumors and is indicated in parentheses: 
HrasG12V;p19Arf-/- mice (3.2%) and HrasG12V;Mdm2m/m;p19Arf-/- mice (13.6%). Data are 
represented as mean ±SEM; **, P < 0.01. 
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Figure 3.5 MDM2C305F mutation correlates with increased p53 activity in HRAS-induced 
tumors. 
 
A. Representative p53 IHC staining of skin tumors from 16 week old HrasG12V;p19Arf-/- and 
HrasG12V;Mdm2m/m;p19Arf-/- mice; scale bar, 200 µm.  
 
B. Representative p21 IHC staining of skin tumors from 16 week old HrasG12V;p19Arf-/- and 
HrasG12V;Mdm2m/m;p19Arf-/- mice; scale bar, 200 µm.  
 
C. Early passage WT, Mdm2m/m, p19Arf-/-, Mdm2m/m;p19Arf-/-, Mdm2m/m;p53-/-, and p53-/- MEFs 
were harvested for Western blot analysis for p53 expression. 
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Figure 3.6 RAS induces RPL23 expression.  
 
A. Extracts from skin tissue of nontumor-bearing WT and Mdm2m/m mice and from their Hras 
transgenic counterparts were analyzed by Western blot. The relative expression of RPL23 and 
RPL11 is shown under the blot. 
 
B. Extracts from skin tissue of non-tumor-bearing p19Arf-/- and Mdm2m/m;p19Arf-/- mice and from 
their Hras transgenic counterparts were analyzed by Western blot. The relative expression of 
RPL23 and RPL11 is shown under the blot. 
 
C. Early passage WT and Mdm2m/m MEFs were infected with retrovirus expressing either pBabe 
vector (-) or pBabe-HRASG12V (+), selected with puromycin for 3 days, then allowed to recover 
for 48 hours before harvesting for Western blot analysis. 
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Figure 3.7 HRAS overexpression induces increased rpl23 transcription. 
 
A. WT MEFs were infected with retrovirus expressing either pBabe vector (-Ras) or pBabe-
HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl23 mRNA expression 
was calculated using -GAPDH as an internal control. Data are represented as mean ±SEM, 
and were analyzed by Student’s t test; ***, P <0.001. 
 
B. Mdm2m/m MEFs were infected with retrovirus expressing either pBabe vector (-Ras) or pBabe-
HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl23 mRNA expression 
was calculated as in (A). 
 
C. p19Arf-/- MEFs were infected with retrovirus expressing either pBabe vector (-Ras) or pBabe-
HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl23 mRNA expression 
was calculated as in (A). 
 
D. Mdm2m/m;p19Arf-/- MEFs were infected with retrovirus expressing either pBabe vector (-Ras) 
or pBabe-HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl23 mRNA 
expression was calculated as in (A). 
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Figure 3.8 HRAS overexpression does not induce increased rpl11 transcription. 
 
A. WT MEFs were infected with retrovirus expressing either pBabe vector (-Ras) or pBabe-
HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl11 mRNA expression 
was calculated using -GAPDH as an internal control. Data are represented as mean ±SEM, 
and were analyzed by Student’s t test; NS, no statistically significant difference between 
samples.  
 
B. Mdm2m/m MEFs were infected with retrovirus expressing either pBabe vector (-Ras) or pBabe-
HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl11 mRNA expression 
was calculated as in (A). 
 
C. p19Arf-/- MEFs were infected with retrovirus expressing either pBabe vector (-Ras) or pBabe-
HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl11 mRNA expression 
was calculated as in (A). 
 
D. Mdm2m/m;p19Arf-/- MEFs were infected with retrovirus expressing either pBabe vector (-Ras) 
or pBabe-HRASG12V (+Ras) and harvested for qPCR mRNA analysis. Relative rpl11 mRNA 
expression was calculated as in (A).  
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Figure 3.9 MDM2C305F mutation may increase relative RPL23 levels independent of p53.  
 
A. Early passage WT and p53-/- MEFs were infected with retrovirus expressing either pBabe 
vector (-) or pBabe-HRASG12V (+), selected with puromycin for 3 days, then allowed to recover 
for 48 hours before harvesting for Western blot analysis. The relative expression of RPL23 and 
RPL11 is shown under the blot.  
 
B. Extracts from WT and Mdm2m/m MEFs and from tissues of 30 week old WT and Mdm2m/m 
mice were analyzed by Western blot. The relative expression of RPL23 is shown under the blot. 
 
C. Representative RPL23 IHC staining of skin tumors from 16 week old HrasG12V;p19Arf-/- and 
HrasG12V;Mdm2m/m;p19Arf-/- mice. Scale bar, 200 m. 
 
D. Early passage WT and Mdm2m/m MEFs were harvested for qPCR mRNA analysis. Relative 
rpl23 mRNA expression was calculated using -GAPDH as an internal control. Data are 
represented as mean ±SEM, and were analyzed by Student’s t test; **, P <0.01. 
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Figure 3.10 MDM2C305F mutation does not alter RPL23 or RPL11 half-life. 
 
A. RPL23 half-life was determined in early passage WT and Mdm2m/m MEFs, which were treated 
with cycloheximide (50 mg/mL) and harvested with SDS lysis buffer at the indicated time points. 
The amount of RPL23 was quantified by densitometry, normalized to the level of actin, and 
plotted. Representative Western blots are shown in (C) and (D). 
 
B. Half-life of RPL11 in WT and Mdm2m/m MEFs as in (A). Representative Western blots are 
shown in (C) and (D). 
 
C. Representative Western blot of the half-life assay shown in (A) and (B) using early passage 
WT MEFs treated with Cycloheximide (50 g/mL) and harvested with SDS lysis buffer at the 
indicated time points. 
 
D. Representative Western blot of the half-life assay shown in (A) and (B) using early passage 
Mdm2m/m MEFs treated with cycloheximide (50 g/mL) and harvested with SDS lysis buffer at 
the indicated time points. 
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Figure 3.11 MDM2C305F mutation does not alter RPL23 localization but induces p53-
independent RPL23 upregulation. 
 
A. Early passage WT and Mdm2m/m MEFs were fixed and stained with rabbit anti-RPL23 
antibody followed by fluorescein isothiocyanate-conjugated anti-rabbit secondary antibody (red), 
and mouse anti-B23/NPM antibody followed by fluorescein isothiocyanate-conjugated anti-
mouse secondary antibody (green). Fluorescence images were captured with a cooled charge-
coupled device color digital camera (Model 2.2.0, Diagnostic) on an Olympus IX81 inverted 
microscope equipped with the appropriate fluorescence filters.  
 
B. Extracts from WT, Mdm2m/m, p53-/-, and Mdm2m/m;p53-/- MEFs were analyzed by Western blot. 
The relative expression of RPL23 is shown below the blot. 
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Figure 3.12 HRAS induces RPL23 protein increase through mTOR signaling.  
 
A. Early passage Mdm2m/m MEFs were infected with retrovirus expressing either pBabe vector 
(-) or pBabe-HRASG12V (+), treated with 200 nM rapamycin, and then harvested for Western blot 
analysis. 
 
B. HEK 293T cells were infected with retrovirus expressing either pBabe vector (-) or pBabe-
HRASG12V (+), treated with 200 nM rapamycin, and then harvested for Western blot analysis. 
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Figure 3.13 HRAS induces RPL23 protein increase through PI3K/MEK signaling. 
 
A. Early passage WT MEFs infected with retrovirus expressing either pBabe vector (-) or 
pBabe-HRASG12V (+) were treated with PI3K inhibitor LY294002 [1 nM (+) or 5 nM (++)] and 
then harvested for Western blot analysis.  
 
B. Early passage WT MEFs infected with retrovirus expressing either pBabe vector (-) or 
pBabe-HRASG12V (+) were treated with MEK inhibitor trametinib [1 nM (+) or 2.5 nM (++)] and 
then harvested for Western blot analysis. 
 
C. HEK 293T cells infected with retrovirus expressing either pBabe vector (-) or pBabe-
HRASG12V (+) were treated with (+) or without (-) PI3K inhibitor LY29004 (10 nM) before 
harvesting for Western blot analysis. 
 
D. HEK 293T cells infected with retrovirus expressing either pBabe vector (-) or pBabe-
HRASG12V (+) were treated with (+) or without (-) MEK inhibitor trametinib (10 nM) before 
harvesting for Western blot analysis. 
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Figure 3.14 HRAS induces p53 expression in the absence of p19ARF.  
 
A. Extracts from skin tissues of non-tumor-bearing p19Arf-/- and Mdm2m/m;p19Arf-/- mice and 
their non-tumor-bearing Hras transgenic counterparts were analyzed by Western blot. The 
relative expression of p53 is shown under the blot.  
 
B. Early passage p19Arf-/- and Mdm2m/m;p19Arf-/- MEFs were infected with retrovirus expressing 
either pBabe vector (-) or pBabe-HRASG12V (+) before harvesting for Western blot analysis. The 
relative expression of p53 is shown under the blot.  
 
C. Extracts from skin tissues of WT and Mdm2m/m mice and their non-tumor-bearing Hras 
transgenic counterparts were analyzed by Western blot. The relative expression of p53 is shown 
underneath the blot. 
 
D. Early passage WT and Mdm2m/m MEFs were infected with retrovirus expressing either pBabe 
vector (-) or pBabe-HRASG12V (+) before harvesting for Western blot analysis. The relative 
expression of p53 is shown under the blot. 
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Figure 3.15 RPL23 is required for RAS-mediated p53 induction in the absence of p19ARF.  
 
A. p19Arf-/- MEFs infected with retrovirus expressing either pBabe vector (-) or pBabe-HRASG12V 
(+) were transfected with a control scrambled RNA duplex (-) or RPL23 siRNA (+) for 2 days. 
Cell extracts were collected and analyzed by Western blot with the indicated antibodies. The 
relative expression of p53 is shown under the blot. 
 
B. Mdm2m/m;p19Arf-/- MEFs were treated and analyzed as in (A).  
 
C. WT MEFs were treated and analyzed as in (A). 
 
D. Mdm2m/m MEFs were treated and analyzed as in (A). 
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Figure 3.16 A model depicting a RAS-RPL23-MDM2-p53 pathway.  
 
A. Oncogenic RAS induces expression of both RPL23 and p19ARF independently. RPL23 and 
p19ARF both bind and inhibit MDM2 to stabilize p53.  
 
B. The RAS-MAPK-ERK and RAS-PI3K-AKT signaling cascades induce mTOR-dependent 
expression of RPL23. 
 
  
A B 
 
87 
 
CHAPTER 4: DISRUPTION OF THE RP-MDM2-P53 PATHWAYS ACCELERATES APC 
LOSS-INDUCED COLORECTAL TUMORIGENESIS4 
INTRODUCTION 
Colorectal cancer is the third most common cancer and the third leading cause of 
cancer-associated death worldwide (Jemal et al., 2009; Kamangar et al., 2006). Adenomatous 
polyposis coli (APC) loss or inactivation is sufficient to induce colorectal tumorigenesis, and 
inactivation of APC through mutation occurs in an estimated 80% of adenomatous polyposis 
(Groden et al., 1991; Kinzler et al., 1991; Kinzler and Vogelstein, 1996; Network, 2012; Nishisho 
et al., 1991). APC loss is also the cause of familial adenomatous polyposis (Groden et al., 
1991). This striking importance of APC in colorectal cancer has led APC to be named the 
‘gatekeeper’ of colonic carcinogenesis (Kinzler and Vogelstein, 1996). 
It has been established that a major function of APC is to degrade cytosolic β-catenin, 
thus preventing the formation of the nuclear β-catenin/T-cell factor-4 transcriptional complex and 
switching off Wnt signaling pathway transduction (Morin et al., 1997). The proto-oncogene c-
MYC has been identified as a target of the Wnt signaling pathway (He et al., 1998; Sansom et 
al., 2004; Van De Wetering et al., 2002). In addition, Sansom et al. discovered that deletion of c-
MYC diminishes the tumorigenic capacity of APC deficiency in the small intestine, establishing 
c-MYC as a critical mediator of intestinal neoplasia following APC loss (Sansom et al., 2007). As 
a transcription factor, the pro-tumorigenic functions of c-MYC have been attributed to its ability 
                                               
4 This chapter is adapted from a research article originally published in Oncogene. Shijie Liu, Yanping 
Zhang and I contributed to the design of the study. Shijie Liu and Jing Yang performed all of the 
experiments. Shijie Liu, Yanping Zhang, and I analyzed the data. I wrote the manuscript. Yanping Zhang, 
Shijie Liu and I edited the manuscript. Yanping Zhang finalized the manuscript. The original citation is as 
follows: Liu, S., Tackmann, N., Yang, J., and Zhang, Y. (2016a). Disruption of the RP-MDM2-p53 pathway 
accelerates APC loss-induced colorectal tumorigenesis. Oncogene. 36, 1374-1383. 
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to regulate a wide spectrum of gene expression programs (Dang et al., 2006; Eilers and 
Eisenman, 2008; Sabò and Amati, 2014). c-MYC target genes are believed to promote cell 
proliferation, tumorigenesis and cell transformation (Dang et al., 2006; Ji et al., 2011; Kim et al., 
2006; Schlosser et al., 2005; Schuhmacher et al., 2001; Zeller et al., 2003). Notably, elevated 
expression of c-MYC can also induce apoptosis (Hoffman and Liebermann, 2008). The 
biological meaning of this function is not yet fully understood, but is thought to result from a 
protective mechanism to counteract the effects of oncogenic activation and avoid propagation of 
transformed cells. 
Mutations in p53, known as a ‘the guardian of the genome’ and an overarching tumor 
suppressor, are the second most common genomic alteration in colorectal cancers (Network, 
2012). Loss of p53 activation has been shown to be important in the progression of c-MYC-
driven cancers. One recent study showed that p53-inactivating mutations are a leading cause of 
the relapse of MYC-driven medulloblastoma, and restoration of p53 activity reduces tumor 
growth and prolongs survival (Hill et al., 2015). On its own, c-MYC overexpression in B cells 
induces lymphomagenesis (Adams et al., 1985), and in c-MYC-driven lymphomas, p53 deletion 
significantly accelerates tumor growth (Schmitt et al., 1999). The role of p53 in APC loss-driven 
cancers is less clear, but some reports have shown that p53 loss can enhance the incidence 
and invasiveness of tumors in ApcMin/+ mice (Halberg et al., 2000). Nevertheless, the intricate 
interactions between c-MYC and p53 have yet to be clarified in the context of APC loss-driven 
tumor environments. 
The regulation of p53 is complex, but it is well established that MDM2 is the primary 
negative regulator of p53. MDM2 regulates p53 both by binding and inhibiting the transactivation 
domain of p53 and also serving as an E3 ubiquitin ligase for p53, causing its proteasomal 
degradation (Honda et al., 1997; Oliner et al., 1993). Upon various cellular stresses, transducer 
proteins bind and inhibit MDM2, thereby stabilizing p53. 
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c-MYC expression causes p53 stabilization and activation through two primary 
pathways. c-MYC induces the expression of p19ARF, which binds and inhibits MDM2 (Chen et 
al., 2013; Zhang et al., 1998; Zindy et al., 1998). In addition, c-MYC serves as a regulator of 
ribosomal biogenesis. When active, c-MYC induces the transcription of ribosomal proteins 
(RPs), which also bind and inhibit MDM2 (Kim et al., 2014; Lohrum et al., 2003; Macias et al., 
2010). This results in dual p19ARF-MDM2-p53 and RP-MDM2-p53 signaling pathways 
responsive to c-MYC overexpression. Deletion of p19ARF or disruption of the RP-MDM2-p53 
pathway by MDM2C305F mutation causes significant acceleration of c-MYC-driven lymphomas 
(Eischen et al., 1999; Macias et al., 2010). In the Eμ-Myc mouse model system these pathways 
are non-redundant, as concomitant disruption of both further accelerates c-MYC-driven 
lymphoma progression (Meng et al., 2015b). 
Although the deletion of c-MYC diminishes APC loss-driven intestinal tumorigenicity 
(Sansom et al., 2007), the elimination of p19ARF does not increase intestinal tumor formation in 
ApcMin/+ mice (Gibson et al., 2005), indicating that p19ARF signaling is not essential in this 
situation. Whether or not the RP-MDM2-p53 response pathway is important in preventing APC 
loss-induced tumor formation has not been explored. In this work, we sought to determine 
whether the RP-MDM2-p53 pathway could respond to APC loss-induced c-MYC upregulation to 
induce p53. To test the importance of this pathway, we crossed ApcMin/+ mice with mice bearing 
an MDM2C305F mutation, which disrupts the binding of RPL11 and RPL5 to MDM2, and analyzed 
intestinal tumorigenesis. 
 
RESULTS 
MDM2C305F mutation has no discernable effect on APC loss-induced small intestinal tumors 
As the loss of APC induces c-MYC expression through the Wnt signaling pathway (He et 
al., 1998), and the RP-MDM2-p53 pathway has been shown to be important in preventing c-
MYC-induced lymphomagenesis (Macias et al., 2010), we sought to determine whether this 
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pathway could also contribute to APC loss-induced tumor prevention. To this end, we crossed 
ApcMin/+ mice, which are prone to developing intestinal tumors, with Mdm2m/m mice, thus 
disrupting the RP-MDM2-p53 pathway. 
As Mdm2m/m mice have been shown to have a normal lifespan (Macias et al., 2010), we 
wanted to first examine normal intestinal tissues from W) and Mdm2m/m mice to ascertain 
whether the MDM2C305F mutation affects normal intestinal homeostasis. We harvested small 
intestine and colon tissue from 8 month old mice and performed both H&E staining and IHC 
staining to detect Ki-67 and cleaved caspase-3 (CC-3). Mdm2m/m mice have a normal intestinal 
epithelium compared with WT mice, with normal appearance of villi and crypts (Figure 4.1a). In 
addition, the Ki-67 and CC-3 staining of the intestinal epithelium did not differ between WT and 
Mdm2m/m mice (Figures 4.1b-c), indicating a similar intestinal proliferative and apoptotic rate 
between the two genotypes. Furthermore, we examined the expression of several intestinal cell 
markers, including an intestinal stem cell marker (lgr5), Paneth cell marker (lyz1), Goblet cell 
marker (muc2) and enteroendocrine cell marker (chga) by qPCR (Sato et al., 2009). No 
significant differences in the expression of any of these markers were detected between WT 
and Mdm2m/m mice in either the small intestine or the colon (Figure 4.1d). 
We next compared APC loss-induced tumor initiation in these mice by analyzing small 
intestinal polyp development in 15 week old ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m littermates. 
Upon gross examination of the small intestine, we did not observe a difference in the incidence 
of small intestinal polyps in the presence of the MDM2C305F mutation (Figure 4.2a). We 
performed histological analysis of the small intestinal tumor tissue and found that the average 
size of the tumors also did not differ between ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice 
(Figure 4.2b). In agreement with this observation, between the two genotypes there was no 
significant difference in overall lifespan (Figure 4.2c). Hence, the MDM2C305F mutation does not 
affect APC loss-induced small intestinal tumorigenesis, which is a major contributor to mortality 
in ApcMin/+ mice. 
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MDM2C305F mutation accelerates APC loss-induced colorectal cancer 
Although the overall survival and small intestinal tumor formation of ApcMin/+;Mdm2+/+ and 
ApcMin/+;Mdm2m/m mice did not differ significantly, we noticed an increased frequency of rectal 
prolapse and bleeding in the ApcMin/+;Mdm2m/m mice. More than 30% of ApcMin/+;Mdm2m/m mice 
presented with rectal prolapse and bleeding compared with <10% of ApcMin/+;Mdm2+/+ mice. 
Rectal prolapse and bleeding are indicative of increased colonic tumor formation, so we 
examined colonic polyps in ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice. We observed 
significantly more polyps in the colon of ApcMin/+;Mdm2m/m mice than in their ApcMin/+;Mdm2+/+ 
counterparts (on average 0.66 polyps per mouse in ApcMin/+;Mdm2+/+ vs 1.75 per mouse in 
ApcMin/+;Mdm2m/m) (Figure 4.3a), further suggesting increased colon tumor initiation. After 
histopathological examination, we determined that the average size of these polyps was 
significantly larger in ApcMin/+;Mdm2m/m mice (2.00 mm in ApcMin/+;Mdm2+/+ vs 2.95 mm in 
ApcMin/+;Mdm2m/m) (Figure 4.3b). Furthermore, the average size of the adenomas found in the 
tumor-bearing colons was also larger in ApcMin/+;Mdm2m/m mice (Figure 4.3c). Although both 
ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice developed small intestinal tumors with almost 
100% penetrance, on average only 40% of ApcMin/+;Mdm2+/+ mice developed colon 
adenocarcinomas, compared with almost 75% of ApcMin/+;Mdm2m/m mice (Figure 4.3d). The 
sizes of colon polyps in ApcMin/+;Mdm2m/m mice were variable, but there were many more large 
polyps (>4 mm) than in ApcMin/+;Mdm2+/+ mice (Figure 4.4a). Although the architecture of the 
normal colonic epithelium in ApcMin/+;Mdm2m/m mice was similar to that of ApcMin/+;Mdm2+/+ mice, 
the architecture of the colon adenocarcinomas in the ApcMin/+;Mdm2m/m mice showed higher 
grade complex glandular structures than the colon adenocarcinomas from ApcMin/+;Mdm2+/+ 
mice of same age (Figure 4.4b). Taken together, these evidences suggest that the disruption of 
the RP-MDM2-p53 pathway by MDM2C305F mutation accelerates APC loss-driven colonic tumor 
initiation and growth. 
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MDM2C305F mutation promotes proliferation and inhibits apoptosis in APC loss-induced colon 
cancers 
We sought to further characterize the colon tumors. To this end, we first performed Ki-67 
staining in normal and tumor samples (Figures 4.5a-b). We observed significantly more cells 
with positive Ki-67 staining in ApcMin/+;Mdm2m/m tumors compared with their WT MDM2 
counterparts (46% in ApcMin/+;Mdm2+/+ vs 60% in ApcMin/+;Mdm2m/m), indicating increased 
proliferation upon MDM2C305F mutation. We also performed IHC staining to detect CC-3 in colon 
and tumor tissues (Figures 4.5c-d). We observed a significantly lower percentage of cells with 
CC-3 staining in ApcMin/+;Mdm2m/m tumors as compared with ApcMin/+;Mdm2+/+ tumors (2.7% of 
cells in ApcMin/+;Mdm2+/+ vs 1.1% in ApcMin/+;Mdm2m/m), indicating a decreased percentage of 
cells undergoing apoptosis. Next, we detected average overall CC-3 levels in these tissues by 
western blot (Figure 4.6a), and observed a similarly muted CC-3 signal in ApcMin/+;Mdm2m/m 
tumors. As a result of the difference in average Actin levels between normal colon and tumor 
tissues, we included Ponceau S staining as an additional loading control. To confirm the CC-3 
results, we performed additional TUNEL assays (Figures 4.6b-c) and observed a significantly 
decreased TUNEL signal in ApcMin/+;Mdm2m/m tumors (5.3% of cells in ApcMin/+;Mdm2+/+ vs 2.4% 
in ApcMin/+;Mdm2m/m). This result is consistent with decreased levels of apoptosis in these cells. 
Together, these results indicate that the MDM2C305F mutation promotes proliferation and inhibits 
apoptosis in colon cancers induced by APC loss. 
 
APC loss-induced colon cancers express high levels of c-MYC and RPL11 
As the MDM2C305F mutation disrupts the binding of RPL11 and RPL5 to MDM2 
(Lindström et al., 2007; Macias et al., 2010), and RPL11 and RPL5 are transcriptional targets of 
c-MYC (Coller et al., 2000; Menssen and Hermeking, 2002) we analyzed c-MYC, RPL11 and 
RPL5 levels to determine if the MDM2C305F mutation affects APC loss-induced c-MYC signaling. 
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First, we performed IHC staining for c-MYC in normal and tumor tissues (Figure 4.7a). As 
expected, there was an increase in c-MYC detected in tumor tissue compared with normal 
tissue and there was no difference in c-MYC levels between the two genotypes. This pattern 
was also observed in IHC staining for RPL11, a downstream target of c-MYC (Figure 4.7b). In 
order to evaluate the expression of c-MYC, RPL11 and RPL5 more precisely, we performed 
qPCR and western blotting using samples from normal colon or colonic adenomas. Consistent 
with IHC staining, we observed an approximately 2.5-fold increase in c-myc, rpl11 and rpl5 
mRNAs in tumor samples of either genotype (Figures 4.7c-e). 
By western blot, we were able to confirm the loss of APC in tumor tissue of both 
ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice, as well as observe a comparable increase in c-
MYC, RPL11 and RPL5 abundance (Figure 4.8a). These results indicate that the MDM2C305F 
mutation does not ultimately affect the expression of upstream c-MYC, RPL11 and RPL5 
signaling in colon cancers and that APC loss still induces relatively high levels of these proteins 
independent of MDM2 mutational status. 
To investigate the apparent discrepancy in tumor formation after MDM2C305F mutation 
between small intestine (Figure 4.2) and colon (Figure 4.3), we also analyzed c-MYC and 
RPL11 levels in normal small intestine and small intestinal adenoma tissues (Figure 4.8b). 
Although we were unable to detect c-MYC in these tissues, we found that RPL11 levels were 
unchanged after small intestinal tumor formation, in contrast to what we observed in colon 
tumors. This provides a potential explanation for the disparity of tumor formation rates in colon 
and small intestine of ApcMin/+;Mdm2m/m mice compared with ApcMin/+;Mdm2+/+ mice, as there is 
likely to be little RP-MDM2-p53 signaling action in small intestinal tissues. Although c-MYC has 
been shown to be an oncogene critical in mediating colorectal tumorigenesis following APC 
deletion, in our hands the role of RPL11 in mediating c-MYC-induced tumorigenesis appears to 
be colon tissue specific. 
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MDM2C305F mutation attenuates p53 activation in colon tumors 
As the MDM2C305F mutation disrupts the binding of RPL11 and RPL5 to MDM2, thus 
abrogating ribosomal stress-mediated p53 induction, we wanted to analyze p53 levels and 
activity in ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mouse colon tumors to determine whether p53 
induction correlated with the observed increase in proliferation and decrease in apoptosis in 
ApcMin/+;Mdm2m/m tumors. We found that in ApcMin/+;Mdm2m/m mouse colon tumors, p53 protein 
levels were notably lower than in tumors from ApcMin/+;Mdm2+/+ mice (Figure 4.9a). The protein 
levels of BAX, a p53 target important for induction of apoptosis (Toshiyuki and Reed, 1995), and 
of MDM2, also a p53 target, followed the same trend. We also compared p53 transcriptional 
activation in these tissues. In normal tissues, we observed no significant difference between the 
relative levels of mdm2 and bax mRNA; however, in tumor tissues, there was significantly less 
transcription of mdm2 and bax (Figures 4.9b-c) in ApcMin/+;Mdm2m/m mice compared with 
ApcMin/+;Mdm2+/+, indicating attenuated p53 induction upon MDM2C305F mutation. 
To more precisely determine whether APC loss will increase signaling to the RP-MDM2-
p53 pathway, we knocked down Apc expression in the colonic tumor cell line HCT116, which 
has WT p53. We infected HCT116 cells with a lentivirus containing short hairpin RNA (shRNA) 
targeting Apc, and after puromycin selection we confirmed a decrease in Apc expression by 
qPCR (Figure 4.10a). As expected, knockdown of Apc induced the expression of c-MYC, 
RPL11 and RPL5 (Figure 4.10b). In addition, p53 was stabilized. We next performed 
immunoprecipitation of MDM2 and probed for RPL11 and RPL5 binding. After Apc knockdown, 
there was a clear increase in both RPL11-MDM2 and RPL5-MDM2 binding, suggesting that 
APC loss triggers RP-MDM2 interaction to activate p53 in colon tumors (Figure 4.10b). Taken 
together, these results collectively suggest that the RP-MDM2-p53 pathway is important for the 
prevention of APC loss-induced colonic tumors. 
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DISCUSSION 
The roles of APC deletion and p53 inactivation in intestinal tumorigenesis are not 
completely understood. Although p53 is widely known as an overarching tumor-suppressor 
protein, APC has been established as the most important intestinal tumor suppressor. Large-
scale sequencing of intestinal tumors has indicated that Apc and p53 are the most frequently 
mutated genes at 81% and 60% of these tumors, respectively (Network, 2012).  
In addition, several mouse models have established that upon Wnt signaling pathway 
activation, the major consequence of APC loss, p53 has critical tumor-suppressive functions 
(Elyada et al., 2011; Schwitalla et al., 2013). It is possible that activation of the Wnt signaling 
target c-MYC drives growth and proliferation, stimulating p53 to perform its tumor-suppressive 
functions but at the same time pressuring its inactivation, allowing for tumor maintenance. Here, 
we confirm that p53 is indeed induced by APC deletion (Figure 4.9). Although inactivating 
mutations of APC are considered to be a first step for colonic carcinogenesis, p53 is thought to 
act as a final barrier to carcinoma formation (Kinzler and Vogelstein, 1996). Our results are 
consistent with this notion. 
We also demonstrate that inactivation of the c-MYC responsive RP-MDM2-p53 pathway 
through MDM2C305F mutation allows for increased APC loss-driven colon 
tumorigenesis. ApcMin/+;Mdm2m/m mice display increased tumor size and incidence compared 
with their ApcMin/+;Mdm2+/+ counterparts (Figure 4.3), which correlates with decreased p53 
protein abundance and activation (Figure 4.9). 
 
The importance of p19ARF- and RP-dependent p53 activation is tissue specific 
Along with others, this work also clarifies that there are distinct and tissue-specific roles 
for the RP-MDM2-p53 and p19ARF-MDM2-p53 pathways in tumorigenesis. Although each of 
these pathways have been shown to be independently critical for the prevention of c-MYC-
driven lymphoma (Meng et al., 2015b), the role of these pathways in APC loss driven, c-MYC-
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dependent tumorigenesis is more ambiguous. It has been previously established that p19ARF 
loss does not accelerate or promote intestinal tumors upon APC loss (Gibson et al., 2005), but 
our work indicates that loss of RP-MDM2 interaction can sensitize mice to APC loss-driven 
colonic tumorigenesis (Figure 4.3). In this study, we observed no difference in survival 
between ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice; however, in both genotypes there were 
many more tumors in the small intestine than colon, which is consistent with previous reports 
(Moser et al., 1992; Moser et al., 1990). Observed differences in colon tumor formation 
depending on MDM2 mutational status may not have an effect on survival because of the 
relatively higher tumor burden in the small intestine compared with the colon. In future studies, it 
would be informative to cross MDM2C305F mice with mice expressing a colon tissue-
specific Apc deletion, such as the CDX2P-CreERT2 Apcflox/flox model (Feng et al., 2013), to 
determine whether differential RP-MDM2-p53 pathway activation could contribute to a 
difference in tumor burden and overall lifespan. 
As RPL11 is a primary RP responder from c-MYC to p53 (Fumagalli et al., 2009a; 
Fumagalli et al., 2012), disruption of RPL11-MDM2 binding by MDM2C305F mutation is likely to 
have little effect on p53 activation if RPL11 protein abundance does not change. It appears from 
our data that c-MYC signaling to RPL11 is much more prominent in colon tissue than in small 
intestine (Figure 4.8), but the reason for this is presently unclear. Although this study 
demonstrates that there are tissue-specific roles for each of the RP-MDM2-p53 and p19ARF-
MDM2-p53 signaling pathways, it also raises questions about why p19ARF signaling is less 
important in APC loss-driven c-MYC activation. 
One possible reason for the difference in activation of these two pathways during colonic 
tumorigenesis could be due to a difference in threshold of c-MYC response. As a global 
transcriptional amplifier (Littlewood et al., 2012), c-MYC can trigger different programs 
depending on certain levels of expression. Both in vitro and in vivo studies have demonstrated 
that p19ARF induction requires a high level of c-MYC expression (Chen et al., 2013; Murphy et 
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al., 2008). On the other hand, c-MYC serves as a direct regulator of ribosomal biogenesis via 
the transcriptional control of RNA and protein components of ribosomes, the gene products 
required for the processing of ribosomal RNA, the nuclear export of ribosomal subunits and the 
initiation of mRNA translation (van Riggelen et al., 2010). It is possible that RP-MDM2-p53 
activation requires a lower level of c-MYC activation than that of the p19ARF-MDM2-p53 
pathway. In mouse model systems, where c-MYC is directly overexpressed (for example, Eμ-
Myc), rather than upregulated by a change in upstream signaling (for example, ApcMin/+), 
p19ARF is critical in prevention of tumorigenesis (Eischen et al., 1999). The presence of the 
RP-MDM2-p53 pathway could explain why deletion of p19ARF does not sensitize mice to APC 
loss-induced intestinal tumorigenesis. 
In this study, we demonstrated that RPL11 and RPL5 are upregulated by the APC-MYC 
axis, correlating with p53 induction and apoptosis. We postulate that the RP-MDM2-p53 
pathway is a fail-safe mechanism for c-MYC-dependent tumorigenesis because it can be 
executed directly after c-MYC activation. It is clear from the ApcMin/+ mouse model and others 
that the interplay of these pathways is tissue specific, and more work will need to be done to 
establish the biological and contextual significance for these tumor-suppressive pathways. 
 
EXPERIMENTAL PROCEDURES 
Mouse experiments 
All mice were bred and maintained on a 12-h light and dark cycle. Mdm2C305F mutant 
mice were generated as previously described (Macias et al., 2010). ApcMin/+ mice on C57BL/6 J 
background were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) (stock 
number J002020). All mice were handled in strict accordance with protocol (10-045) approved 
by the Institutional Animal Care and Use Committee at The University of North Carolina at 
Chapel Hill. 
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Histological analysis 
Intestines were dissected and flushed gently with cold phosphate-buffered saline and 
rolled into a compact circle. They were then fixed in 10% formalin overnight, dehydrated in 50% 
ethanol and stored in 70% ethanol until they were transferred to the Histology Research Core 
Facility at the University of North Carolina at Chapel Hill (UNC) for paraffin embedding. Sections 
(4 μm) were cut and then processed for H&E staining or for IHC staining. For IHC staining, 
sections were deparaffinized in SafeClear II (Fisher Scientific, Waltham, MA, USA) and 
rehydrated in gradient alcohols (100%, 95%, 85%, 70%, H2O). Antigen retrieval was performed 
by boiling slides in 10 mM sodium citrate buffer, pH 6.0. Endogenous peroxidase activity was 
quenched with 3% H2O2 in methanol for 15 min. To develop the staining, we used the 
VECTASTAIN Elite ABC kit (PK6100, Vector Laboratories) following the manufacturer’s 
instructions. Slides were counterstained with Harris’ hematoxylin (Sigma, St Louis, MO, USA) 
and then dehydrated and mounted in Permount (Fisher Scientific). The following primary 
antibodies were used: rabbit monoclonal anti-Ki-67 (NeoMarkers, Fremont, CA, USA, #RM-
9106), rabbit polyclonal anti-CC-3 (Cell Signaling, Beverly, MA, USA, #9661), rabbit polyclonal 
anti-c-MYC (Santa Cruz, Dallas, TX, USA, N262) and rabbit polyclonal anti-RPL11 
(homemade). All primary antibodies were incubated overnight. For TUNEL assays, sections 
were deparaffinized following the IHC protocol, and then stained with the Apoptosis Detection 
Kit (S7100, Millipore, Billerca, MA, USA) following the manufacturer’s instructions. 
 
Quantitative PCR 
Total RNA was prepared from mouse tissues using Trizol Reagent (Invitrogen, Carlsbad, 
CA, USA, #15596-026). RNA concentration was determined using a NanoDrop 
spectrophotometer (Thermo Scientific, Waltham, MA, USA, NanoDrop 2000c) and quality was 
assessed by agarose gel electrophoresis. Complementary DNA was synthesized using 
Superscript III reverse transcriptase (Invitrogen, 18080-051). qPCR was performed with SYBR 
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Green probes using the Applied Biosystems (Carlsbad, CA, USA) 7900HT Fast Real-Time PCR 
system. Thermal cycling conditions were 50 °C for 2 min, 95 °C for 5 min, followed by 40 cycles 
of 95 °C for 15 s and 60 °C for 1 min. Target gene transcript levels were normalized to β-actin 
transcript levels obtained in each sample via the subtraction of the Ct value of β-actin from the 
Ct value for each target gene. Results were expressed as the fold-change in transcript levels. 
Primers used for qPCR were as follows: β-actin, 5′-GGCTGTATTCCCCTCCATCG-3′ and 5′-
CCAGTTGGTAACAATGCCATGT-3′; c-myc, 5′-TGAGCCCCTAGTGCTGCAT-3′ and 5′-
AGCCCGACTCCGACCTCTT-3′; rpl11, 5′-CAATATCTGCGTCGGGGAGA-3′ and 5′-
TTCCGCAACTCATACTCCCG-3′; rpl5, 5′-AGCATTGACGGTCAGCCTGGTG-3′ and 5′-
CTGACCCATGATGTGCTTCCGATG-3′; bax, 5′-GGACAGCAATATGGAGCTGCAGAGG-3′ and 
5′-GGAGGAAGTCCAGTGTCCAGCC-3′; mdm2, 5′-TGTGTGAGCTGAGGGAGATG-3′ and 5′-
CACTTACGCCATCGTCAAGA-3′; lgr5, 5′-CAAGCCATGACCTTGGCCCTG-3′ and 5′-
TTTCCCAGGGAGTGGATTCTATT-3′; lyz1, 5′-GGAATGGATGGCTACCGTGG-3′ and 5′-
CATGCCACCCATGCTCGAAT-3′; muc2, 5′-CGGTTCCAGAACCATACCTG-3′ and 5′-
GGTCAGCAGCCTCTCACATT-3′; chga, 5′-CACAGCAGCTTTGAGGATGA-3′ and 5′-
ATGGGGGACTCTTGGTTAGG-3′. 
 
Protein analysis 
For western blotting, proteins were extracted from tissues as previously described 
(Macias et al., 2010). Briefly, mouse tissue was homogenized and lysed in 0.5% NP-40 lysis 
buffer. Proteins were detected by using either Pico or Dura enhanced chemiluminescence 
systems (Thermo Scientific, SuperSignal West Dura Substrate). The following primary 
antibodies were used: rabbit polyclonal anti-c-MYC (N262; Santa Cruz), mouse monoclonal 
anti-p53 (NCL-505; Novocastra, Buffalo Grove, IL, USA), mouse monoclonal anti-MDM2 (2A10, 
homemade), rabbit polyclonal anti-CC-3 (#9661; Cell Signaling), rabbit polyclonal anti-APC 
(NBP2-15422; Novus Biologicals, Littleton, CO, USA), rabbit polyclonal anti-BAX (554104, BD 
 
100 
 
Biosciences, San Jose, CA, USA), rabbit polyclonal anti-RPL11 and RPL5 (made in house as 
previously described) (Macias et al., 2010). For protein analysis of HCT116 cells (purchased 
and authenticated from the UNC Tissue Culture Facility, Chapel Hill, NC, USA), we 
homogenized and lysed cells in 0.1% NP-40 lysis buffer. For each sample, 2.5 mg of protein 
extract was incubated with antibodies against MDM2 (4B11) overnight at 4 °C before incubation 
with protein A beads for 60 min. Immunoprecipitates were washed three times in ice-cold lysis 
buffer, resuspended in sodium dodecyl sulfate loading buffer and subjected to western blot 
analysis. 
 
Lentiviral vector and infection 
For shRNA transduction, a pLKO.1-puro vector (Addgene, Cambridge, MA, USA) 
containing shRNA targeting human Apc (5′-GAAAGTGGAGGTGGGATATTA-3′) and a 
scrambled control (5′-CAACAAGATGAAGAGCACCAA-3′) were used. We made the viral 
particles in HEK-293 T cells using pspAX2 and pMD2.G plasmids. Twenty-four hours after 
infection, positively infected HCT116 cells were selected with puromycin. Stable shRNA 
knockdown cell lines were used for further analysis. 
 
Statistical analysis 
Results are represented as mean ±SEM. Differences in tumor size measurements and 
tumor numbers were evaluated for significance using the unpaired t-test. Quantitative PCR data 
and IHC quantification differences were also evaluated for significance using the unpaired t-test. 
Variances were not significantly different within treatment groups. A P-value <0.05 was 
considered significant for all analyses. Significant differences between experimental groups 
were: *P<0.05, **P<0.01 or ***P<0.001. Each experiment was performed at least two times. At 
least three mice per group were used for every experiment. No blinding or randomization were 
used. Calculations were performed using the GraphPad Prism 5 software (La Jolla, CA, USA). 
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Ethics statement 
This investigation has been conducted in accordance with ethical standards, the 
Declaration of Helsinki, national and international guidelines, and has been approved by the 
authors' institutional review board. 
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Figure 4.1 MDM2C305F mutation has no discernable effect on intestinal homeostasis. 
 
A. H&E staining of small intestine and colon isolated from 8 month old WT and Mdm2m/m mice. 
Scale bar, 200 μm. 
 
B. Ki-67 IHC staining of proliferating cells in small intestine and colon isolated from 8 month old 
mice. Proliferating cells are located at the bottom of crypts in both the small intestine and colon. 
Scale bar, 200 μm. 
 
C. IHC staining of CC-3 to probe for apoptotic cells (indicated by arrows) in small intestine and 
colon tissue isolated from 8 month old mice. Scale bar, 100 μm.  
 
D. mRNA expression of lgr5, lyz1, muc2 and chga in small intestine or colon from 8 month old 
WT or Mdm2m/m mice was analyzed by qPCR. n=3 for each genotype. Error bars, ±SEM. 
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Figure 4.2 MDM2C305F mutation has no discernable effect on APC loss-induced small 
intestinal tumors. 
 
A. Small intestines were isolated from 15 week old mice, and polyp numbers per mouse were 
counted under a dissection microscope (n=12 for each genotype).  
 
B. The average cross sectional areas (CSAs) of H&E-stained small intestinal adenomas were 
determined quantitatively using publicly available ImageJ software. 
 
C. Kaplan-Meier survival curves for ApcMin/+;Mdm2+/+ (n=40) and ApcMin/+;Mdm2m/m (n=18) mice 
are shown. The median survival times did not differ significantly between the two genotypes. 
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Figure 4.3 MDM2C305F mutation increases prevalence of APC loss-induced colon cancer. 
 
A. Colon tissue was isolated from 15 week old mice, and polyp numbers per mouse were 
counted under a dissection microscope. Error bars, ±SEM.; *P<0.05.  
 
B. The average size of colonic polyps in each genotype (n=12 mice). ApcMin/+;Mdm2m/m mice had 
significantly more large (44 mm) polyps. Error bars, ±SEM; *P<0.05.  
 
C. The average cross sectional areas (CSA) of H&E stained colon adenomas were determined 
quantitatively using ImageJ. Error bars, ±SEM;*P<0.05.  
 
D. The incidence of colon tumors in each genotype (n =12), measured by percentage of mice 
with observed colon tumors.  
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Figure 4.4 MDM2C305F mutation changes the pathophysiology of APC loss-induced colon 
cancer. 
 
A. Pictures depicting the colonic polyps from ApcMin/+;Mdm2+/+ or ApcMin/+;Mdm2m/m mice under a 
dissection microscope. Adenomas from ApcMin/+;Mdm2m/m mice appeared significantly larger.  
 
B. Representative H&E-stained sections from ApcMin/+;Mdm2+/+ or ApcMin/+;Mdm2m/m mouse 
colon (normal) and colon adenoma (tumor) tissue. Scale bar, 500 μm. 
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Figure 4.5 APC loss-induced colon cancers containing MDM2C305F mutation grow quickly.  
 
A. Ki-67 IHC staining of proliferating cells in colon (normal) and colonic adenoma (tumor) tissue 
isolated from 15 week old mice. In normal colon, the proliferating cells are located at the bottom 
of crypts, whereas tumor cells are highly proliferative. Scale bar, 200 μm. 
 
B. Percentage of Ki-67-positive cells in colonic adenomas was calculated quantitatively from five 
images using ImageJ. Error bars, ±SEM; **P<0.01.  
 
C. Apoptosis was measured by IHC staining of CC-3 in colon (normal) and colonic adenoma 
(tumor) tissue. Scale bar, 100 μm.  
 
D. Percentage of CC-3 positive cells in colonic adenomas was calculated quantitatively from five 
images using ImageJ. Error bars, ±SEM; ***P<0.001.  
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Figure 4.6 MDM2C305F mutation inhibits apoptosis in APC loss-induced colon cancers.  
 
A. Western blotting was performed with protein lysates isolated from colonic polyps (tumor) or 
adjacent normal colon tissues (normal). n =3 for each group. Pon S, Ponceau S staining. 
 
B. Apoptosis was measured by TUNEL staining in colon (normal) and colonic adenoma (tumor) 
tissue. In normal colon, apoptotic cells are located at the tips of the villi. Scale bar, 125 μm.  
 
C. Percentage of TUNEL-positive cells from colonic adenomas was calculated quantitatively 
from five images using ImageJ. Error bars, ±SEM; ***P<0.001. 
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Figure 4.7 APC loss-induced colon cancers express increased levels of c-MYC and 
RPL11. 
  
A. IHC staining was performed in colon (normal) and colonic adenomas (tumor) to detect the 
expression of c-MYC. Scale bar, 75 μm.  
 
B. IHC staining was performed in colon (normal) and colonic adenomas (tumor) to detect the 
expression of RPL11. Scale bar, 75 μm.  
 
C. qPCR analysis of mRNA expression of c-myc in colon (normal) or colonic adenomas (tumor) 
from ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice. n=3 for each genotype. Error bars, ±SEM; 
**P<0.01, ***P<0.001.  
 
D. qPCR analysis of mRNA expression of rpl11 in colon (normal) or colonic adenomas (tumor) 
from ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice. n=3 for each genotype. Error bars, ±SEM; 
**P<0.01, ***P<0.001.  
 
E. qPCR analysis of mRNA expression of rpl5 in colon (normal) or colonic adenomas (tumor) 
from ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice. n=3 for each genotype. Error bars, ±SEM; 
*P<0.05, ***P<0.001. 
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Figure 4.8 APC loss-induced colon tumors, but not small intestine tumors, express 
increased levels RPL11. 
 
A. Western blotting analysis of protein lysates isolated from colon (normal) or adjacent colonic 
adenomas (tumor) with three mice per genotype. APC expression was undetectable in colonic 
adenomas, implying the loss of both WT alleles. The bar graph illustrates the quantification of 
the western blot. Error bars, ±SEM; *P<0.05, **P<0.01.  
 
B. Western blotting analysis of protein lysates isolated from small intestine (normal) or adjacent 
adenomas (tumor) with three mice per genotype. c-MYC expression was undetectable in small 
intestinal tissue. The bar graph illustrates the quantification of the western blot. Error bars, 
±SEM. 
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Figure 4.9 MDM2C305F mutation attenuates p53 activation in APC loss-induced colon 
cancers.  
 
A. Western blotting analysis of protein lysates isolated from colon (normal) or adjacent colonic 
adenomas (tumor) with three mice per genotype. p53 and MDM2 were undetectable in normal 
colon. The bar graph illustrates the relative protein levels in tumor samples from 
ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice. Error bars, ±SEM; *P<0.05.  
 
B. qPCR analysis of relative mRNA expression of mdm2 in colon (normal) or colonic adenomas 
(tumor) from ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice. n=3 for each genotype. Error bars, 
±s.e.m.; NS, not significant, *P<0.05.  
 
C. qPCR analysis of relative mRNA expression of bax in colon (normal) or colonic adenomas 
(tumor) from ApcMin/+;Mdm2+/+ and ApcMin/+;Mdm2m/m mice. n =3 for each genotype. Error bars, 
±SEM, **P<0.01. 
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Figure 4.10 MDM2C305F mutation attenuates RP-mediated p53 activation in APC loss-
induced colon cancers. 
 
A. qPCR analysis of relative mRNA expression of Apc in HCT116 cells infected with lentivirus 
containing either a negative control scrambled shRNA (shNC) or Apc shRNA (shApc). Error 
bars, ±SEM; ***P<0.001.  
 
B. HCT116 cells were infected with lentivirus containing shRNA targeting either Apc (shApc) or 
a scrambled control (shNC). Following selection with puromycin, immunoprecipitation (IP) of 
MDM2 was performed, followed by western blotting with the indicated antibodies. Quantification 
of protein expression was performed using ImageJ, and the relative protein expression is 
indicated under the blots. The amount of RPL11 or RPL5 immunoprecipitated (relative to MDM2 
IP protein levels) is also indicated under each IP blot. 
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CHAPTER 5: DISRUPTING MDM2 E3 LIGASE ACTIVITY PROLONGS SURVIVAL IN MYC-
INDUCED LYMPHOMA5 
INTRODUCTION 
p53, also known as “the guardian of the genome,” is an important transcription factor 
that is capable of tumor suppression through promoting or repressing the transcription of genes 
involved in cell cycle arrest, senescence, apoptosis, and metabolic regulation (Lane, 1992). The 
regulation of p53 is thought to be primarily mediated by MDM2 and MDMX, which form a 
heterodimer through their RING domains (Wade et al., 2010). Together, MDM2 and MDMX 
regulate p53 both by binding to p53 and inhibiting its gene transactivation activity, as well as 
promoting p53 ubiquitination, nuclear export, and proteasomal degradation. MDM2 harbors E3 
ubiquitin ligase activity, while MDMX does not (Shvarts et al., 1996), but it is hypothesized that 
the MDM2/MDMX heterodimer is able to promote more efficient p53 inhibition than MDM2 alone 
(Linares et al., 2003). 
p53 is continuously transcribed and translated, but upon the induction of a stress, such 
as DNA damage or oncogene activation, MDM2 and MDMX inhibitory functions are repressed 
by various upstream factors, promoting the stabilization and activation of p53. After resolving 
the stress, the cell must return p53 protein and activity to basal levels or risk the consequences 
of prolonged apoptosis, cell cycle arrest, or senescence signals. Interestingly, mice lacking 
mdm2 or mdmx exhibit p53 dependent embryonic lethality, demonstrating the importance of 
each protein to proper p53 regulation (de Oca Luna et al., 1995; Jones et al., 1995; Parant et 
al., 2001). Further targeted knockin mouse models have explored the contributions of individual 
                                               
5 This chapter represents preliminary data from ongoing research. I have performed all experiments under 
the direction of Yanping Zhang.  
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MDM2 and MDMX functions towards in vivo p53 regulation. For instance, MDM2- or MDMX-p53 
binding in the absence of MDM2-MDMX heterodimer formation or MDM2 E3 ligase activity is 
insufficient to control p53 during embryogenesis (Itahana et al., 2007). In this in vivo study, a 
mutation in the RING domain of MDM2 (MDM2C462A) prevents its ability to ubiquitinate p53 and 
interact with MDMX. Mice homozygous for this mutation demonstrated p53-dependent 
embryonic lethality. Similarly, it has been shown that MDM2/MDMX heterodimer formation is 
critical for controlling p53 activation during embryonic development (Huang et al., 2011; Pant et 
al., 2011).  
 On the other hand, mice containing a mutation in the C-terminal domain of MDM2 
(MDM2Y487A), which disrupts MDM2 E3 ligase activity while maintaining MDM2-MDMX 
interaction, survive to adulthood and exhibit normal lifespans even though p53 degradation is 
absent (Tollini et al., 2014). However, these mice are abnormally susceptible to sub lethal doses 
of ionizing radiation (IR), succumbing to hematopoietic failure an average of 22 days after 
treatment. This suggests that, though MDM2 E3 ligase function is dispensable for basal p53 
regulation, it is especially important for regulating p53 in response to stress. This study 
underscored the situation-specific importance of individual MDM2/MDMX functions towards p53 
regulation. To fully understand p53 regulation, it is important to determine under which contexts 
various MDM2/MDMX functions are required. 
 Although it has been demonstrated that MDM2 E3 ligase activity is important for 
reducing p53 levels and activity following acute DNA damage stress, it is unknown whether 
other stresses require such careful intervention. In this study, MDM2Y487A mice were crossed 
with Eμ-Myc mice to determine whether there is a difference in the necessity of MDM2 E3 ligase 
activity-mediated p53 regulation in vivo between an acute DNA-damaging stress versus chronic 
oncogenic c-MYC overexpression. 
 Eμ-Myc mice overexpress c-MYC in B-lymphoid cells due to the integration of c-myc 
under the control of the IgG heavy chain enhancer element (Harris et al., 1988). This 
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overexpression leads to hyperproliferation of B cells and development of lymphoma within about 
3 months of birth. Eμ-Myc mice lacking p53 demonstrate even faster tumor development and 
death (Hsu et al., 1995). c-MYC induces p53 activation through several pathways. For example, 
c-MYC induces transcriptional upregulation of the p19ARF tumor suppressor, which can bind to 
MDM2 and promote its degradation as well as sequester MDM2 in the nucleolus and prevent its 
interaction with p53 (Kamijo et al., 1998; Weber et al., 1999; Zhang et al., 1998). c-MYC also 
plays a large role in regulating ribosome biogenesis, in part through increasing the transcription 
of ribosomal proteins (RPs), which also bind to MDM2 and inhibit its ability to regulate p53 
(Dang, 2013; van Riggelen et al., 2010; Zhang and Lu, 2009). 
 Here I present preliminary data suggesting that c-MYC activation does not mandate p53 
regulation through MDM2 E3 ligase activity. This data also suggests that hampering p53 
degradation mediates prolonged animal survival during oncogenic stress. 
 
RESULTS 
Loss of MDM2 E3 ligase function prolongs survival during MYC-induced lymphoma 
Previous work has demonstrated that mice bearing a tyrosine to alanine substitution in 
the C-terminal tail region of MDM2 (MDM2Y487A) are viable, phenotypically normal, and born at 
expected Mendelian ratios (Tollini et al., 2014). In this study, Eµ-Myc mice were crossed with 
Mdm2Y487A/Y487A mice to obtain Eµ-Myc;Mdm2Y487A/Y487A mice. Similar to Mdm2Y487A/Y487A mice, 
Eµ-Myc;Mdm2Y487A/Y487A mice were born at expected ratios (data not shown). It has been 
observed that Mdm2Y487A/Y487A mice present with slightly lower body weight than WT mice. In the 
presence of the Eµ-Myc transgene, both male and female Eµ-Myc;Mdm2Y487A/Y487A mice also 
weigh slightly less than their WT counterparts (Figure 5.1). 
Previous work has shown that acute DNA damage stress that is sub lethal in WT mice 
induces lethality in Mdm2Y487A/Y487A mice. Although Mdm2Y487A/Y487A mice live normal lifespans 
compared to WT mice, in the presence of the Eµ-Myc transgene, it appears that the MDM2Y487A 
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mutation significantly increased average survival compared to mice with WT MDM2 (Figure 5.2). 
Interestingly, although Eµ-Myc;Mdm2Y487A/Y487A mice develop lymphomas with 100% penetrance, 
the survival extension does not appear to have a high penetrance, as about half of Eµ-
Myc;Mdm2Y487A/Y487A mice appear to succumb to lymphoma at the same rate as WT mice. As a 
result, there is not a large difference in the median survival time between the two genotypes 
(98.5 days for Eµ-Myc;Mdm2+/+ mice versus 107.0 days for Eµ-Myc;Mdm2Y487A/Y487A mice), but 
intriguingly ~50% of Eµ-Myc;Mdm2Y487A/Y487A mice display significant lifespan extension 
compared to Eµ-Myc;Mdm2+/+ mice (Figure 5.2). 
MDM2Y487A mice demonstrate increased basal p53 stability along with increased p53 
stability and activity in response to stress (Tollini et al., 2014). In order to explore the reason for 
the differences in lifespan before and after the median survival times of Eµ-Myc;Mdm2+/+ and 
Eµ-Myc;Mdm2Y487A/Y487A mice, p53 levels and activity were examined in various tissues isolated 
from the mice both before and after the onset of lymphoma symptoms.  
First, spleens from 8 week old mice of each genotype were harvested. Splenomegaly is 
a common feature in Eµ-Myc mice and is indicative of increased B-cell lymphoma infiltration. 
Prior to the onset of lymphoma symptoms, there appears to be no difference in spleen size 
between Eµ-Myc;Mdm2+/+ and Eµ-Myc;Mdm2Y487A/Y487A mice (Figure 5.3a). In addition, there 
appears to be little difference in p53 protein levels at this age (Figure 5.3b). However, there 
appears to be a slight increase in p21 expression (indicative of increased p53 activity) in Eµ-
Myc;Mdm2Y487A/Y487A mice compared to their Eµ-Myc;Mdm2+/+ counterparts. 
Next, thymus and lymph node tissue from these mice were examined. At 8 weeks of 
age, there did not appear to be any gross morphological differences between the two 
genotypes. Unexpectedly, average p53 protein levels appeared to be greater in in both tissues 
examined from Eµ-Myc;Mdm2+/+ compared to Eµ-Myc;Mdm2Y487A/Y487A mice (Figure 5.4). On the 
other hand, p21 levels appeared to be increased in Eµ-Myc;Mdm2Y487A/Y487A mice compared to 
Eµ-Myc;Mdm2+/+ mice, possibly indicating that the increased p53 protein levels observed in 
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select Eµ-Myc;Mdm2+/+ mice could be due to p53 mutation, which has been shown to be 
stabilized in cancerous cells (Lang et al., 2004; Olive et al., 2004). At the same time, thymic 
tissue isolated from Eµ-Myc;Mdm2Y487A/Y487A mice appeared to have greater cleaved caspase-3 
(CC-3) staining than Eµ-Myc;Mdm2+/+ mice, indicating increased levels of apoptosis, which is 
often correlated with p53 activity. On the other hand, the opposite trend was present in lymph 
tissue, with Eµ-Myc;Mdm2+/+ tissue displaying higher CC-3 levels (Figure 5.4). The reason for 
this discrepancy is currently unclear. 
 
Loss of MDM2 E3 ligase function allows for increased c-MYC-induced p53 stabilization 
To determine whether loss of MDM2 E3 ligase function could allow for increased p53 
stabilization and activation in a cell-based system, WT and Mdm2Y487A/Y487A MEFs were infected 
with retrovirus expressing c-MYC or a pBABE vector (Figure 5.5). As expected, c-MYC 
overexpression promoted p19ARF expression and p53 stabilization in WT MEFs. Despite the 
inability of MDM2Y487A to degrade p53, further stabilization of p53 was also observed upon c-
MYC overexpression in Mdm2Y487A/Y487A MEFs. It has been previously shown that prolonged 
DNA damage further increases the stabilization of p53 in Mdm2Y487A/Y487A MEFs, likely due to a 
combination of the inability of MDM2Y487A to degrade p53 and stress-induced increased p53 
transcription and translation (Tollini et al., 2014). Compared to WT MEFs, Mdm2Y487A/Y487A MEFs 
demonstrate elevated p53 levels basally and upon c-MYC overexpression. However, the ratio of 
p53 protein level increase between basal and after c-MYC expression appears to be similar 
between the two genotypes (3.40 fold vs 3.98 fold). It is possible that with prolonged exposure 
to c-MYC, p53 levels in Mdm2Y487A/Y487A MEFs could continue to rise beyond that of WT MEFs, 
as has been shown to occur in the presence of DNA damage. Although it has been previously 
shown that Mdm2Y487A/Y487A MEFs express increased basal p53 protein levels compared to WT 
MEFs, upon the introduction of c-MYC, p53 activity does not appear to be different between the 
two genotypes, as indicated by similar MDM2 expression. 
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Following the onset of lymphoma symptoms, including enlarged lymph nodes, hunched 
posture, slow movement, and irregular breathing (Harris et al., 1988), tissues were harvested 
from age-matched mice to assess p53 stability and activity by Western blot. In spleen tissue, 
average p53 protein levels and activity were slightly higher in Eµ-Myc;Mdm2Y487A/Y487A mice 
(Figure 5.6), while in lymph nodes p53 protein levels are more clearly elevated in Eµ-
Myc;Mdm2Y487A/Y487A mice compared to Eµ-Myc;Mdm2+/+ mice (Figure 5.7). In addition, elevated 
MDM2 protein levels indicate increased p53 activity in lymph tissue (Figure 5.7). Thymic tissue 
demonstrated a similar phenotype, as average p53 and MDM2 levels appeared to be increased 
in Eµ-Myc;Mdm2Y487A/Y487A mice (Figure 5.8). Despite p53 stabilization in these tissues, changes 
p21 and CC-3 levels were less obvious, indicating the possibility that p53 targets may be 
differentially induced. 
In order to further evaluate p53 activity in Eµ-Myc;Mdm2Y487A/Y487A mice following 
lymphoma development, qPCR analysis was performed. As expected, in spleen and lymph 
tissue, there appeared to be no change in p53 mRNA transcription (Figure 5.9), which suggests 
that changes in p53 protein levels are likely due to changes in protein stability or translation. In 
addition, p53-mediated transcription of several target genes, including mdm2, bax, and apaf1, is 
significantly upregulated in spleens from Eµ-Myc;Mdm2Y487A/Y487A mice compared to Eµ-
Myc;Mdm2+/+ mice. In lymph tissue, mdm2 and p21 transcription also appear to be elevated, but 
this difference is not statistically significant. Together these data suggest the possibility that the 
increased survival of Eµ-Myc;Mdm2Y487A/Y487A mice following lymphoma is because of increased 
p53 stability, allowing for increased p53 tumor suppressive activity. However, further analyses 
will be required to make more definitive conclusions.  
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DISCUSSION & FUTURE DIRECTIONS 
Loss of MDM2 function allows for increased survival during c-MYC-induced lymphomagenesis 
It is clear that the loss of MDM2 E3 ligase activity correlates with increased survival in a 
subset of mice overexpressing c-MYC (Figure 5.2). However, the reason for this increased 
survival is still unclear, and significantly more analyses are needed to elucidate this mechanism 
from several potential causes.  
First, it is possible that loss of MDM2 E3 ligase activity and MDM2-mediated p53 
degradation allows for low level increases in p53 stability and activity that benefit a subset of 
mice. Although this is not clear from the preliminary data, there are some indications that this 
may be the case, including the increased transcription of p53 target genes in spleen tissue of 
Eµ-Myc;Mdm2Y487A/Y487A mice, which has a large population of B cells (Figure 5.9). It will be 
important to compare tissues from Eµ-Myc;Mdm2+/+ and Eµ-Myc;Mdm2Y487A/Y487A mice to mice 
lacking the Eµ-Myc transgene to determine whether p53 is truly differentially activated or 
stabilized. Although there are indications that loss of MDM2 E3 ligase activity could allow for 
increased p53 stability and activity in some tissues, there appears to be significant 
heterogeneity between Eµ-Myc-expressing mice. In order to extrapolate further, it will be 
necessary to analyze more samples. It will also be essential to analyze tumor growth, 
senescence, and apoptotic rates in Eµ-Myc;Mdm2+/+ and Eµ-Myc;Mdm2Y487A/Y487A mice in order 
to determine if the MDM2Y487A mutation correlates with decreased tumor growth and increased 
senescence or apoptosis, both of which are indicative of increased p53 activity.  
Second, it is possible that p19ARF loss, which is common in Eµ-Myc mice (Eischen et 
al., 1999), may occur at different rates in these mice, possibly due to changes in the feedback 
loop of p53 to p19ARF signaling. It has been shown that p53 activation results in the 
downregulation of p19ARF through unknown mechanisms. It is possible that in Eµ-
Myc;Mdm2Y487A/Y487A mice, increased p53 activity could cause p19ARF levels to be slightly 
reduced compared to Eµ-Myc;Mdm2+/+ (prior to potential p19ARF deletion). Reducing p19ARF 
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expression could lessen oncogenic pressure for p19ARF deletion while still allowing for some 
p19ARF-mediated tumor suppressive functions. It is possible that p19ARF deletion occurs less 
frequently in Eµ-Myc;Mdm2Y487A/Y487A mice, allowing for increased latency to tumor formation. 
Analysis of p19ARF status in these mice will be critical to determine whether p19ARF signaling 
could be differentially regulated in the presence of the MDM2Y487A mutation. 
Third, it is possible that the loss of MDM2 E3 ligase could through unknown mechanisms 
bias oncogenic pressure against p53 deletion or mutation; however, this mechanism seems 
unlikely. For example, it has been previously shown that cell lines chronically treated with nutlin-
3, a potent inhibitor of MDM2-p53 binding and non-genotoxic activator of p53, develop 
resistance to this drug and exhibit elevated rates of p53 mutation compared to vehicle treated 
cells (Aziz et al., 2011). This suggests that increased p53 stability and activity, which typically 
results in cell death or growth arrest, likely drives selection of p53 inactivation in cancer cells. 
This effect has also been observed in cancer patients with WT p53, who upon undergoing p53-
activating chemotherapies acquire both resistance to the chemotherapy and either p53 deletion 
or mutation (Christiansen et al., 2001; Leonard et al., 2002). Disrupting MDM2 E3 ligase activity 
has been shown to allow for increased p53 protein stability and activity in response to DNA 
damage (Tollini et al., 2014). Thus, it is more likely that MDM2Y487A mutation would bias p53 
towards deletion or mutation, which could feasibly lead to decreased overall survival of Eµ-
Myc;Mdm2Y487A/Y487A mice compared to Eµ-Myc;Mdm2+/+ mice, which is the opposite of the 
observed survival phenotype. To investigate this possibility, the p53 mutational status of the 
tissues examined in this study will need to be determined. 
 
Stress-specific necessity of MDM2 E3 ligase activity 
 The longer lifespan of Eµ-Myc;Mdm2Y487A/Y487A mice compared to Eµ-Myc;Mdm2+/+ mice 
does support certain conclusions pertaining to stress-related p53 regulation. First, while it is 
clear that MDM2 E3 ligase activity is necessary for in vivo p53 regulation following acute, sub 
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lethal DNA damage-induced stress (Tollini et al., 2014), it is dispensable to organismal survival 
in the presence of chronic oncogenic stress. In fact, loss of MDM2 E3 ligase function appears to 
provide a survival advantage in this situation. 
The reason for this differential necessity for MDM2 E3 ligase activity is likely due to the 
intensity and location of the stress. In the case of acute DNA damage, p53 is rapidly stabilized. 
Although c-MYC overexpression is capable of inducing a p53-dependent apoptotic program in 
cells (Hermeking and Eick, 1994), transgenic c-MYC overexpression in the mouse likely 
promotes p53 stabilization more slowly than irradiation. In addition, the sub lethal IR treatment 
described in the first study of the MDM2Y487A mouse was a whole body treatment, while the Eµ-
Myc transgene is only expressed in B cells (Harris et al., 1988; Tollini et al., 2014). While undue 
p53 activation throughout the body clearly causes lethality (de Oca Luna et al., 1995; Jones et 
al., 1995; Ringshausen et al., 2006), in the absence of extrinsic apoptotic stress to other tissues 
p53-mediated B cell death is unlikely to promote organismal demise. For example, patients 
undergoing chimeric antigen receptor (CAR) T cell therapy commonly (and intentionally) ablate 
B cells (Kochenderfer and Rosenberg, 2013). In the presence of chronic stress, it is also 
possible that other p53-regulating proteins could cooperate towards regulating p53 stability. 
Although it remains clear that MDM2 is the primary E3 ubiquitin ligase for p53, other E3 
ubiquitin ligases targeting p53 have been described (Dornan et al., 2004; Leng et al., 2003). It is 
possible that during acute stress, MDM2-mediated p53 degradation is required to rapidly bring 
p53 to safe levels following resolution of the stress to prevent organismal death. On the other 
hand, in the presence of chronic oncogenic stress, it is possible that p53 is not stabilized to 
these same levels that require MDM2 E3 ligase activity, which would allow for p53 to be 
degraded by other E3 ligases instead. It will be important to determine whether p53 is still 
degraded in Eµ-Myc;Mdm2Y487A/Y487A mice. Although much work remains to be done, these 
preliminary data are encouraging towards demonstrating a stress-specific role for MDM2 E3 
ligase activity in p53 regulation. 
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EXPERIMENTAL PROCEDURES 
Mouse experiments 
All mice were bred and maintained on a 12 h light and dark cycle. Mdm2Y487A mutant 
mice were generated as previously described (Tollini et al., 2014). To generate Eµ-
Myc;Mdm2Y487A/Y487A mice, Eμ-Myc male mice were bred with Mdm2Y487A/Y487A female mice. The 
resultant Eµ-Myc;Mdm2Y487A/+ or Eµ-Myc;Mdm2Y487A/Y487A male mice were then bred with 
Mdm2Y487A/Y487A female mice. Eμ-Myc mice on C57BL/6 J background were purchased from The 
Jackson Laboratory (Bar Harbor, ME, USA) (stock number 002728). For survival studies, mice 
were examined regularly for early signs of lymphoma and monitored for tumor progression and 
signs of morbidity. Moribund mice were humanely euthanized. All mice were handled in strict 
accordance with protocols approved by the Institutional Animal Care and Use Committee at The 
University of North Carolina at Chapel Hill. 
 
Protein analysis 
For western blotting, proteins were extracted from tissues as previously described (Liu et 
al., 2016a). Briefly, mouse tissue was homogenized and lysed in 0.5% NP-40 lysis buffer. 
Proteins were detected using either ECL and Dura enhanced chemiluminescence systems 
(Thermo Scientific, SuperSignal West Dura Substrate). The following primary antibodies were 
used: mouse monoclonal anti-p53 (PAb 122, Thermo Scientific), mouse monoclonal anti-MDM2 
(2A10, homemade), and rabbit polyclonal anti p19ARF (Ab80, Abcam) Rabbit polyclonal 
antibodies to p21 were gifts from Dr. Yue Xiong (University of North Carolina at Chapel Hill, 
Chapel Hill, NC). 
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Quantitative PCR 
Total RNA was prepared from mouse tissues using QuickRNATM MiniPrep Kit (Zymo 
Research, Irvine, CA, USA, #11-328). RNA concentration was determined using a NanoDrop 
spectrophotometer (Thermo Scientific, Waltham, MA, USA, NanoDrop 2000c). Complementary 
DNA was synthesized using iScriptTM DNA Synthesis Kit (Bio-Rad, Hercules, CA, USA, 
#1708889). qPCR was performed with SYBR Green probes using the Applied Biosystems 
(Carlsbad, CA, USA) 7900HT Fast Real-Time PCR system. Thermal cycling conditions were 
50 °C for 2 min, 95 °C for 5 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. 
Target gene transcript levels were normalized to gapdh transcript levels obtained in each 
sample via the subtraction of the Ct value of gapdh from the Ct value for each target gene. 
Results were expressed as the fold-change in transcript levels. Primers used for qPCR were as 
follows: gapdh, 5’-GAAAGCTGTGGCGTGATGG-3’ and 5’-AGTGAGCTTCCCGTTCAGC-3’; 
p53, 5’-TGAACCGCCGACCTATCCTTA-3’ and 5’-GGCACAAACACGAACCTCAAA-3’; mdm2, 
5′-TGTGTGAGCTGAGGGAGATG-3′ and 5′-CACTTACGCCATCGTCAAGA-3’; p21, 5’-
TCCACAGCGATATCCAGACA-3’ and 5’-AGACAACGGCACACTTTGCT-3’; bax, 5’- 
GGACAGCAATATGGAGCTGCAGAGG-3’ and 5’-GGAGGAAGTCCAGTGTCCAGCC-3’; apaf1, 
5’- CGGTGAAGGTTGTGGAATGTCATTACCG-3’ and 5’-
GGATTTCTCCATTGTCATCTCCAGTTGC-3’; tigar, 5’-CGATCTCACGAGGACTAAGCAGACC-
3’ and 5’-GCGCCATGGCTCACAACTAAGATGC-3’. 
 
Cell culture 
Primary MEFs were isolated on embryonic (E) day 13.5 and grown in a 37°C incubator 
with 5% CO2 in Dulbecco’s modified Eagle’s medium supplied with 10% fetal bovine serum and 
penicillin-streptomycin. For retroviral infections, WT, and Mdm2Y487A/Y487A MEFs were infected 
with retroviruses expressing c-MYC or pBabe control vector, and selected with puromycin (2.5 
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μg/ml) for 3 days. Infected MEFs were then allowed to recover for 48 h before harvesting for 
analysis.  
 
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism 5 Software (GraphPad 
Software). Kaplan-Meier survival curves were generated to assess lifespan. Quantitative PCR 
data are represented as mean ±SEM, and were analyzed by the Student’s t test. 
 
Ethics statement 
This investigation has been conducted in accordance with ethical standards, the 
Declaration of Helsinki, national and international guidelines, and has been approved by the 
authors' institutional review board. 
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Figure 5.1 MDM2Y487A mutation correlates with slightly lower body weight 
Eμ-Myc;Mdm2+/+ male (n=21) and female (n=21) as well as Eμ-Myc;Mdm2Y487A/Y487A male (n=16) 
and female (n=13) mice were weighed and observed weekly. Data represent means ±SEM. 
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Figure 5.2 Disruption of MDM2 E3 ligase activity prolongs survival during c-MYC-induced 
lymphomagenesis.  
 
Kaplan-Meier survival curves for Eμ-Myc;Mdm2+/+ (n=22) and Eμ-Myc;Mdm2Y487A/Y487A (n=22) 
mice are shown. There was a significant difference between survival curves for Eμ-Myc;Mdm2+/+ 
and Eμ-Myc;Mdm2Y487A/Y487A mice (analyzed by log-rank test; P=0.0255).  
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Figure 5.3 Eμ-Myc;Mdm2Y487A/Y487A spleens do not display increased p53 stabilization prior 
to lymphoma development 
 
A. Spleens from 8 week old Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) mice 
were harvested, weighed, and normalized to body weight. Data are represented as mean 
±SEM. NS means no significant difference. 
 
B. Spleens from 8 week old Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) mice 
were harvested and analyzed by WB. 
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Figure 5.4 Eμ-Myc;Mdm2Y487A/Y487A thymic tissue and lymph nodes do not display 
increased p53 stabilization prior to lymphoma development. 
 
A. Thymic tissue from 8 week old Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) 
mice were harvested and analyzed by WB. 
 
B. Lymph nodes from 8 week old Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) mice 
were harvested and analyzed by WB. 
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Figure 5.5 Mdm2Y487A/Y487A MEFs display increased p53 stabilization following c-MYC 
overexpression 
 
WT and Mdm2Y487A/Y487A MEFs were infected with retrovirus containing either c-MYC (+) or a 
pBABE vector (-). Following infection, the cells were selected with puromycin and then 
harvested for analysis by western blot. 
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Figure 5.6 Following lymphoma onset, spleens isolated from Eμ-Myc;Mdm2Y487A/Y487A mice 
display increased p53 stability. 
 
Spleens from age-matched Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) mice with 
symptoms of lymphoma were harvested and analyzed by WB. Quantification of protein levels 
relative to Eμ-Myc;Mdm2+/+ mice is shown below the blot. 
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Figure 5.7 Following lymphoma onset, lymph nodes isolated from Eμ-Myc;Mdm2Y487A/Y487A 
mice display variable p53 stability. 
 
Lymph nodes from age-matched Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) mice 
with symptoms of lymphoma were harvested and analyzed by WB. Quantification of protein 
levels relative to Eμ-Myc;Mdm2+/+ mice is shown below the blot. 
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Figure 5.8 Following lymphoma onset, thymi isolated from Eμ-Myc;Mdm2Y487A/Y487A mice 
display slightly increased p53 stability. 
 
Thymic tissue from age-matched Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) mice 
with symptoms of lymphoma were harvested and analyzed by WB. Quantification of protein 
levels relative to Eμ-Myc;Mdm2+/+ mice is shown below the blot. 
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Figure 5.9 Following lymphoma onset, Eμ-Myc;Mdm2Y487A/Y487A mice display slightly 
increased p53 activity in spleen but not lymph node tissue. 
 
A. Spleens from age-matched Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) mice 
with symptoms of lymphoma were harvested and analyzed by qPCR. Data are represented as 
mean ±SEM. *, P<0.05; **, P<0.01; ***, P<0.001. 
 
B. Lymph nodes from age-matched Eμ-Myc;Mdm2+/+ (n=4) and Eμ-Myc;Mdm2Y487A/Y487A (n=4) 
mice with symptoms of lymphoma were harvested and analyzed by qPCR. Data are 
represented as mean ±SEM.  
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
Though p53 continues to be one of the most well-studied proteins due to its wide-
ranging stress-response functions, our understanding of p53 and its regulation is continuously 
evolving. These changes in our understanding are in part due to the progression of in vivo 
modeling, which has allowed us to delineate the physiologically relevant conditions contributing 
to p53-mediated activation and tumor suppression. 
It has been clearly demonstrated that MDM2 and MDMX are master regulators of p53 
(Wade et al., 2010). It is also known that many upstream signals contribute to inhibition of 
MDM2 and/or MDMX to allow for p53 stabilization and activation, including p19ARF and RPs. 
However, mapping the relative contributions of these upstream signals to the inhibition of MDM2 
or MDMX has been a difficult challenge within the field. Further, determining the signals that 
reestablish p53 inhibition following its activation will be important towards understanding p53 
biology. The characterization of the MDM2C305F mouse has allowed for numerous advances in 
our understanding of RP-MDM2-p53 regulation in the presence of cancer-inducing transgenes. 
Meanwhile, the MDM2Y487A mouse has allowed us to further understand p53 regulation following 
the resolution of stress. 
 
Evolving views of the RP-MDM2-p53 pathway in tumor prevention 
RPs work independently of p19ARF to inhibit MDM2 
Ribosomal biogenesis is a highly-coordinated process in which small perturbations can 
have big consequences. RPs have been shown to inhibit MDM2 E3 ligase activity in the 
presence of nucleolar and oncogenic stresses, which contributes to p53 stabilization and 
activation. Although it has been demonstrated in vitro that approximately 16 RPs bind to MDM2 
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(Liu et al., 2016b), very few of these interactions have been examined in vivo. The MDM2C305F 
mouse was the first (and so far only) in vivo model to disrupt RP-MDM2 interaction without 
directly altering RPs, and this mouse demonstrated that RP-MDM2 signaling was critical for 
tumor prevention driven by c-MYC (Macias et al., 2010). However, the general heterogeneity of 
cancer and tumor driver signaling warrants further exploration of RP-MDM2-p53-mediated 
tumor prevention. 
In response to c-MYC overexpression, both p19ARF and RPs bind to MDM2 and inhibit 
its ubiquitination of p53 (Eischen et al., 1999; Macias et al., 2010). Meanwhile, p19ARF 
regulates ribosomal biogenesis at multiple steps (Lessard et al., 2010; Saporita et al., 2011; 
Sugimoto et al., 2003). These findings allowed for the possibility that p19ARF contributes to 
p53 activation via disrupting ribosomal biogenesis and facilitating RP-mediated MDM2 inhibition. 
The work presented here demonstrates that this is not the case. Specifically, Chapters 2 and 3 
show that RP-MDM2 binding is not dependent on the presence of p19ARF in its ability to 
regulate p53 and prevent tumorigenesis. This is principally demonstrated by reduced latency to 
death upon concomitant RP-MDM2 interaction disruption and p19ARF deletion (Figure 
2.3). However, this work does not completely rule out the possibility that p19ARF-mediated 
regulation of ribosomal biogenesis enhances its p53-activating functions. 
This work further explored the relative necessity of either RP or p19ARF signaling 
towards p53 activation, which appears to be dependent on the upstream oncogenic signal. For 
example, in the presence of the Eµ-Myc transgene, disruption of either p19ARF-MDM2 or RP-
MDM2 interaction resulted in early tumorigenesis (Eischen et al., 1999; Macias et al., 2010), 
while concomitant disruption further increased the speed of tumor formation (Figure 2.3). In 
contrast, HrasG12V transgene overexpression only allowed for tumor formation in the absence of 
p19ARF, but not upon RP-MDM2 binding disruption (Figure 3.1). This work confirms that 
p19ARF signaling through MDM2 is critical for p53 activation in the context of Eµ-Myc and 
HrasG12V transgenic overexpression. In contrast, work presented here and published by others 
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has indicated that p19ARF is not required for p53-mediated activation and tumor suppression in 
all contexts. In the presence of the ApcMin allele, RP-MDM2 interaction appears to serve a more 
protective role than p19ARF-MDM2 interaction, as p19ARF deletion does not alter APC-loss 
induced tumorigenesis (Gibson et al., 2005), while loss of RP-MDM2 interaction increases colon 
tumor formation (Figure 4.3). Together, these studies solidify the notion that though p19ARF 
regulates ribosomal biogenesis and participates in p53 regulation, these likely represent two 
independent MDM2-regulating protein interactions. 
 
RP expression and RP-MDM2 interaction is differentially regulated by upstream signals 
Ribosomal proteins are often upregulated in cancer. It has been previously shown that 
that the c-MYC oncogene is a master regulator of ribosomal biogenesis and RP protein 
expression, but the work presented here also demonstrates that RPs are upregulated in 
response to other oncogenic drivers. Specifically, this work shows that RPL23, but not RPL11 or 
RPL5, is upregulated in response to HRASG12V overexpression (Figure 3.6-8). To my 
knowledge, this work is the first report of a RAS-upregulated ribosomal protein. Interestingly, the 
regulation of RPL23 by RAS occurs both through increased rpl23 transcription (Figure 3.7), and 
mTOR-dependent translation (Figure 3.12). RPL11 and RPL5 are also transcriptionally 
upregulated in APC-loss-induced colon tumors (Figure 4.3).  
It is important to recognize that oncogenic signals do not occur in isolation. For example, 
some activating RAS mutations have been shown to contribute to c-MYC stabilization, further 
facilitating cancer progression (Sears et al., 1999; Sears et al., 2000). It is therefore likely that c-
MYC signaling is also altered in the context of HrasG12V transgene expression, possibly 
contributing to the differential RPL23 protein production. It is also unsurprising that RPs would 
be upregulated in APC-loss-induced tumors (Figure 4.3), given that c-MYC has been shown to 
be an important driver of cancer in these tumors (Sansom et al., 2007). 
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There are some indications that tissue specific RP-regulation occurs, though it is difficult 
to make direct comparisons between the models used in these studies. For example, in the 
presence of the ApcMin allele, which induces tumor formation throughout the intestinal tract upon 
loss of APC heterozygosity, ribosomal protein RPL11 and RPL5 expression were increased in 
colon tumor tissue, but not in small intestinal tumor tissue (Figure 4.8). From this, it is possible 
to speculate that local tissue signaling dictates RP expression and RP-MDM2 interaction, even 
in the presence of the same driver mutation. This result is particularly meaningful in the context 
of human cancers. In humans, deletion of the Apc gene is the cause of a familial disorder linked 
to increased colorectal tumor formation, and the ApcMin mouse models this deletion. 
Interestingly, ApcMin mice develop small intestinal tumors with almost 100% penetrance, but 
small intestinal tumors are relatively rare in humans, even in the presence of Apc deletion (Pan 
and Morrison, 2011). However, it is particularly interesting that the presence of the MDM2C305F 
mutation accelerates colon tumor formation in ApcMin mice, as in combination with the tissue-
specific induction of RPL11 and RPL5, this indicates that RP-MDM2-p53 signaling may be a 
more important modulator of colon tumor progression than what had been previously 
appreciated. Importantly, as RPs are abundantly expressed in almost all cells, this also 
suggests that upstream signaling dictates when and where RP-MDM2 interactions occur, and 
the degree to which they alter p53 signaling.  
This work also contributes to the well-supported notion that MDM2 requires different 
signals to inhibit p53 during the presence of specific stimuli. Ribosomal proteins are present in 
almost all cell types, and though in the context of protein translation it is likely that they are 
acting similarly, it is possible that free RPs interact with MDM2 in a stress-specific manner. For 
instance, in RAS-expressing MEFs, both p19ARF and RPL23 were required for MDM2 inhibition 
(Figure 3.14), while RPL11 and RPL5 contributed to MDM2 inhibition in colon tissues bearing 
APC deletion (Figures 4.9-10). It is unknown why multiple RPs bind to MDM2. From these 
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studies, it is possible to speculate that individual RPs may respond either to unique oncogenic 
signals or in a tissue dependent manner to confer varying degrees of p53 stabilization.  
Further investigation will be required to parse out the specific signals dictating differential 
RP-MDM2-p53 signaling. Although much work remains to be done in order to fully understand 
the contexts for RP-mediated p53 regulation, the MDM2C305F mouse model remains a useful tool 
for characterizing the circumstances under which RPL5/RPL11-MDM2 interaction is required. 
 
Relative necessity of MDM2 E3 ligase activity towards p53 regulation 
In addition to altering our perception about how p53 is activated in response to 
oncogenic stress, this work has also contributed to our understanding about how p53 is 
regulated following the resolution of stress. Previously held views in the field advocated that 
MDM2-mediated p53 ubiquitination/degradation is important for preventing lethal p53 activation, 
and this idea is well-supported by in vitro studies (Haupt et al., 1997; Honda et al., 1997). 
Surprisingly, the MDM2Y487A mouse, in which MDM2 E3 ligase activity is disrupted while MDM2-
MDMX interaction is maintained, clearly demonstrated that MDM2 E3 ligase activity is not 
required for regulating basal p53 levels throughout the lifespan (Tollini et al., 2014). In contrast, 
mouse models bearing targeted disruption of the MDM2-MDMX heterodimer have largely 
demonstrated p53-dependent embryonic lethality (Huang et al., 2011; Itahana et al., 2007; Pant 
et al., 2011), indicating that the MDM2-MDMX heterodimer may be the primary mechanism of 
basal p53 regulation. Although it has been proposed that the MDM2-MDMX heterodimer is 
required for MDM2 E3 ligase activity towards p53 (Kawai et al., 2007), the MDM2Y487A mouse 
suggests that the other functions of this heterodimer are critical for basal p53 regulation, 
including MDM2- or MDMX-p53 binding and transactivation inhibition. Although not definitively 
proven, results from several studies suggest that the MDM2-MDMX heterodimer promotes more 
efficient p53 binding and transactivation inhibition than individual MDM family proteins alone. 
For instance, Pant et al. observed decreased binding of MDMXΔRING to p53R172H (Pant et al., 
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2011), which harbors a missense mutation rendering it transcriptionally inactive (Lang et al., 
2004). Others in the Zhang lab have also observed that MDM2- and MDMX-p53 binding is 
impaired in Mdm2-/-;p53ER/- and MdmX-/-;p53ER/- MEFS compared to p53ER/- MEFs (unpublished 
observations). Other functions of the heterodimer, including recruitment of post-translational p53 
modifiers like p300, could also play a role in p53 regulation. 
While MDM2 E3 ligase activity appears to be dispensable for basal p53 regulation in 
vivo, both in vitro and in vivo studies agree that it is critical for p53 regulation following stress-
induced p53 stabilization. The specific necessity of MDM2 E3 ligase activity was first 
demonstrated in adult MDM2Y487A mice, which suffer increased sensitivity to sub lethal IR-
induced DNA damage, evidenced by p53-dependent lethality and hematopoietic failure. 
Clarifying these studies further, the work presented in Chapter 5 offers the possibility that MDM2 
E3 ligase activity may only be required for degrading p53 after certain types of stress or in 
certain tissues. In contrast to demonstrating p53 dependent lethality in response to sub lethal 
DNA damage, MDM2Y487A mice demonstrate increased survival in response to c-MYC-
overexpression-induced tumorigenesis (Figure 5.2). c-MYC overexpression has been shown to 
initiate an endogenous apoptotic program (Evan et al., 1992), in part mediated by p53 
(Hermeking and Eick, 1994). c-MYC overexpression also promotes the inhibition of MDM2 E3 
ligase activity through the induction of p19ARF- and RP-MDM2 interactions. It was unknown 
whether oncogene activation would promote robust stabilization of p53 in the absence of MDM2 
E3 ligase function. The Eμ-Myc model is well-known to engage p53, and the absence of MDM2 
E3 ligase function further promotes p53 stabilization, allowing for p53 activation and tumor 
suppression via cell cycle arrest, metabolic, or apoptotic mechanisms. Although MDM2Y487A 
mice demonstrate increased survival (Figure 5.2), it remains to be determined if the loss of 
MDM2 E3 ligase activity drives the increased p53 stabilization observed in these mice. 
Combined, these studies point to the idea that, while dispensable under normal conditions, 
MDM2-mediated p53 degradation is essential following the resolution of stress. Further, 
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different stresses may induce p53 stabilization to varying degrees, which may dictate the 
necessity of MDM2 E3 ligase-mediated p53 degradation. 
MDM2 is often overexpressed in tumors bearing WT p53, contributing to its functional 
silencing. It is therefore conceivable that p53 reactivation via MDM2 inhibition could promote 
tumor regression. In fact, several non-genotoxic small molecule inhibitors of MDM2-p53 binding 
have shown significant tumor suppressing capabilities in tumor xenografts (Shangary et al., 
2008; Vassilev et al., 2004). However, mouse models have suggested that complete restoration 
of p53 function should be used with caution, as abundant p53 activity is especially toxic 
(Ringshausen et al., 2006; Tollini et al., 2014; Zhang et al., 2014a). The relative normalcy of the 
MDM2Y487A mouse points to the fact that MDM2 E3 ligase inhibition on its own does not promote 
lethal p53 activation in vivo. The work presented in this dissertation is also suggestive that 
MDM2 E3 ligase inhibition could be a safe way to promote p53 stabilization, activation, and 
tumor suppression without promoting overt toxicity. In fact, several small molecule inhibitors of 
MDM2 E3 ligase activity have already been developed. The first, HLI98, was identified through 
a high throughput screen probing for inhibitors of MDM2 autoubiquitination (Yang et al., 2005). 
In cells, HLI98 decreased p53 ubiquitination and promoted subsequent p53 activation. However, 
HLI98 appears to lack specificity for MDM2, and may affect E2 loading on other E3 ligases. 
HLI98 derivative compounds, including MPD, MEL23 and MEL24, have been developed in an 
attempt to increase the specificity of inhibition, but these compounds also appear to have MDM2 
and p53-independent activity (Herman et al., 2011; Roxburgh et al., 2012). Although MDM2 E3 
ligase inhibition may be a feasible strategy for WT p53 activation, the pharmacology of MDM2 
E3 ligase inhibitors must be further improved if they are to be used in the clinic. 
On the other hand, studies in the MDM2Y487A mouse also suggest that MDM2 E3 ligase 
inhibition could promote extreme toxicity in combination with whole body DNA damaging 
chemotherapies, as this would increase whole-body p53 activation. Tissue-targeted therapies, 
such as targeted radiation, could be used to avoid this problem. However, further exploration of 
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p53 and its regulation in cancer will be important to understand the uses or repercussions of 
p53-reactivating therapies. 
 
Future Directions 
RP-MDM2-mediated p53 regulation 
The studies presented in this dissertation relied heavily on the MDM2C305F mouse to 
examine under which conditions certain RP-MDM2 interactions are required for p53-mediated 
tumor suppression. Although useful, this model only allows us to test the effects of RPL11- and 
RPL5-MDM2 binding. Although it has been postulated that RPL11 and RPL5 are uniquely 
important for RP-mediated p53 activation, the work presented in Chapter 3 points to a novel role 
for RPL23 in p19ARF, RPL11, and RPL5 independent tumor prevention. Interestingly, the 
MDM2C305F mouse presents with elevated levels of RPL23, which appear to protect the mice 
from HRAS-induced tumorigenesis (Figure 3.1).  
 Although the MDM2C305F mouse allowed us to discover a role for RPL23 in HRAS-
mediated tumorigenesis, the in vivo consequences of RPL23-MDM2 interaction were not able to 
be directly tested in this study. In the future, it would be useful to examine mice in which other 
RP-MDM2 interactions are disrupted, while RPL11 and RPL5 interactions are maintained. This 
could be possible through mutation of the MDM2 central acidic domain in vivo. Systematic 
mutation of the MDM2 acidic domain and overexpression in vitro, coupled with 
immunoprecipitation of RPs could allow for the identification of mutations disrupting specific RP-
MDM2 interactions. Further, generating in vivo models using these identified mutations could 
allow us to directly test the idea that specific RP-MDM2 interactions are respondent to specific 
upstream signals.  
This work also demonstrates that activated RAS overexpression can drive the 
expression of RPL23, but this mechanism has not been elucidated. We have demonstrated that 
rpl23 transcription is upregulated in response to HRASG12V overexpression (Figure 3.7), but 
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determining the downstream transcription factors required for this transactivation will be 
important for future studies. Several RPs have been demonstrated to be downstream p53 
targets, but thus far RPL23 has not been identified as such (He and Sun, 2007; Xiong et al., 
2011; Zhang et al., 2013c). Further, the studies presented here suggest that HRAS-induced 
RPL23 expression does not require p53 (Figure 3.14). In order to identify chromatin binding 
transcription factors contributing to increased RAS-induced rpl23 transcription, it may be useful 
to perform reverse ChIP assays in cells overexpressing RAS. This method combines 
immunoprecipitated DNA probes (specific for the promoter region of interest) with mass 
spectroscopic analysis to identify chromatin binding proteins in an unbiased manner (Rusk, 
2009). Elucidating novel regulators of ribosomal proteins and ribosome biosynthesis will allow 
us to further understand how oncogenes promote increased proliferation as well as p53 
activation. Further, HRASG12V mutation is not the most common RAS alteration found in 
melanomas. The NRAS isoform is much more commonly altered in melanoma (Chin et al., 
1997), and in the future it may be interesting and more clinically relevant to examine RP-MDM2-
p53 interaction in a mutated NRAS setting. 
 
MDM2 E3 ligase activity and MDM2-MDMX interaction 
The relative contributions of MDM2 E3 ligase activity and MDM2/MDMX heterodimer 
formation to p53 regulation are still being investigated. The normal survival of the MDM2Y487A 
mouse directly contrasts with mice bearing alterations disrupting MDM2-MDMX 
heterodimerization, which present with embryonic lethality (Table 1.2). However, disruption of 
MDM2-MDMX binding has also been shown to have less severe consequences in adult mice. 
Mice bearing a Cre-inducible MDMX RING deletion allele (MdmXflxRING) were healthy following 
MDMX RING deletion, suggesting that MDM2-MDMX heterodimer formation is dispensable for 
the regulation of p53 activity in adult mice. Whether p53 stability is affected by this loss has not 
been determined in adult mice and remains an interesting question. In addition, MDMX deletion 
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coupled with p53 reactivation in adult mice is also relatively well-tolerated (Garcia et al., 2011). 
From these studies, it is unclear whether the MDM2-MDMX heterodimer directly participates in 
p53 regulation following stress in vivo. As such, it would be interesting to examine the p53-
dependent stress response in adult mice bearing MDMX RING domain deletion. This could be 
achieved by examining MdmXflxRING/flxRING mice following Cre-mediated recombination and RING 
domain deletion. Interestingly, following sub lethal IR treatment MdmX+/- mice demonstrated 
lethality, and MdmXΔRING/+ mice did not (Pant et al., 2011). While not conclusive, these data are 
suggestive that MDM2-MDMX heterodimer formation may not be required for stress-induced 
p53 regulation in vivo. Understanding the individual necessities of these MDM family protein 
functions in different contexts is imperative to understanding p53 regulation. 
 
Concluding Remarks 
Mouse modeling has proven to be an important tool in the study of p53. It has facilitated 
the understanding of both the upstream modifying factors that contribute to p53 activation (like 
RPs and p19ARF), as well as mechanisms responsible for p53 regulation following stress-
induced activation. Continued innovation and exploration is necessary towards understanding 
p53 regulation in cancer as amazingly the tens of thousands of p53 studies have yet to yield 
clinically relevant diagnostics or therapeutics. This increased knowledge will help to inform novel 
cancer therapies with the end goal of improving patient outcomes. 
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